(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 14 April 2005 (14.04.2005)

PCT

(10) International Publication Number WO 2005/033100 A1

- (51) International Patent Classification⁷: C07D 405/04, C07H 15/00, C07D 205/08
- (21) International Application Number:

PCT/CH2004/000584

(22) International Filing Date:

15 September 2004 (15.09.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

03405719.0

7 October 2003 (07.10.2003) E

- (71) Applicant (for all designated States except US): LIPI-DEON BIOTECHNOLOGY AG [CH/CH]; Hermann-Hiltbrunner-Weg 25, CH-8713 Uerikon (CH).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): CARREIRA, Erick [US/CH]; Chapfstrasse 73, CH-8126 Zumikon (CH). HAUSER, Helmut [AT/CH]; Hermann-Hiltbrunnerweg 25, CH-8713 Uerikon (CH). KVAERNO, Lisbet [DK/CH]; Kronenstrasse 37, App. 16, CH-8006 Zürich (CH). RITTER, Tobias [DE/CH]; Neugasse 52, CH-8005 Zürich (CH). WERDER, Moritz [CH/CH]; Marktgasse 16, CH-5620 Bremgarten (CH).


- (74) Agent: CARRIERA, Andrea; Isler & Pedrazzini AG, Gotthardstrasse 53, Postfach 6940, CH-8023 Zürich (CH).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL HYPOCHOLESTEROLEMIC COMPOUNDS



(57) Abstract: The present invention relates to novel hypocholesterolemic compounds of formula (I) useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels as well as to pharmaceutical compositions comprising said compounds alone or in combination with other active agents.

1

Novel hypocholesterolemic compounds

The present invention relates to novel hypocholesterolemic compounds useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels as well as to pharmaceutical compositions comprising said compounds alone or in combination with other active agents.

Atherosclerotic coronary heart disease represents the major cause for death and cardiovascular morbidity in the western world. Risk factors for atherosclerotic coronary heart disease include hypertension, diabetes mellitus, family history, male gender, cigarette smoke as well as serum cholesterol. Elevated concentrations of serum cholesterol have been demonstrated by a number of clinical studies to be a major contributing factor in the development and progression of atherosclerosis, which is characterized by the formation of cholesterol-containing plaques in the aorta and lesser arteries.

In mammals, 1/3 of the serum cholesterol is derived from exogenous dietary sources which enters the body through absorption in the intestine and 2/3 of the serum cholesterol are derived through endogenous de novo synthesis in the liver involving a complex set of enzyme-catalyzed reactions and regulatory mechanisms.

Recently it has been shown that intestinal cholesterol absorption is an energy-independent, protein-mediated process (Hauser, H. et al, Biochemistry 1998, 37, 17843-17850; Schulthess, G. et al, Biochemistry 2000, 39, 12623-12631; Werder, M. et al, Biochemistry 2001, 40, 11643-11650) rather than a passive diffusion process. The proteins facilitating intestinal cholesterol absorption were identified as two brush border membrane-resident scavenger receptors (Hauser, H. et al, Biochemistry 1998, 37,

2

17843-17850; Werder, M. et al, Biochemistry 2001, 40, 11643-11650). Both in vitro and in vivo animal experiments confirmed the presence of these two scavenger receptors in the intestinal BBM and proved that they are responsible for the protein-mediated cholesterol uptake.

Various 2-azetidinone compounds have been reported as being useful in lowering cholesterol and/or in inhibiting the formation of cholesterol-containing lesions in mammalian arterial walls: For example WO 93/02048, WO 94/17038, WO 95/08532, PCT/US95/03196, U.S. Pat. No.5,633,246 describe 2-azetidinone compounds with different substituents at the 3-position, and U.S. Pat. No. 5,756,470 discloses 2-azetidinones having varying substituents at the 4 position. Other azetidinone derivatives include for example elastase inhibitory substituted azetidinones disclosed in European Patent 199,630B1 and European Patent Application 337,549A1. The most prominent representative of these 2-azetidinones, Ezetimibe (also known under trade names Zetia™ and Ezetrol®), has been in use as a cholesterol-lowering drug in monotherapy and in dual therapy combined with a statin. the first representative of the new class of cholesterollowering drugs that inhibit intestinal cholesterol absorption by targeting the two scavenger receptors in the intestinal brush border membrane described above.

However, it has been shown that the 2-azetidinones upon administration are readily absorbed and extensively metabolized into the pharmalogically active glucuronide of which over 95% remained in the intestinal wall upon direct administration as the glucuronide (van Heek, M. et al. Br. J. Pharmacol. 2000, 129, 1748-1754). In addition side effects such as allergic reactions including rash and angiodema have been reported.

Applicants have now discovered that the compounds of the present invention with the structural characteristics as depicted in formula I and in particular formulas II and III are able to inhibit the protein-mediated process mentioned above by which cholesterol absorption is mediated, while overcoming the above described disadvantages of compounds known in the art. Thus the compounds of the present invention are particularly useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels.

In a first aspect, the present invention thus relates to novel hypocholesterolemic compounds of formula I, and in particular to compounds of formulas II and III having a four- or five-membered ring, respectively.

In one embodiment, the present invention is directed to a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof,

wherein

P represents -N< or -C=,

X represents independently of each other $-CH_2-$, CR_1 (sp₂-hybridised), O, -NH-, =N-, -CO- or -CS-, wherein R_1 represents H or NR_2 , wherein R_2 represents H or lower alkyl, which optionally is linked to Z such that a bicyclic structure is formed;

n represents 1 or 2,

 R_a represents H, lower alkyl, $-OR_3$, $-O(CO)R_3$, $-O(CO)OR_3$, $-O(CO)NR_3R_4$, $-NR_3R_4$, $-NR_3(CO)R_4$, $-COOR_3$, $-CONR_3R_4$, $-COOR_3$

4

CH=CHCOOR $_3$, -CF $_3$, -CN, -NO $_2$, SO $_3$ H, PO $_3$ H or halogen, wherein R $_3$ and R $_4$ represent H or lower alkyl,

PCT/CH2004/000584

 R_b represents H, OH, $-OSO_2Me$, $-OSO_2W$ wherein W represents optionally substituted aryl or heteroaryl, $-OCO(CHOH)_2COOR_5$ wherein R_5 represents H or lower alkyl; or represents the formula $-Sp_3-R_6$,

wherein Sp_3 represents a covalent bond, -O-, $-OCH_2-$, $-OSO_2CH_2-$, $-OSO_2-$, $-OSO_2-$ (p) C_6H_4O- and R_6 represents one of carbohydrate structures A-D:

$$R_7O_{III}$$
 OR_8 OR_{11} OR_7 OR_8 OR_8 OR_8 OR_8 $OR_{12}O_{III}$ OR_9 $OR_{13}OR_7$ OR_8 $OR_{14}OR_9$ $OR_{14}OR_9$ $OR_{14}OR_{11}OR_9$ $OR_{14}OR_{11}OR_9$

wherein

 R_7 , R_8 , R_9 , R_{11} , R_{12} , R_{13} and R_{14} represent independently of each other H, lower alkyl, aryl(lower alkyl), -CO-lower alkyl, -CO-aryl, -SO₃ or -PO₃,

 R_{10} represents $-CH_2OR_{16}$ or $-COOR_{17}$, and

 R_{15} represents $-CH_2OR_{16}$, $-COOR_{17}$, $-CH_2NH_2$, $-CH_2OPO_3^-$ or $-CH_2OSO_3^-$, wherein R_{16} and R_{17} independently of each other represent H, lower alkyl, aryl(lower alkyl), -CO-lower alkyl, -CO-aryl, $-SO_3^-$ or $-PO_3^-$,

z represents optionally substituted anyl or heteroaryl,

sp₁ represents a spacer unit, such as a straight-chain or branched lower alkyl group $-(CH_2)_p$ -, wherein p is from 2-6, which is unsubstituted, mono or poly-substituted by -OH, $-OR_{18}$, halogen or cyano group, wherein one or more -CH₂- groups may independently be replaced by -O-, -CO-, -CO-,

sp₂ represents an optional spacer unit, such as a covalent bond or a straight-chain or branched lower alkyl group - $(CH_2)_{q^-}$, wherein q is from 1-6, which is unsubstituted, mono or poly-substituted by -OH, -OR₂₀, halogen or cyano group, wherein one or more -CH₂- groups may independently be replaced by -O-, -CO-, -CO-O-, -O-CO-, -NR₂₁-, -NR₂₁- CO-, -CO-NR₂₁-, -CH=CH-, -C \equiv C- -and wherein R₂₀ and R₂₁ represents a hydrogen atom or lower alkyl;

Y represents optionally substituted aryl or heteroaryl,

with the proviso, that if P = -N <, n=1, X = -CO- and Sp_2 represents a covalent bond, R_6 may not represent carbohydrate structures A or D for $Sp_3 = -O-$ and R_6 may not represent carbohydrate B for $Sp_3 = -OCH_2-$.

Preferably, if P = -N<, n=1, X = -CO- and Sp_2 represents a covalent bond, R_b may not represent H or OH and Sp_3 may not represent a covalent bond, -O- or -OCH₂-.

In a preferred embodiment, the present invention is directed towards compounds of formula I wherein P = -N <, n = 1 and X = -CO-, -CS-, $-CH_2-$ or -NH-.

Thus, the present invention is preferably directed towards compounds of formula IIa-d

Thus, the present invention is directed towards compounds of formula IIIa-f:

Thus, the present invention is further directed towards compounds of formula IIIg-h:

WO 2005/033100

8

PCT/CH2004/000584

 R_a preferably represents H, lower alkyl, $-OR_3$, $-NR_3R_4$, $-COOR_3$, $-COOR_3R_4$, $-CH=CHCOOR_3$, $-CF_3$, -CN, $-NO_2$, SO_3H , PO_3H or halogen, more preferably H, lower alkyl, $-OR_3$, $-NR_3R_4$, $-COOR_3$, $-CONR_3R_4$ or halogen, most preferably H, lower alkyl, $-OR_{19}$ or halogen, wherein R_3 and R_4 represent independently of each other H or lower alkyl.

 R_b preferably represents H, OH, $-OSO_2Me$, $-OSO_2W$ wherein W represents Phenyl (Ph) or isomers of salicylic acid (all combinations of disubstituted phenyl with OH and COOH substituents); or the formula $-Sp_3-R_6$, wherein Sp_3 preferably represents a covalent bond, -O-, $-OCH_2-$ or $-OSO_2CH_2-$ and R_6 represents one of carbohydrate structures A-D, preferably carbohydrate structures A, B or D. More preferably R_b represents H, OH, $-OSO_2Me$, $-OSO_2Ph$; or the formula $-Sp_3-R_6$, wherein Sp_3 preferably represents a covalent bond, -O-, $-OCH_2-$ or $-OSO_2CH_2-$ and R_6 represents one of carbohydrate structures A-D, preferably carbohydrate structures A, B or D.

 $\mathrm{Sp_1}$ preferably represents a straight-chain or branched $-(\mathrm{CH_2})_{\mathfrak{m}}$ -group, which is unsubstituted, mono or poly-substituted by $-\mathrm{OH}$, $-\mathrm{OR_{18}}$, halogen or cyano group, wherein $\mathrm{R_{18}}$ represents hydrogen or lower alkyl and m is 1 to 3. More preferably $\mathrm{Sp_1}$ represents a $-(\mathrm{CH_2})_3$ -, which is unsubstituted or substituted by $-\mathrm{OH}$ or halogen.

Sp₂ preferably represents a straight-chain or branched $-(CH_2)_p$ -group, which is unsubstituted, mono or poly-substituted by -OH, $-OR_{20}$, halogen or cyano group, wherein R_{20} represents hydrogen or lower alkyl and p is 1 to 3. More preferably Sp₁ represents an unsubstituted $-(CH_2)_p$ -, wherein p is 1 to 3, most preferably a covalent bond.

 R_{15} preferably represents $-CH_2OR_{16}$, $-COOR_{17}$ or $-CH_2NH_2$, wherein R_{16} and R_{17} independently of each other represent H, lower alkyl, aryl(lower alkyl), -CO-lower alkyl, -CO-aryl, $-SO_3$ or $-PO_3$, preferably H, acetyl or benzyl.

9

 R_7 , R_8 , R_9 , R_{11} , R_{12} , R_{13} , and R_{14} preferably represent independently of each other H, lower alkyl, aryl-lower alkyl, -CO-lower alkyl, -CO-aryl, more preferably, H, acetyl or benzyl.

The term "optionally substituted aryl group" should be understood to include an aromatic ring system having 4 to 10, preferably 5, 6 or 10 ring atoms. The aryl group can be substituted with one or more substituents, which may be the same or different, and are selected from a group as defined hereinafter. Non-limiting examples of suitable aryl groups include phenyl, naphthalene or tetraline groups, most preferably phenyl groups substituted by halogeno, preferably fluoro.

The term "optionally substituted heteroaryl" should be understood to include an aromatic ring system of 5 to 14, preferably 5 to 10, more preferably 5 to 6 or 10 ring atoms, in which one or more of the atoms in the ring system is/are atoms other than carbon, for example nitrogen, oxygen or sulfur. The heteroaryl can be optionally substituted by one or more substituents, which may be the same or different, and are selected from a group as defined hereinafter. Examples of suitable 6-membered heteroaryl groups include pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl and the like. Examples of useful 5-membered heteroaryl rings include furyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxazolyl and isoxazolyl. Useful bicyclic groups are benzo-fused ring systems derived from the heteroaryl groups named above, e.g., quinolyl, phthalazinyl, quinazolinyl, benzo-furanyl, benzothienyl and indolyl.

The term "lower alkyl" should be understood to include straight chain and branched hydrocarbon groups having from 1 to 8, preferably 1 to 6, more preferably from 1 to 3 carbon atoms, which may be optionally substituted. Non-limiting examples of suitable lower alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, fluoromethyl and trifluoromethyl.

WO 2005/033100

PCT/CH2004/000584

10

The term "branched" should be understood to represent a linear straight chain hydrocarbon group having one or more lower alkyl groups such as methyl, ethyl or propyl, attached to it.

The term "lower alkoxy" should be understood to include "lower alkyl-O-"-groups, wherein the lower alkyl groups are as described above and have from 1 to 8, preferably 1 to 6, more preferably from 1 to 3 carbon atoms. Methoxy, ethoxy and isopropoxy groups are especially preferred.

The term "aryl(lower alkyl)" should be understood to include an aryl(lower alkyl) group in which the aryl and lower alkyl are as previously described. Non-limiting examples of suitable aryl(lower alkyl) groups include benzyl, phenethyl and naphthlenylmethyl.

If not otherwise indicated, the term "optionally substituted" should be understood to represent substituents independently selected from the group consisting of aryl, heteroaryl, aryl(lower alkyl), (lower alkyl)aryl, aralkenyl, heteroaralkyl, alkylheteroaryl, heteroaralkenyl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halogen, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, aminoalkyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, preferably lower alkyl, hydroxy, lower alkoxy, cyano, alkylthio, amino, -NH(lower alkyl), -N(lower alkyl)2 (which alkyls can be the same or different), carboxy, -C(O)O-(lower alkyl) and halogen. Those skilled in the art will recognize that the size and nature of the substituent(s) will affect the number of substituents which can be present.

The term "halogen" should be understood to include fluoro, chloro, bromo. iodo, preferably, fluoro and chloro, most preferably, fluoro.

It is understood that all isomers, including enantiomers,

WO 2005/033100

stereoisomers, rotamers, tautomers and racemates of the compounds of formula I and in particular the compounds of formulas II and III are contemplated as being part of this invention. The invention includes stereoisomers in optically pure form and in admixture, including racemic mixtures. Isomers can be prepared using conventional techniques, either by reacting optically pure or optically enriched starting materials or by separating isomers of a compound of formula I and in particular the compounds of formulas II and III. In a preferred embodiment the stereochemistry in the central ring is such that the substituents at the 3- and 4-position are in trans configuration to each other.

In yet a further embodiment, preferred combinations of groups R_a and R_b include combinations wherein R_b is as defined hereinabove and is in para-position (in relation to the linker Sp_2) and R_a is as defined hereinabove, most preferably H, and is in metaposition.

Thus in a further preferred embodiment the present invention is directed towards a compound of formula IVa,

$$P_1$$
 P_2 P_3 P_4 P_5 P_6 P_8 P_8 P_8

IVa

wherein R_a , R_b , Sp_1 , Sp_2 , P, X, Y, Z and n are as defined hereinabove.

Such preferred combinations are thus compounds of formulas IIa-f and IIIa-h wherein R_b is as defined hereinabove and is in paraposition (in relation to the linker Sp_2) and R_a is as defined

PCT/CH2004/000584

hereinabove, most preferably H, and is in meta-position.

Further preferred embodiments include combinations, wherein Sp₂ is a covalent bond and Y and Z represent optionally substituted phenyl rings.

Thus in a further preferred embodiment the present invention is directed towards a compound of formula IVb,

$$R_{22}$$
 R_{21}
 R_{21}

dVI

wherein R_a , R_b , Sp_1 , P and X are as defined hereinabove and wherein R $_{21}$ and R_{22} preferably represent H, lower alkyl, lower alkoxy or halogen, most preferably in para-position.

Such combinations are thus compounds of formulas IIa-f and IIIa-h wherein Sp_2 is a covalent bond and Y and Z represent optionally substituted phenyl rings.

Compounds of formula I and in particular compounds of formulas
II and III may be prepared using methods of preparation kwnon in
the art and are described in the following paragraphs:

The 2-azetidinone portions of the compounds of formula II can be prepared by known methods, such as are disclosed in U.S. Pat. Nos. 5,631,365, 5,756,470, 5,767,115, 5,846,966, 6,207,822, U.S. Provisional Patent Application No. 60/279,288 filed Mar. 28, 2001, and PCT Patent Application WO 93/02048, each of which is incorporated herein by reference. Compounds of formula IIa according to the invention may then be obtained by further linkage

to appropriate carbohydrate structures using literature procedures as illustrated by the Examples.

13

Compounds of formula IIb may be obtained through conversion of β-lactams to thiolactams, most commonly performed with Lawesson's reagent (Verkoyen, C. and Rademacher, P. Chem. Ber. 1985, 118, 653-660; Yde, B. et al. Tetrahedron 1984, 40, 2047-2052; Steliou, K.; Mrani, M. J. Am. Chem. Soc. 1982, 104, 3104-3106; Clader, J. W. et al. J. Med. Chem. 1996, 39, 3684-3693).

Compounds of formula IIc may be obtained through conversion of β-lactams to azetidines, which may be achieved by a number of wellknown methods in the art, such as (1) direct one-step reduction with reducing agents of the composition AlH_xCl_{3-x}, such as chlorodihydroalane or alane (Jackson, M. B. et al. Aust. J. Chem. 1983, 36, 779), or diborane (Jackson, M. B. et al.; Aust. J. Chem. 1983, 36, 779-788), AlHCl₂ and DIBAL-H (Yamashita, M. and Ojima, I. J. Am. Chem. Soc. 1983, 105, 6339-6342; Ojima, I. et al. J. Org. Chem. 1991, 56, 5263-5277); and (2) cyclodehydration of 1,3-amino alcohols using various methods (Sohar, P. et al. Chem. Soc. Perkin Trans. 2 2000, 287-293; Suga, H. et al. S. J. Am. Chem. Soc. 1994, 116, 11197-11198; Barluenga, J. et al. Tetrahedron 1996, 52, 3095-3106; Obika, S. et al. Tetrahedron Lett. 2003, 44, 5267-5270) as also outlined in the Examples.

The preparation of compounds of formula IIIa is effected as outlined in Scheme I through initial Sharpless asymmetric amino hydroxylation reaction of the desired trans-1,2-disubstituted alkenes (Demko, Z. P. et al. Org. Lett. 2000, 2, 2221-2223; O'Brien, P. Angew. Chem. Int. Edit. Engl. 1999, 38, 326-329; Bodkin, J. A.; McLeod, M. D. J. Chem. Soc. Perkin Trans. 1 2002, 2733-2746), followed by chromatographic separation to obtain the desired regioisomeric product. Subsequent cleavage of the paratoluene sulfonamide group furnishes a primary amine which upon Buchwald-Hartwig arylation reaction (Hartwig, J. F. Acc. Chem. Res. 1998, 31, 852-860; Wolfe, J. P.; Wagaw, S.; Marcoux, J. F.;

WO 2005/033100

Buchwald, S. L. Acc. Chem. Res. 1998, 31, 805-818) and subsequent exposure to triphosgene eventually leads to the formation of the desired oxazolidinones of formula IIIa. Alternatively, they can be accessed as outlined in the Examples.

Scheme 1

Compounds of formula IIIe may be obtained e.g. as illustrated in Scheme II using known methods in the art (Mish, M. R. et al. J. Am. Chem. Soc. 1997, 119, 8379-8380; Guerra, F. M. et al. Org. Lett. 2000, 2, 4265-4267). Alternatively, compounds in which sp₂ is not a covalent bond can be synthesized as demonstrated in the Examples.

Scheme II

The preparation of pyrazolidinones of formula IIIc proceeds in an analogous strategy to that reported in the literature as illustrated in Scheme III (Lou, B. S. et al. J. Org. Chem. 1995, 60, 5509-5514; Tomkinson, N. C. O. Rodd's Chemistry of Carbon Compounds (2nd Edition), Asymmetric Catalysis, Ed. M. Sainsbury 2001, 5, 199-258).

$$Ar_3$$
 OTBS Ar_3 OTBS Ar_3 OTBS Ar_3 OTBS Ar_3 OTBS Ar_4 Ar_5 Ar_5 Ar_5 Ar_7 Ar_8 Ar_8 Ar_8 Ar_8 Ar_8 Ar_8 Ar_8 Ar_8 Ar_9 $Ar_$

Scheme III

It has been found that the use of sulfonate linkages in e.g. the Rb or Sp3 group, i.e. linking carbohydrates to the phenylene ring is particularly beneficial in that the S=O double bonds in the linkages may function as hydrogen bond acceptors compared to the more non-polar nature of a C-glycoside linkage. Such linkages have not yet been reported to link carbohydrates to other kinds of molecules. Furthermore the linkages are non-hydrolyzable, i.e. the carbohydrates are not hydrolyzed off.

It has further been shown that the compounds of the invention display superior pharmacological activities and are able to overcome the drawbacks of known cholesterol-lowering agents using well-established methods in the art, e.g. evaluation of their IC₅₀ value for cholesterol uptake in rabbit brush border membrane vesicles (BBMV) as well as in Caco-2 cells (Hauser, H. et al, Biochemistry 1998, 37, 17843-17850; Schulthess, G. et al, Biochemistry 2000, 39, 12623-12631; Werder, M. et al, Biochemistry 2001, 40, 11643-11650; Boffelli, D. et al. FEBS Lett. 1997,

16

411, 7-11) (see also Table I).

Thus, the compounds of the invention, e.g. compounds of formula I and their pharmaceutically acceptable acid addition salts, exhibit pharmacological activity and are, therefore, useful as pharmaceuticals. The compounds of the invention have been shown to effectively inhibit cholesterol absorption and are therefore useful in the treatment and/or prevention of atherosclerosis and of the reduction of cholesterol levels.

Thus in yet a further aspect, the present invention is directed to a method of treatment and/or prevention of atherosclerosis, of the reduction of cholesterol levels and of treating or preventing a vascular condition, comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I and in particular a compound of formulas II and III.

The novel compounds of formula I can be used, for example, in the form of pharmaceutical compositions containing a therapeutically effective amount of the active ingredient, if appropriate together with inorganic or organic, solid or liquid, pharmaceutically acceptable carriers suitable for enteral, e.g. oral, or parenteral administration. Accordingly, tablets or gelatin capsules are used that contain the active ingredient together with diluents, typically lactose, dextrose, saccharose, mannitol, sorbitol, cellulose and/or lubricants, e.g. diatomaceous earth, talcum, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol. Tablets may also contain binders, typically magnesium aluminium silicate, starches, typically corn starch, wheat starch, rice starch or arrow root starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and, if desired, disintegrators, typically starches, agar, alginic acid or a salt thereof, e.g. sodium alginate, and/or effervescent mixtures, or absorbents, colourants, flavourings and

sweeteners.

WO 2005/033100

Thus in another aspect, the invention relates to a pharmaceutical composition comprising a compound of formula I, and in particular a compound of formulas II and III (and optionally other therapeutically effective agents), and a pharmaceutically acceptable carrier for the treatment or prevention of artheriosclerosis or for the reduction of cholesterol levels.

17

PCT/CH2004/000584

The terms "effective amount" and "therapeutically effective amount" mean that amount of a compound of formula I and in particular compounds of formulas II and III (and optionally other therapeutically effective agents), that will elicit a biological or medical response of a tissue, system, animal or mammal, which includes alleviation of the symptoms of the condition or disease being treated and the prevention, slowing or halting of progression of one or more conditions, for example atherosclerosis, hypercholesterolemia.

The pharmaceutical compositions so obtained which, if desired, contain further pharmacologically active substances, are prepared in a manner known per se by conventional mixing, granulating, sugar-coating, solution or lyophilising methods and contain from about 0.1% to 100%, preferably from about 1% to about 50%, lyophilisate to about 100%, of active ingredient.

The compounds, compositions and treatments of the present invention can be administered by any suitable means which produce contact of these compounds with the site of action in the body, for example in the plasma, liver or small intestine of a mammal or human. Thus the novel compounds of formula I may also be used in the form of compositions for parenteral, oral, transdermal administration or infusion solutions. Such solutions are preferably isotonic aqueous solutions or suspension which, e.g. in the case of lyophilised compositions that contain the active ingredient by itself or together with a carrier, such as manni-

18

tol, can be prepared before use. The pharmaceutical compositions can be sterilised and/or can contain excipients, typically preservatives, stabilisers, wetting agents and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers.

In yet a further aspect, the invention relates to a kit comprising an effective amount of a compound of formula I and in particular a compound of formulas II and III in a pharmaceutically acceptable carrier (and optionally an effective amount of another therapeutically effective agent), optionally in separate compartments.

The following non-limiting Examples illustrate the abovedescribed invention in more detail.

EXAMPLES

Materials and Methods: Reactions in anhydrous solvents were all performed using oven dried glassware under an atmosphere of ar-Reagent grade solvents were all purchased from chemical qon. companies and used without prior purification. For chromatic purification, technical grade solvents were distillated prior to use. TLC was performed using Machery-Nagel Alugram Sil G/UV254 TLC plates and visualized with ultraviolet light at 254 nm and 12 g phosphor molybdic acid in 250 mL EtOH or 10% H₂SO₄ in MeOH (v/v). Chromatographic purification of products was accomplished using dry column vacuum chromatography on Merck Silica Gel 60 (15 - 40 μm) according to literature procedures (Pedersen, D. S. and Rosenbohm, C. Synthesis 2001, 2431-2434); fractions containing product were pooled, the solvents were evaporated under reduced pressure and the residue was dried under high vacuum to give the product. NMR spectra were recorded on a Varian Mercury 300MHz apparatus operating at 300 MHz and 75 MHz for ¹H and ¹³C,

19

respectively, and chemical shifts (δ) were referenced to the internal solvent signals. IR-Spectra were recorded in CHCl₃ on a Perkin Elmer Spectrum RX I FT-IR apparatus (thin films on NaCl plates) and are reported as absorption maxima in cm⁻¹. Elemental analysis was performed by the Mikroelementaranalytisches Laboratorium at the ETH, Zürich. High resolution matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) was recorded in positive ion mode.

20

Example 1

V

LiAlH₄ (114 mg, 3.0 mmol) and AlCl₃ (390 mg, 2.9 mmol) were suspended in anhydrous ether (15 mL) and refluxed for 30 min. Trans-1-(4-fluorophenyl)-3-[(3-phenyl)-propyl]-4-phenyl-2-azetidinone (361 mg, 1.00 mmol; prepared according to Browne, M. et al. Tetrahedron Lett. **1995**, 36, 2555-2558) dissolved in anhydrous ether (15 mL) was added and after stirring at reflux for 30 min, the suspension was cooled and H_2O (5 mL) was added dropwise followed by addition of 50% sat. aq. NaHCO₃ (30 mL). The layers were separated, the aqueous layer was extracted with EtOAc/hexane and ether and the combined organic layer was washed successively with sat. aq. NaHCO₃ (20 mL) and H_2O (20 mL), evaporated on celite and purified by dry column vacuum chromatography (3.7 x 3.3 cm) on silica gel eluting with a gradient of 0-10% EtOAc in hexane (v/v) to give the desired compound **V** (281 mg, 81%) as a colourless oil.

¹H-NMR (300 MHz, CDCl₃) δ : 7.51-7.14 (10H, m), 6.87 (2H, t, J = 8.7 Hz), 6.38 (2H, dd, J = 4.7, 9.0 Hz), 4.46 (1H, d, J = 6.8 Hz), 4.17 (1H, t, J = 6.8 Hz), 3.35 (1H, dd, J = 6.8, 7.5 Hz), 2.69-2.58 (3H, m), 1.85-1.56 (4H, m). ¹³C-NMR (75 MHz, CDCl₃) δ : 157.64, 154.52, 148.53, 142.69, 141.95 (C), 128.66, 128.25, 127.47, 125.99, 125.73, 115.41, 115.12, 113.04, 112.94 (CH), 74.37 (CH), 56.05 (CH₂), 42.09 (CH), 35.85, 33.52, 28.92 (CH₂). IR (cm⁻¹): 3026, 2933, 2852, 1603, 1508, 1473, 1453, 1321, 1222, 1120, 823, 773, 747, 699. MALDI-MS (C₂₄H₂₄FN): [MH]⁺ 346.1982 (calcd. 346.1971). Anal. Calcd for C₂₄H₂₄FN: C, 83.44; H, 7.00; N,

21

4.05. Found: C, 83.45; H, 7.06; N, 4.27.

Example 2

WO 2005/033100

VI

a)

VIa

Ezetimibe (commercially obtained or synthesized according to Wu, G. Z. et al., J. Org. Chem. 1999, 64, 3714-3718) (5.530 g, 13.5 mmol) was suspended in 2-propanol (70 mL), aq. NaOH (2M, 15 mL) followed by Ac_2O (3.0 mL, 32 mmol) were added and the solution was stirred for 5 h followed by addition of sat. aq. NaHCO₃ (200 mL). After extraction with EtOAc (4 x 50 mL), the combined organic layer was washed successively with sat. aq. NaHCO₃ (50 mL) and H_2O (50 mL), evaporated on celite and purified by dry column vacuum chromatography (5.2 x 5.5 cm) on silica gel eluting with a gradient of 0-100% EtOAc in hexane (v/v) to give the corresponding azetidinone acetate (5.930 g, 97%) as a white foam.

¹H-NMR (300 MHz, CDCl₃) δ : 7.31 (2H, d, J = 8.7 Hz), 7.29-7.18

WO 2005/033100

(4H, m), 7.09 (2H, d, J = 8.7 Hz), 6.99 (2H, t, J = 8.7 Hz), 6.92 (2H, t, J = 8.7 Hz), 4.67 (1H, bs), 4.61 (1H, d, J = 2.5 Hz), 3.08-3.04 (1H, m), 2.75 (1H, bs), 2.29 (3H, s), 1.97-1.85 (4H, m). 13 C-NMR (75 MHz, CDCl₃) δ : 169.16, 167.23, 163.56, 160.46, 160.32, 157.24, 150.58, 139.94, 139.90, 134.85, 133.53, 133.50 (C), 127.32, 127.21, 126.78, 122.38, 118.34, 118.23, 115.95, 115.65, 115.35, 115.07 (CH), 72.95, 60.81, 60.33 (CH), 36.61, 25.07 (CH₂), 21.19 (CH₃). IR (cm⁻¹): 3443, 3019, 2936, 2862, 1747, 1605, 1509, 1427, 1388, 1370, 1221, 1198, 1157, 1016, 835, 757, 668. MALDI-MS (C₂₆H₂₃F₂NO₄): [MH-H₂O]⁺ 434.1556 (calcd. 434.1568); [MNa]⁺ 474.1485 (calcd. 474.1493))

22

PCT/CH2004/000584

Subsequently the acetate (1.864 g, 4.13 mmol) was dissolved in anhydrous DMF (25 mL), imidazole (939 mg, 13.8 mmol) and TBDMSCl (1.853 g, 12.3 mmol) were added sequentially and the solution was stirred for 3 h followed by addition of 50% sat. aq. NaHCO₃ (150 mL). After extraction with EtOAc (4 x 40 mL), the combined organic layer was washed successively with sat. aq. NaHCO₃ (40 mL) and H_2O (40 mL), evaporated on celite and purified by dry column vacuum chromatography (4.2 x 5.5 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give the corresponding silylated azetidinone acetate (2.137 g, 91%) as a colourless oil.

¹H-NMR (300 MHz, CDCl₃) δ: 7.31 (2H, d, J = 8.7 Hz), 7.26-7.20 (4H, m), 7.10 (2H, d, J = 8.7 Hz), 6.98 (2H, t, J = 8.7 Hz), 6.91 (2H, t, J = 8.7 Hz), 4.67 (1H, t, J = 5.3 Hz), 4.58 (1H, d, J = 1.9 Hz), 3.06-3.02 (1H, m), 2.28 (3H, s), 1.96-1.80 (4H, m), 0.88 (9H, s), 0.02 (3H, s), -0.16 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ: 169.16, 167.06, 163.42, 160.47, 160.16, 157.23, 150.62, 140.50, 135.10, 133.74, 133.70 (C), 127.26, 127.14, 126.77, 122.37, 118.27, 118.16, 115.89, 115.58, 115.03, 114.76 (CH), 73.74, 60.67, 60.53 (CH), 37.94 (CH₂), 25.73 (CH₃), 24.55 (CH₂), 20.99 (CH₃), 18.07 (C), -4.74, -5.05 (CH₃). IR (cm⁻¹): 2953, 2930, 2857, 1752, 1606, 1510, 1472, 1426, 1385, 1370, 1252, 1219,

23

1197, 1166, 1140, 1102, 1086, 1015, 912, 835, 777, 736. MALDI-MS: [MH-TBDMSOH] + 434.1556 (calcd. 434.1568); [MNa] + 588.2347 (calcd. 588.2358). Anal. Calcd for C₃₂H₃₇F₂NO₄Si: C, 67.94; H, 6.59; N, 2.48. Found: C, 67.94; H, 6.64; N, 2.37)

The silylated azetidinone acetate (5.123 g, 9.06 mmol) was dissolved in CH_2Cl_2 (200 mL), neutral alumina (50 g) was added and the suspension was evaporated to dryness. The coated alumina was dried shortly under vacuum and then heated to $70^{\circ}C$ for 5.5 h. After cooling, the alumina was extracted with 10% MeOH in CH_2Cl_2 (8 x 50 mL) and the combined organic extracts were evaporated on celite and purified by dry column vacuum chromatography (5.4 x 5.5 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give the silylated azetidinone phenol **VIa** (3.919 g, 83%) as a white foam.

¹H-NMR (300 MHz, CDCl₃) δ: 7.26-7.14 (6H, m), 6.99-6.83 (6H, m), 6.16 (1H, bs), 4.65 (1H, t, J = 5.3 Hz), 4.52 (1H, d, J = 1.9 Hz), 3.04-2.98 (1H, m), 1.92-1.76 (4H, m), 0.86 (9H, s), 0.00 (3H, s), -0.17 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ: 167.82, 163.28, 160.42, 156.12, 140.50, 140.45, 133.57 (C), 128.92, 127.19, 127.15, 127.08, 118.43, 118.32, 116.05, 115.85, 115.55, 115.01, 114.72 (CH), 73.82, 61.17, 60.35 (CH), 38.07 (CH₂), 25.89 (CH₃), 24.68 (CH₂), 18.25 (C), -4.54, -4.84 (CH₃). IR (cm⁻¹): 3351, 2953, 2938, 2857, 1722, 1615, 1604, 1510, 1450, 1391, 1361, 1252, 1223, 1156, 1103, 1087, 863, 834, 776, 760. MALDI-MS: [MH-TBDMSOH] 392.1451 (calcd. 392.1462); [MH] 524.2409 (calcd. 524.2433); [MNa] 546.2242 (calcd. 546.2252). Anal. Calcd for $C_{30}H_{35}F_{2}NO_{3}Si$: C, 68.81; H, 6.74; N, 2.67. Found: C, 68.61; H, 6.82; N, 2.66.

24

b)

VIb

The silylated azetidinone phenol VIa (176 mg, 0.336 mmol) was dissolved in anhydrous CH_2Cl_2 (10 mL), anhydrous pyridine (0.5 mL) followed by MsCl (0.1 mL, 1.29 mmol) were added and the solution was stirred for 22 h, diluted with EtOAc (50 mL) and washed sequentially with sat. aq. $NaHCO_3$ (20 mL) and H_2O (20 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.2x3.3 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give the intermediate mesylate VIb (195.5 mg, 92%) as a colourless oil.

¹H-NMR (300 MHz, CDCl₃) δ : 7.35 (2H, d, J = 8.7 Hz), 7.28 (2H, d, J = 8.7 Hz), 7.26-7.18 (4H, m), 6.98 (2H, t, J = 8.7 Hz), 6.93 (2H, t)(2H, t, J = 8.7 Hz), 4.67 (1H, dd, J = 4.4, 6.2 Hz), 4.59 (1d, J = 1.9 Hz), 3.16 (3H, s), 3.04-3.00 (1H, m), 1.93-1.79 (4H, m), 0.87 (9H, s), 0.01 (3H, s), -0.16 (3H, s). 13 C-NMR (75 MHz, $CDC1_3$) δ : 166.83, 163.46, 160.57, 160.21, 157.34, 148.88, 140.53, 140.49, 137.07, 133.59, 133.56 (C), 127.36, 127.28, 127.18, 122.94, 118.26, 118.16, 116.04, 115.73, 115.10, 114.81 (CH), 73.79, 60.67, 60.41 (CH), 37.97 (CH₂), 37.59, 25.76 (CH₃), 24.60 (CH_2) , 18.11 (C), -4.71, -5.02 (CH_3) . IR (cm^{-1}) : 2952, 2931, 2857, 1752, 1605, 1509, 1371, 1252, 1220, 1176, 1153, 1102, 1086, 971, 871, 777. MALDI-MS: [MH-TBDMSOH] * 470.1228 835, (calcd. 470.12376); [MNa] + 624.2029 (calcd. 624.2027). Anal. Calcd for $C_{31}H_{37}F_{2}NO_{5}SiS: C$, 61.87; H, 6.20; N, 2.33. Found: C, 61.69; H, 6.19; N, 2.15).

25

c)

The intermediate mesylate received in the previous step (67.7 mg, 0.112 mmol) was dissolved in THF (2 mL), TBAF (0.2 mL, 1M in THF) was added and the solution was stirred for 1.5 h, diluted with EtOAc (20 mL) and washed successively with sat. aq. NaHCO $_3$ (10 mL) and H $_2$ O (10 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.2 x 2.0 cm) on silica gel eluting with a gradient of 0-90% EtOAc in hexane (v/v) to give the desired mesylated azetidinone **VI** (37.0 mg, 68%) as a white solid after coevaporation with hexane (10 mL).

¹H-NMR (300 MHz, CDCl₃) δ : 7.37-7.17 (8H, m), 7.03-6.91 (4H, m), 4.69 (1H, t, J = 5.9 Hz), 4.65 (1H, d, J = 1.9 Hz), 3.16 (3H, s), 3.07-3.01 (1H, m), 2.63 (1H, bs), 2.03-1.84 (4H, m). ¹³C-NMR (75 MHz, CDCl₃) δ : 167.11, 163.76, 160.68, 160.50, 157.44, 148.89, 139.92, 136.86, 133.41 (C), 127.40, 127.27, 122.98, 118.35, 118.24, 116.10, 115.79, 115.45, 115.18, 115.11 (CH), 73.03, 60.48, 60.41 (CH), 37.63 (CH₃), 36.48, 25.00 (CH₂). IR (cm⁻¹): 3428, 2937, 1744, 1604, 1510, 1426, 1369, 1221, 1176, 1152, 1103, 1016, 971, 912, 872, 835, 788, 734. MALDI-MS: [MH-H₂Ol⁺ 470.1239 (calcd. 470.1238); [MNal⁺ 510.1164 (calcd. 510.1163). Anal. Calcd for $C_{25}H_{23}F_{2}NO_{5}S$: C, 61.59; H, 4.75; N, 2.87. Found: C, 61.79; H, 4.89; N, 2.76.

Example 3

PCT/CH2004/000584

LiAlH₄ (58 mg, 1.5 mmol) and AlCl₃ (202 mg, 1.5 mmol) were suspended in anhydrous ether (15 mL), refluxed for 30 min and cooled to 0°C. The mesylate **VIb** obtained in step 2b) (195.5 mg, 0.325 mmol) dissolved in anhydrous ether (5 mL) was added and after stirring at 0°C for 15 min, sat. aq. NaHCO₃ (1 mL) was added dropwise. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.6 x 3.3 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give the intermediate silylated azetidine (146.4 mg, 77%) as a colourless oil.

 1 H-NMR (300 MHz, CDCl₃) δ : 7.49 (2H, d, J = 8.7 Hz), 7.30 (2H, d, J = 8.7 Hz), 7.18 (2H, dd, J = 5.0, 8.7 Hz), 6.98 (2H, t, J =8.7 Hz), 6.85 (2H, t, J = 8.7 Hz), 6.31 (2H, dd, J = 4.4, 9.3 Hz), 4.58 (1H, t, J = 5.3 Hz), 4.40 (1H, d, J = 6.8 Hz), 4.11(1H, t, J = 7.2 Hz), 3.28 (1H, t, J = 7.2 Hz), 3.17 (3H, s),2.56-2.49 (1H, m), 1.77-1.50 (4H, m), 0.88 (9H, s), 0.01 (3H, s), -0.15 (3H, s). $^{13}C-NMR$ (75 MHz, $CDCl_3$) δ : 163.22, 159.99, 157.69, 154.57, 148.23, 148.07, 141.97, 140.62 (C), 127.13, 127.03, 122.25, 115.43, 115.13, 114.96, 114.68, 113.00, 112.90 (CH), 73.86, 73.29 (CH), 55.88 (CH₂), 41.88 (CH), 37.90 (CH_2) , 37.43 (CH_3) , 29.43 (CH_2) , 25.85 (CH_3) , 18.24 (C), -4.53, -4.88 (CH₃). IR (cm⁻¹): 2932, 2856, 1605, 1509, 1473, 1372, 1331, 1252, 1222, 1198, 1171, 1151, 1090, 970, 870, 836, 776. MALDI-MS: [MH-TBDMSOH] + 456.1442 (calcd. 456.14449); [MNa] + 610.2236 (calcd. 610.22348). Anal. Calcd for $C_{31}H_{39}F_2NO_4SiS$: C, 63.34; H, 6.69; N, 2.38. Found: C, 63.49; H, 6.87; N, 2.33.

This intermediate silylated azetidine (146.3 mg, 0.249 mmol) was dissolved in anhydrous THF (5.0 mL, teflon bottle) at 0°C, anhydrous pyridine (1.0 mL) followed by HF·pyridine complex (1.0 mL) were added and the solution was stirred at 0°C for 1 h and at room temperature for 7 h, diluted with ether (30 mL) and washed with sat. aq. NaHCO₃ (3 x 10 mL). The organic layer was evapo-

rated on celite and purified by dry column vacuum chromatography $(4.2 \times 2.0 \text{ cm})$ on silica gel eluting with a gradient of 0-90% EtOAc in hexane (v/v) to give the desired mesylated azetidine VII (100.0 mg, 85%) as a white foam.

¹H-NMR (300 MHz, CDCl₃) δ : 7.50 (2H, d, J = 8.7 Hz), 7.28 (2H, d, J = 8.7 Hz), 7.22 (2H, dd, J = 5.6, 8.7 Hz), 7.01 (2H, t, J = 8.7 Hz), 6.84 (2H, t, J = 8.7 Hz), 6.30 (2H, dd, J = 4.3, 9.3 Hz), 4.57 (1H, t, J = 5.6 Hz), 4.41 (1H, d, J = 6.8 Hz), 4.12 (1H, t, J = 6.8 Hz), 3.30 (1H, dd, J = 6.8, 7.5 Hz), 3.16 (3H, s), 2.55 (1H, dt, J = 6.8, 7.5 Hz), 1.93 (1H, bs), 1.88-1.53 (4H, m). ¹³C-NMR (75 MHz, CDCl₃) δ : 163.62, 160.37, 157.74, 154.61, 148.22, 148.01, 141.89, 139.95, 139.91 (C), 127.46, 127.28, 127.17, 122.29, 115.46, 115.42, 115.13, 113.02, 112.92 (CH), 73.43, 73.28 (CH), 55.92 (CH₂), 41.81 (CH), 37.49 (CH₃), 36.28, 29.85 (CH₂). IR (cm⁻¹): 3416, 2938, 2853, 1508, 1367, 1221, 1196, 1171, 1149, 970, 871, 823. MALDI-MS (C₂₅H₂₅F₂NO₄S): [MH-H₂O]⁺ 456.1447 (calcd. 456.1445); [M]⁺ 473.1481 (calcd. 473.1472); [MNa]⁺ 496.1380 (calcd. 496.1370).

Example 4

VIII

The silylated azetidinone phenol **VIa** obtained in step 2a) (143 mg, 0.273 mmol) and C-(hydroxymethyl)-2,3,4,6-tetra-O-benzyl- β -D-

WO 2005/033100

28

PCT/CH2004/000584

glucopyranoside (prepared according to RajanBabu, T. V. and Reddy, G. S. J. Org. Chem. 1986, 51, 5458-5461; 180 mg, 0.325 mmol) were dissolved in anhydrous THF (10 mL) at 0°C, Bu₃P (0.20 mL, 0.80 mmol) and 1,1'-(azodicarbonyl)dipiperdine (206 mg, 0.82 mmol) were added sequentially and the suspension was allowed to warm to ambient temperature over several hours and stirred for 24 h. EtOAc/hexane (1:4 (v/v), 20 mL) was added, the suspension was filtered through celite (2 x 10 mL EtOAc/hexane (1:4 (v/v)) washings) and the filtrate was evaporated on celite and purified by dry column vacuum chromatography (4.1 x 3.3 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give the corresponding C-glycoside (60.1 mg, 21%) as a colourless oil.

¹H-NMR (300 MHz, CDCl₃) δ : 7.37-7.17 (26H, m), 7.04-6.89 (6H, m), 4.96 (2H, bs), 4.89 (1H, d, J = 9.3 Hz), 4.86 (1H, d, J = 8.7Hz), 4.69 (1H, t, J = 5.3 Hz), 4.63-4.53 (5H, m), 4.21 (1H, d, J= 10.6 Hz), 4.10 (1H, dd, J = 5.0, 10.6 Hz), 3.85-3.52 (7H, m), 3.07-3.02 (1H, m), 2.01-1.78 (4H, m), 0.91 (9H, s), 0.05 (3H, s), -0.13 (3H, s). 13 C-NMR (75 MHz, CDCl₃) δ : 167.25, 158.74, 140.53, 140.49, 138.29, 137.85, 137.79, 137.65, 133.81 (C), 129.53, 128.32, 128.28, 128.18, 127.96, 127.81, 127.78, 127.74, 127.66, 127.54, 127.48, 127.18, 127.08, 126.90, 118.22, 118.12, 115.77, 115.47, 115.30, 114.98, 114.70 (CH), 87.12, 79.14, 78.25, 77.87, 77.71 (CH), 75.56, 75.11, 75.03 (CH₂), 73.82 (CH), 73.44, 68.93, 67.23 (CH₂), 61.02, 60.47 (CH), 38.10 (CH₂), 25.89 (CH_3) , 24.71 (CH_2) , 18.24 (C), -4.54, -4.83 (CH_3) . IR (cm^{-1}) : 2951, 2929, 2858, 1749, 1608, 1510, 1454, 1386, 1361, 1250, 1223, 1156, 1141, 1101, 1028, 911, 835, 777, 735, 699. MALDI-MS $(C_{65}H_{71}F_2NO_8Si): [MNa]^+ 1082.4831 (calcd. 1082.4815).$

This C-Glycoside (72 mg, 0.068 mmol) was subsequently dissolved in EtOH (5 mL), $Pd(OH)_2/C$ (20% (w/w), 40 mg) was added and the suspension was evacuated 4 times with H_2 and stirred under an H_2 -atmosphere for 17 h. The suspension was evaporated on celite and

purified by dry column vacuum chromatography (3.8 x 2.0 cm) on silica gel eluting with a gradient of 0-100% EtOAc in hexane followed by 10% MeOH in CH_2Cl_2 (v/v) to give the debenzylated C-glycoside (28 mg, 59%) as colourless oil.

¹³C-NMR (75 MHz, CDCl₃) δ : 167.22, 163.28, 160.05, 158.36, 157.03, 140.57, 133.75, 130.30, 129.52, 127.22, 127.11, 118.23, 115.83, 115.54, 116.35, 115.05, 114.91, 114.76, 79.16, 78.33, 77.70, 73.88, 70.18, 69.52, 67.75, 61.54, 60.79, 60.57, 38.14, 25.91, 24.81, 18.27, -4.51, -4.80. IR (cm⁻¹): 3391, 2930, 2858, 1747, 1609, 1510, 1387, 1362, 1223, 1140, 1086, 1043, 1014, 835, 758. MALDI-MS ($C_{37}H_{47}F_{2}NO_{8}Si$): [MH-TBDMSOH] + 568.2132 (calcd. 568.2147); [MNa] + 722.2939 (calcd. 722.2937).

Subsequently , the debenzylated C-Glycoside (27.0 mg, 0.039 mmol) was dissolved in THF (1.0 mL), TBAF (0.2 mL, 1M in THF) was added and the solution was stirred for 15 h, diluted with CH_2Cl_2 , evaporated on celite and purified by dry column vacuum chromatography (3.5 x 2.0 cm) on silica gel eluting with a gradient of 0-18% MeOH in CH_2Cl_2 (v/v) to give the desired C-glycoside VIII (14.0 mg, 62%) as a white solid after coevaporation with hexane (10 mL).

¹H-NMR (300 MHz, CD₃OD) δ : 7.33-7.23 (6H, m), 7.05-6.94 (6H, m), 4.78 (1H, d, J = 1.9 Hz), 4.59 (1H, t, J = 5.3 Hz), 4.29 (1H, dd, J = 1.5, 10.3 Hz), 4.13 (1H, dd, J = 5.6, 10.6 Hz), 3.85 (1H, d, J = 11.2 Hz), 3.67-3.61 (1H, m), 3.57-3.51 (1H, m), 3.44-3.37 (2H, m), 3.31-3.28 (2H, m), 3.11-3.06 (1H, m), 1.97-1.81 (4H, m). ¹³C-NMR (75 MHz, CD₃OD) δ : 169.20, 160.12, 130.69, 128.36, 128.25, 128.14, 119.52, 119.41, 116.35, 116.04, 115.93, 115.63, 115.35, 81.55, 79.49, 79.39, 73.35, 71.30, 71.23, 68.77, 62.66, 61.74, 60.86, 37.22, 25.84. MALDI-MS (C₃₁H₃₃F₂NO₈): [MH-TBDMSOH] ⁺ 568.2143 (calcd. 568.2147); [MNa] ⁺ 608.2073 (calcd. 608.2072).

30

Example 5

IX

a)

IXa

Methyl 2,3,4-Tri-O-benzyl- α -D-glucopyranoside (prepared according to Jaramillo, C. et al; Chiara, J. L.; Martinlomas, M. J. Org. Chem. 1994, 59, 3135-3141; 1.181 g, 2.54 mmol) was dissolved in anhydrous CH_2Cl_2 (25 mL) at 0°C, anhydrous pyridine (3.0 mL) followed by MsCl (0.50 mL, 6.4 mmol) were added and the solution was stirred at 0°C for 1 h and at room temperature for 7 h followed by addition of sat. aq. NaHCO₃ (50 mL). The layers were separated and the aqueous layer extracted with EtOAc (3 x 25 mL). The combined organic layer was washed successively with sat. aq. NaHCO₃ (25 mL) and H₂O (25 mL), evaporated on celite and purified by dry column vacuum chromatography (4.1 x 3.3 cm) on silica gel eluting with a gradient of 0-100% CH_2Cl_2 in hexane (v/v) followed by 0.25-1.0% MeOH in CH_2Cl_2 (v/v) to give the corresponding mesylate (1.303 g, 94%) as a colourless oil after coevaporation with acetonitrile (3 x 10 mL).

¹H-NMR (300 MHz, CDCl₃) δ : 7.39-7.26 (15H, m), 5.02 (1H, d, J = 10.6 Hz), 4.92 (1H, d, J = 10.6 Hz), 4.84 (1H, d, J = 10.6 Hz), 4.80 (1H, d, J = 12.5 Hz), 4.66 (1H, d, J = 11.8 Hz), 4.63 (1H, d, J = 10.6 Hz), 4.60 (1H, d, J = 3.7 Hz), 4.41-4.32 (2H, m), 4.02 (1H, t, J = 9.3 Hz), 3.85 (1H, dt, J = 3.7, 10.0Hz), 3.52 (1H, dt, J = 3.7, 6.2 Hz), 3.50 (1H, bs), 3.39 (3H, s), 2.98 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ : 138.30, 137.75, 137.56 (C), 128.36, 128.30, 127.94, 127.84, 127.76, 127.57 (CH), 98.06, 81.73, 79.69, 76.86 (CH), 75.73, 75.09, 73.44 (CH₂), 68.59 (CH), 68.36 (CH₂), 55.46, 37.54 (CH₃). IR (cm⁻¹): 3031, 2913, 1497, 1454, 1359, 1177, 1089, 1074, 1046, 1003, 965, 931, 813, 739, 699. MALDI-MS: [MNa] ⁺ 565.1873 (calcd. 565.1872). Anal. Calcd for C₂₉H₃₄O₈S: C, 64.19; H, 6.32. Found: C, 63.99; H, 6.27.

31

Subsequently, this mesylate (1.290 g, 2.38 mmol) was dissolved in EtOH (25 mL), KOSCMe (869 mg, 7.61 mmol) was added and the unclear solution was stirred at reflux for 4 h (orange precipitate). After cooling, 50% sat. aq. NaHCO3 (100 mL) was added and the suspension was extracted with EtOAc (3 x 50 mL). The combined organic layer was washed successively with sat. aq. NaHCO3 (50 mL) and $\rm H_2O$ (50 mL), evaporated on celite and purified by dry column vacuum chromatography (4.1 x 3.3 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give the corresponding thioacetate (1.189 g, 96%) as a light orange solid.

¹H-NMR (300 MHz, CDCl₃) δ: 7.41-7.32 (15H, m), 5.03 (1H, d, J=10.6 Hz), 4.94 (1H, d, J=10.6 Hz), 4.86 (1H, d, J=10.6 Hz), 4.82 (1H, d, J=11.8 Hz), 4.69 (1H, d, J=11.8 Hz), 4.66 (1H, d, J=11.8 Hz), 4.66 (1H, d, J=10.6 Hz), 4.58 (1H, d, J=3.1 Hz), 4.02 (1H, t, J=9.0 Hz), 3.81 (1H, dt, J=2.5, 7.5 Hz), 3.55 (1H, dd, J=3.7, 9.3 Hz), 3.48 (1H, dd, J=3.1, 13.7 Hz), 3.40 (3H, s), 3.35 (1H, t, J=9.5 Hz), 3.08 (1H, dd, J=7.5, 13.7 Hz), 2.36 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ: 194.67, 138.46, 137.90, 137.78 (C), 128.33, 128.29, 128.03, 127.94, 127.85, 127.81, 127.74, 127.53

32,

(CH), 97.72, 81.69, 80.36, 79.78 (CH), 75.64, 75.04, 73.22 (CH₂), 69.23 (CH), 55.02 (CH₃), 30.73 (CH₂), 30.39 (CH₃). IR (cm⁻¹): 3063, 3031, 2908, 1694, 1497, 1454, 1358, 1201, 1156, 1136, 1092, 1072, 1050, 1029, 999, 955, 737, 698, 630. MALDI-MS: [MNa]⁺ 545.1974 (calcd. 545.1974). Anal. Calcd for $C_{30}H_{34}O_6S$: C, 68.94; H, 6.56. Found: C, 68.77; H, 6.63.

The thioacetate received above (1.180 g, 2.26 mmol) was then dissolved in AcOH (25 mL), KOAc (4.082 g, 41.6 mmol) followed by Oxone (2KHSO $_5$ ·KHSO $_4$ ·K $_2$ SO $_4$, 4.019 g, 8.69 mmol) were added and after stirring for 15 h, sat. aq. NaHCO $_3$ (100 mL), H $_2$ O (50 mL) and sat. aq. Na $_2$ CO $_3$ (50 mL) were carefully added. After extraction with EtOAc (4 x 40 mL), the combined organic layer was washed with sat. aq. Na $_2$ CO $_3$ (50 mL), evaporated on celite and purified by dry column vacuum chromatography (4.0 x 3.3 cm) on silica gel eluting with a gradient of 0-90% EtOAc in hexane (v/v) followed by 0-50% MeOH in EtOAc (v/v) to give the corresponding sulfonate salt (1.116 g, 90%) as a white solid.

¹H-NMR (300 MHz, CD₃OD) δ: 7.37-7.21 (15H, m), 4.90 (1H, d, J = 11.2 Hz), 4.86 (1H, d, J = 10.6 Hz), 4.84 (1H, d, J = 11.2 Hz), 4.73 (1H, d, J = 3.1 Hz), 4.72 (1H, d, J = 11.2 Hz), 4.64 (1H, d, J = 12.5 Hz), 4.60 (1H, d, J = 11.2 Hz), 4.16 (1H, t, J = 9.2 Hz), 3.90 (1H, t, J = 9.3 Hz), 3.55 (1H, dd, J = 3.4, 9.3 Hz), 3.48 (3H, s), 3.30-3.22 (2H, m), 2.92 (1H, dd, J = 10.0, 14.3 Hz). ¹³C-NMR (75 MHz, CD₃OD) δ: 140.03, 139.57, 139.55 (C), 129.42, 129.31, 129.15, 128.93, 128.89, 128.84, 128.67, 128.59 (CH), 98.53, 83.03, 81.65, 81.52 (CH), 76.44, 75.83, 73.85 (CH₂), 68.52 (CH), 55.95 (CH₃), 53.65 (CH₂). IR (cm⁻¹): 3484, 3030, 2922, 1497, 1454, 1360, 1230, 1198, 1177, 1156, 1093, 1058, 1028, 736, 696. MALDI-MS (C₂₈H₃₁NaO₈S): [MNa] + 573.1536 (calcd. 573.1535).

Finally, the obtained sulfonate salt (696 mg, 1.26 mmol) was suspended in anhydrous acetonitrile/ CH_2Cl_2 (10 mL, 1:1 (v/v)) at 0°C, Ph_3P (1.002 g, 3.8 mmol) and thionyl chloride (0.40 mL, 5.5

33

mmol) were added sequentially and the suspension was stirred at room temperature for 13 h. EtOAc/hexane (1:4 (v/v), 100 mL) was added, the suspension was filtered through celite (4 x 15 mL EtOAc/hexane (1:3 (v/v)) washings) and the filtrate was evaporated and dried shortly under vacuum to give the desired sulfonyl chloride **IXa** (657 mg, 95%) as a yellowish oil.

¹H-NMR (300 MHz, CDCl₃) δ : 7.42-7.28 (15H, m), 5.05 (1H, d, J = 10.6 Hz), 4.96 (1H, d, J = 11.8 Hz), 4.85 (1H, d, J = 10.6 Hz), 4.83 (1H, d, J = 11.8 Hz), 4.67 (1H, d, J = 12.5 Hz), 4.60 (1H, d, J = 11.2 Hz), 4.60 (1H, d, J = 3.1 Hz), 4.33 (1H, t, J = 9.6 Hz), 4.07 (1H, t, J = 9.0 Hz), 3.85 (1H, dd, J = 1.2, 13.7 Hz), 3.55 (1H, d, J = 9.3 Hz), 3.52 (1H, t, J = 10.0 Hz), 3.46 (3H, s), 3.26 (1H, t, J = 9.5 Hz). ¹³C-NMR (75 MHz, CDCl₃) δ : 138.02, 137.57, 137.06 (C), 128.58, 128.36, 128.30, 128.23, 128.12, 127.92, 127.66 (CH), 98.00, 81.56, 79.41, 78.49 (CH), 75.85, 74.76, 73.38, 66.75 (CH₂), 65.93 (CH), 55.90 (CH₃). MALDI-MS (C₂₈H₃₁ClO₇S): [MNa] + 569.1378 (calcd. 569.1377).

b)

IXb

The sulfonyl chloride IXa obtained in step 5a) (197 mg, 0.36 mmol) was suspended in anhydrous CH_2Cl_2 (5 mL), anhydrous pyri-

34

dine (0.5 mL) followed by the silylated azetidinone phenol VIa obtained in step 2a) (70.0 mg, 0.13 mmol) were added and the solution was stirred for 22 h, diluted with EtOAc (25 mL) and washed sequentially with sat. aq. NaHCO₃ (10 mL) and H₂O (10 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.3 x 2.0 cm) on silica gel eluting with a gradient of 0-35% EtOAc in hexane (v/v) to give the corresponding glycosylated azetidinone (125.5 mg, 91%) as a colourless oil/glass.

 $^{1}\text{H-NMR}$ (300 MHz, CDCl₃) δ : 7.37-7.14 (23H, m), 7.00 (2H, t, J = 8.7 Hz), 6.95 (2H, t, J = 8.7 Hz), 5.05 (1H, d, J = 11.2 Hz), 4.97 (1H, d, J = 11.2 Hz), 4.84 (1H, d, J = 11.8 Hz), 4.82 (1H, d, J = 10.6 Hz), 4.69 (1H, t, J = 6.8 Hz), 4.67 (1H, d, J = 12.5Hz), 4.60 (1H, d, J = 3.7 Hz), 4.56 (1H, d, J = 12.5 Hz), 4.54 (1H, d, J = 10.6 Hz), 4.29 (1H, t, J = 9.5 Hz), 4.06 (1H, t, J =9.0 Hz), 3.57 (1H, t, J = 3.1 Hz), 3.53 (1H, d, J = 3.1 Hz), 3.46 (3H, s), 3.26 (1H, t, J = 9.3 Hz), 3.14 (1H, dd, J = 10.0, 14.3 Hz), 2.96 (1H, dt, J = 1.9, 6.8 Hz), 1.97-1.78 (4H, m), 0.90 (9H, s), 0.04 (3H, s), -0.13 (3H, s). 13 C-NMR (75 MHz, $CDCl_3$) δ : 166.62, 163.27, 160.37, 160.03, 157.14, 148.91, 140.33, 138.05, 137.63, 137.29, 136.67, 133.45, 133.42 (C), 128.44, 128.31, 128.18, 128.04, 127.96, 127.86, 127.65, 127.15, 127.03, 126.97, 123.15, 118.13, 118.03, 115.93, 115.64, 115.02, 114.75 (CH), 97.92, 81.67, 79.60, 79.23 (CH), 75.78, 74.86 (CH₂), 73.78(CH), 73.37 (CH₂), 65.64, 60.66, 60.48 (CH), 55.73 (CH₃), 51.63, $38.06 \text{ (CH}_2)$, $25.85 \text{ (CH}_3)$, $24.69 \text{ (CH}_2)$, 18.22 (C), -4.54, -4.87 (CH_3) . IR (cm^{-1}) : 3032, 2930, 2858, 1750, 1605, 1510, 1455, 1386, 1252, 1220, 1153, 1086, 1073, 1048, 870, 836, 755, 699. MALDI-[MNa] + 1056.3969 (calcd. 1056.3964). Anal. Calcd MS: $C_{58}H_{65}F_2NO_{10}SiS$: C, 67.35; H, 6.33; N, 1.35. Found: C, 67.43; H, 6.44; N, 1.33.

Subsequently the glycosylated azetidinone (105.1 mg, 0.102 mmol) was dissolved in EtOH (5 mL), $Pd(OH)_2/C$ (20% (w/w), 33 mg) was

added and the suspension was evacuated 4 times with $\rm H_2$ and stirred under an $\rm H_2$ -atmosphere for 6 h. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.2 x 2.0 cm) on silica gel eluting with a gradient of 0-10% MeOH in $\rm CH_2Cl_2$ (v/v) to give the debenzylated azetidinone (63.2 mg, 81%) as a colourless oil.

¹H-NMR (300 MHz, acetone- d_6) δ : 7.55 (2H, d, J = 8.7 Hz), 7.42 (2H, d, J = 8.7 Hz), 7.37 (2H, dd, J = 5.9, 8.4 Hz), 7.28 (2H, dd)dd, J = 5.0, 9.3 Hz), 7.11-7.01 (4H, m), 4.96 (1H, d, J = 1.9Hz), 4.84 (1H, t, J=5.3 Hz), 4.69 (1H, d, J=3.7 Hz), 4.61 (1H, d, J = 5.0 Hz), 4.35 (1H, d, J = 3.1 Hz), 4.16 (1H, dt, J =1.2, 10.0 Hz), 3.87 (1H, dd, J = 1.2, 14.9 Hz), 3.79 (1H, d, J = 1.27.5 Hz), 3.65 (1H, t, J = 9.0 Hz), 3.56 (1H, dd, J = 10.0, 14.9 Hz), 3.45-3.40 (1H, m), 3.38 (3H, s), 3.27-3.14 (2H, m), 2.00-1.88 (4H, m), 0.87 (9H, s), 0.05 (3H, s), -0.15 (3H, s). 13 C-NMR (75 MHz, acetone- d_6) δ : 167.25, 163.96, 160.84, 160.75, 157.65, 150.14, 141.91, 141.87, 138.13, 134.95, 134.91 (C), 128.32, 128.23, 123.84, 118.98, 118.88, 116.43, 116.12, 115.49, 115.21 (CH), 100.74, 74.77, 74.42, 73.55, 73.04, 68.01, 61.25, 60.50 (CH), 55.56 (CH_3) , 52.83, 38.50 (CH_2) , 26.16 (CH_3) , 25.34 (CH_2) , 18.65 (C), -4.47, -4.71 (CH₃). IR (cm⁻¹): 3396, 2951, 2931, 2857, 1754, 1701, 1605, 1510, 1426, 1385, 1250, 1220, 1151, 1088, 1053, 1015, 988, 872, 836, 778. MALDI-MS $(C_{37}H_{47}F_2NO_{10}SSi)$: [MNa] + 786.2559 (calcd. 786.2556).

This debenzylated azetidinone (58.9 mg, 0.077 mmol) was dissolved in anhydrous THF (2.5 mL, teflon bottle), anhydrous pyridine (0.5 mL) followed by HF-pyridine complex (0.5 mL) were added and the solution was stirred for 14.5 h, diluted with ether (20 mL) and washed with sat. aq. NaHCO $_3$ (3 x 5 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.2 x 2.0 cm) on silica gel eluting with a gradient of 0-10% MeOH in CH_2Cl_2 (v/v) to give the desired azetidinone **Ixb** (44.9 mg, 90%) as a white solid.

WO 2005/033100

36

PCT/CH2004/000584

¹H-NMR (300 MHz, acetone- d_6) δ : 7.56 (2H, d, J = 8.7 Hz), 7.43 (2H, d, J = 8.7 Hz), 7.37 (2H, dd, J = 5.6, 8.7 Hz), 7.30 (2H, dd)dd, J = 4.7, 9.0 Hz), 7.06 (2H, d, J = 9.3 Hz), 7.03 (2H, d, J = 9.3 Hz)8.7 Hz), 4.99 (1H, d, J = 2.5 Hz), 4.69 (1H, d, J = 3.7 Hz), 4.61 (1H, d, J=5.0 Hz), 4.42 (1H, d, J=3.7 Hz), 4.34 (1H, bs), 4.15 (1H, dt, J = 1.2, 8.7 Hz), 3.86 (1H, dd, J = 1.2, 14.9 Hz), 3.79 (1H, d, J = 8.1 Hz), 3.65 (1H, t, J = 8.7 Hz), 3.57 (1H, dd, J = 10.0, 14.9 Hz), 3.44-3.38 (1H, m), 3.38 (3H, s),3.32-3.14 (2H, m), 2.08-1.86 (4H, m). $^{13}C-NMR$ (75 MHz, acetone d_6) δ : 167.42, 163.87, 160.85, 157.67, 150.13, 142.52, 138.18, 134.93 (C), 128.35, 128.22, 128.13, 123.83, 119.01, 118.89, 116.44, 116.13, 115.40, 115.11 (CH), 100.74, 74.77, 73.56, 73.04, 72.77, 68.01, 61.27, 60.56 (CH), 55.56 (CH₃), 52.83, 37.54, 25.70 (CH₂). IR (cm⁻¹): 3395, 2925, 1732, 1604, 1509, 1365, 1219, 1148, 1103, 1051, 1014, 871, 834, 752. MALDI-MS: [MNa] $^+$ 672.1693 (calcd. 672.1691). Anal. Calcd for $C_{31}H_{33}F_2NO_{10}S$: C, 57.31; H, 5.12; N, 2.16. Found: C, 57.34; H, 5.26; N, 2.21.

c)

LiAlH₄ (57 mg, 1.5 mmol) and AlCl₃ (200 mg, 1.5 mmol) were suspended in anhydrous ether (15 mL), refluxed for 30 min and cooled to 0° C. The azetidinone IXb obtained under step 5b) (26.8 mg, 0.041 mmol) dissolved in anhydrous THF (1 mL, 2 x 0.5 mL rinse) was added and after stirring at 0° C for 10 min, sat. aq. NaHCO₃ (1 mL) was added dropwise. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.7 x 2.0 cm) on silica gel eluting with a gradient of 0-12% MeOH in CH₂Cl₂ (v/v) to give the desired azetidine IX (20.4 mg, 78%) as a colourless oil.

¹H-NMR (300 MHz, acetone- d_6) δ : 7.63-7.59 (2H, m), 7.49-7.42 (2H, m), 7.36-7.29 (2H, m), 7.10-7.01 (2H, m), 6.92-6.77 (2H, m), 6.40-6.35 (2H, m), 4.72 (1H, d, J = 3.7 Hz), 4.62 (1H, d, J = 5.0 Hz), 4.61 (1H, bs), 4.52 (1H, d, J = 6.9 Hz), 4.31 (2H, t, J

37

= 4.4 Hz), 4.21-4.15 (2H, m), 3.90 (1H, dd, J = 1.2, 14.9 Hz), 3.76 (1H, d, J = 8.1 Hz), 3.68 (1H, dd, J = 3.7, 9.3 Hz), 3.66-3.57 (2H, m), 3.41 (3H, s, OMe), 3.38-3.31 (1H, m), 3.25 (1H, dt, J = 5.0, 13.7 Hz), 2.62 (1H, dd, J = 6.8, 14.3 Hz), 1.92-1.84 (1H, m), 1.74-1.57 (3H, m). 13 C-NMR (75 MHz, acetone- d_6) δ : 163.90, 160.69, 158.31, 155.22, 149.93, 149.72, 149.52, 142.90, 142.84 (C), 129.60, 129.44, 128.30, 128.24, 128.13, 123.51, 122.99, 115.95, 115.91, 115.66, 115.40, 115.11, 113.87, 113.77, 113.67, 113.57 (CH), 100.84, 74.86, 74.03, 73.68, 73.14, 72.87, 68.09 (CH), 56.67 (CH₂), 55.63 (CH₃), 52.83 (CH₂), 42.78 (CH), 37.60, 29.83 (CH₂). IR (cm⁻¹): 3390, 2935, 2850, 1605, 1508, 1474, 1366, 1221, 1147, 1052, 1015, 874, 824, 755. MALDI-MS (C₃₁H₃₅F₂NO₉S): [MH-H₂O]⁺ 618.1968 (calcd. 618.1973); [MH]⁺ 636.2045 (calcd. 636.2079); [MNa]⁺ 658.1901 (calcd. 658.1898).

Example 6

a)

38

The above sulfonyl chloride Xa was prepared according to the methods described under step 5a) using C-(Hydroxymethyl)-2,3,4,6-tetra-O-benzyl- β -D-glucopyranoside (prepared according to RajanBabu, T. V.; Reddy, G. S. J. Org. Chem. 1986, 51, 5458-5461) as the starting material.

b)

The sulfonyl chloride Xa obtained under step 6a) (871 mg, 1.26 mmol) was suspended in anhydrous CH_2Cl_2 (10 mL), anhydrous pyridine (1.0 mL) followed by the silylated azetidinone phenol VIa obtained in step 2a) (334 mg, 0.634 mmol) were added and the solution was stirred for 13 h, diluted with EtOAc (50 mL) and washed sequentially with sat. aq. $NaHCO_3$ (20 mL) and H_2O (20 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.3 x 3.3 cm) on silica gel eluting with a gradient of 0-100% CH_2Cl_2 in hexane (v/v) to give the corresponding glycosylated azetidinone (657 mg, 92%) as a white foam.

¹H-NMR (300 MHz, CDCl₃) δ : 7.37-7.15 (28H, m), 7.01 (2H, t, J = 8.7 Hz), 6.96 (2H, t, J = 8.7 Hz), 5.03-4.81 (4H, m), 4.73-4.51 (6H, m), 3.95 (1H, t, J = 8.4 Hz), 3.78 (4H, bs), 3.57-3.53 (1H, m), 3.48 (1H, d, J = 1.2 Hz), 3.40 (1H, t, J = 9.0 Hz), 3.24 (1H, dd, J = 9.3, 14.9 Hz), 3.02-2.95 (1H, m), 1.97-1.80 (4H, m), 0.92 (9H, s), 0.06 (3H, s), -0.11 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ : 166.72, 163.24, 160.35, 160.01, 157.13, 149.25, 140.37, 140.33, 137.90, 137.65, 137.58, 137.12, 136.97, 136.52, 133.52, 133.48 (C), 128.46, 128.32, 128.28, 128.17, 128.02, 127.97, 127.81, 127.76, 127.67, 127.63, 127.52, 127.13, 127.02, 123.32, 118.13, 118.02, 115.90, 115.60, 115.01, 114.72 (CH), 86.83, 79.13, 78.83, 77.73 (CH), 75.56, 75.00, 74.85 (CH₂), 74.19, 73.77 (CH), 73.31 (CH₂), 68.36, 60.57, 60.53 (CH), 51.31, 38.03 (CH₂), 25.85 (CH₃), 24.67 (CH₂), 18.20 (C), -4.57, -4.87 (CH₃). IR (cm⁻¹): 2951, 2929, 2858, 1751, 1605, 1510, 1454, 1386, 1362, 1251,

WO 2005/033100

PCT/CH2004/000584

1220, 1151, 1102, 871, 835, 776, 754, 699. MALDI-MS: [MNa] † 1146.4440 (calcd. 1146.4434). Anal. Calcd for $C_{65}H_{71}F_{2}NO_{10}SiS$: C, 69.43; H, 6.36; N, 1.25. Found: C, 69.27; H, 6.47; N, 1.28.

The glycosylated azetidinone obtained above (236 mg, 0.210 mmol) was then dissolved in EtOH/EtOAc (10 mL, 1:1 (v/v)), $Pd(OH)_2/C$ (20% (w/w), 73 mg) was added and the suspension was evacuated 4 times with H_2 and stirred under an H_2 -atmosphere for 3.5 h. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.6 x 2.0 cm) on silica gel eluting with a gradient of 0-20% MeOH in CH_2Cl_2 (v/v) to give the debenzylated azetidinone (145 mg, 90%) as a white foam.

¹H-NMR (300 MHz, acetone- d_6) δ : 7.55 (2H, dd, J = 6.5, 8.7 Hz), 7.47 (2H, d, J = 8.4 Hz), 7.40-7.20 (4H, m), 7.11-6.98 (4H, m), 4.97 (1H, dd, J = 2.3, 10.5 Hz), 4.83 (1H, bs), 4.61 (1H, bs), 4.48 (1H, bs), 4.30 (1H, bs), 3.90-3.81 (3H, m), 3.71-3.64 (1H, m), 3.56-3.38 (5H, m), 3.25-3.14 (2H, m), 2.66 (1H, t, J=7.2Hz), 1.98-1.81 (4H, m), 0.88 (9H, s), 0.05 (3H, s), -0.15 (3H, s). 13 C-NMR (75 MHz, acetone- d_6) δ : 168.30, 161.88, 151.25, 142.96, 139.63, 139.16, 139.13, 135.98 (C), 131.56, 129.36, 129.28, 124.92, 120.00, 119.90, 117.46, 117.16, 116.62, 116.52 (CH), 82.13, 80.16, 76.75, 75.44, 74.46, 72.35 (CH), 63.64 (CH₂), 61.60, 61.55 (CH), 54.03, 39.52 (CH₂), (CH_3) , 26.35 (CH_2) , 19.68 (C), -3.44, -3.69 (CH_3) . IR (cm^{-1}) : 3380, 2930, 2858, 1749, 1604, 1510, 1385, 1363, 1220, 1172, 1149, 1088, 1032, 1016, 872, 835, 757. MALDI-MS: [MNa] + 786.2563 (calcd. 786.2556). Anal. Calcd for $C_{37}H_{47}F_2NO_{10}SiS$: C, 58.17; H, 6.20; N, 1.83. Found: C, 58.02; H, 6.26; N, 1.85.

The debenzylated azetidinone (31.5 mg, 0.041 mmol) was then dissolved in anhydrous THF (2.5 mL, teflon bottle), anhydrous pyridine (0.5 mL) followed by HF·pyridine complex (0.5 mL) were added and the solution was stirred for 24 h, diluted with ether (20 mL) and washed with sat. aq. NaHCO₃ (3 x 5 mL). The organic layer

PCT/CH2004/000584

was evaporated on celite and purified by dry column vacuum chromatography (4.3 x 2.0 cm) on silica gel eluting with a gradient of 0-20% MeOH in CH_2Cl_2 (v/v) to give the desired azetidinone X (9.8 mg, 37%) as a white solid.

¹H-NMR (300 MHz, acetone- d_6) δ : 7.55 (2H, d, J = 8.7 Hz), 7.47 (2H, d, J = 8.7 Hz), 7.36 (2H, dd, J = 5.6, 8.7 Hz), 7.29 (2H, dd, J = 4.8, 9.2 Hz), 7.06 (2H, d, J = 8.7 Hz), 7.03 (2H, d, J = 9.0 Hz), 4.98 (1H, d, J = 2.5 Hz), 4.68 (1H, bs), 4.58 (1H, bs), 4.38 (1H, bs), 4.27 (1H, bs), 3.89-3.80 (3H, m), 3.66 (1H, d, J = 10.6 Hz), 3.54-3.36 (5H, m), 3.24-3.14 (2H, m), 2.00-1.86 (4H, m). ¹³C-NMR (75 MHz, acetone- d_6) δ : 168.48, 151.29, 143.63, 139.23, 136.09 (C), 129.37, 129.29, 129.19, 124.97, 120.05, 119.94, 117.49, 117.18, 116.46, 116.18 (CH), 82.17, 80.18, 76.78, 74.49, 73.79, 72.42 (CH), 63.67 (CH₂), 62.35, 61.63 (CH), 54.06, 38.62, 26.75 (CH₂). IR (cm⁻¹): 3364, 2924, 1734, 1509, 1388, 1220, 1148, 1102, 872, 835, 769. MALDI-MS (C₃₁H₃₃F₂NO₁₀S): [MNa] * 672.1744 (calcd. 672.1691).

Example 7

WO 2005/033100

XI

LiAlH₄ (57 mg, 1.5 mmol) and AlCl₃ (200 mg, 1.5 mmol) were suspended in anhydrous ether (15 mL), refluxed for 30 min and cooled to 0° C. The azetidinone **X** obtained in Example 6 (41.3 mg, 0.054 mmol) dissolved in anhydrous ether (5 mL) was added and

after stirring at 0°C for 10 min, sat. aq. NaHCO₃ (1 mL) was added dropwise. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.2 x 2.0 cm) on silica gel eluting with a gradient of 0-20% MeOH in CH_2Cl_2 (v/v) to give the corresponding azetidine (38.2 mg, 94%) as a white foam.

¹H-NMR (300 MHz, acetone- d_6) δ : 7.58 (2H, d, J = 8.7 Hz), 7.47 (2H, d, J = 8.7 Hz), 7.29 (2H, dd, J = 5.6, 8.7 Hz), 7.05 (2H, dd, J = 5.6, 8.7 Hz)t, J = 8.7 Hz), 6.88 (2H, t, J = 9.0 Hz), 6.37 (2H, dd, J = 4.7) 9.0 Hz), 4.71 (1H, t, J = 5.5 Hz), 4.61 (1H, d, J = 5.0 Hz), 4.49 (2H, d, J = 6.8 Hz), 4.30 (1H, bs), 4.17 (1H, t, J = 7.2Hz), 3.92-3.83 (3H, m), 3.74-3.66 (1H, m), 3.57-3.40 (5H, m), 3.32-3.15 (2H, m), 2.63-2.56 (1H, m), 1.82-1.56 (4H, m), 0.87 (9H, s), 0.04 (3H, s), -0.17 (3H, s). ¹³C-NMR (75 MHz, acetone) d_6) δ : 164.97, 161.76, 159.31, 156.21, 150.76, 150.47, 150.45, 143.77, 143.11, 143.07 (C), 129.35, 129.22, 124.60, 116.95, 116.65, 116.48, 116.19, 114.86, 114.75 (CH), 82.15, 80.21, 76.81, 75.43, 74.99, 74.52, 72.41 (CH), 63.70, 57.54, 53.95 (CH_2) , 43.62 (CH), 39.47, 31.22 (CH_2) , 27.20 (CH_3) , 19.70 (C), -3.40, -3.68 (CH₃). IR (cm⁻¹): 3377, 2930, 2856, 1605, 1508, 1472, 1361, 1252, 1222, 1147, 1090, 1015, 871, 836, 776, 760. MALDI-MS $(C_{37}H_{49}F_{2}NO_{9}SSi): [MNa]^{+} 772.2767 \text{ (calcd. } 772.2763).$

The azetidine obtained above (34.3 mg, 0.046 mmol) was dissolved in anhydrous THF (2.5 mL, teflon bottle), anhydrous pyridine (0.5 mL) followed by HF·pyridine complex (0.5 mL) were added and the solution was stirred for 14 h, diluted with ether (20 mL) and washed with sat. aq. $NaHCO_3$ (3 x 5 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.9 x 2.0 cm) on silica gel eluting with a gradient of 0-18% MeOH in CH_2Cl_2 (v/v) to give the desired azetidine XI (20.2 mg, 69%) as a colourless oil.

¹H-NMR (300 MHz, acetone- d_6) δ : 7.61 (2H, d, J = 8.1 Hz), 7.48

(2H, d, J = 8.7 Hz), 7.30 (2H, dd, J = 5.6, 8.7 Hz), 7.04 (2H, dd)t, J = 8.7 Hz), 6.89 (2H, m), 6.38 (2H, dd, J = 4.4, 8.7 Hz), 4.60 (2H, d, J = 4.4 Hz), 4.52 (1H, d, J = 6.8 Hz), 4.45 (1H, d, J = 2.5 Hz), 4.29 (2H, d, J = 4.4 Hz), 4.19 (1H, t, J = 6.8 Hz), 4.03-3.83 (3H, m), 3.80-3.67 (1H, m), 3.60-3.31 (6H, m), 3.25 (1H, p, J = 4.4 Hz), 2.62 (1H, dd, J = 7.5, 14.3 Hz), 1.92-1.82(1H, m), 1.78-1.61 (3H, m). 13 C-NMR (75 MHz, acetone- d_6) δ : 164.04, 155.14, 149.92, 149.71, 149.47, 142.77, 129.48 (C), 128.19, 128.16, 128.05, 123.52, 123.03, 115.87, 115.58, 115.39, 115.32, 115.05, 113.78, 113.69, 113.61, 113.51 (CH), 81.09, 79.15, 75.76, 73.98, 73.46, 72.75, 71.36 (CH), 62.63, 56.60, 52.88 (CH₂), 42.68 (CH), 37.52, 29.61 (CH₂). IR (cm⁻¹): 3370, 2933, 1605, 1508, 1474, 1360, 1220, 1146, 1087, 1015, 873, 823, 771. MALDI-MS $(C_{31}H_{35}F_2NO_9S)$: $[MH-H_2O]^+$ 618.1973 (calcd. 618.1973); [M] + 635.1996 (calcd. 635.2001); [MNa] + 658.1900 (calcd. 658.1898).

Example 8

XII

43

a)

XIIa

Ezetimibe (commercially obtained or synthesized according to Wu, G. Z. et al., J. Org. Chem. 1999; 279 mg, 0.681 mmol) was dissolved in anhydrous DMF (5 mL), imidazole (262 mg, 3.84 mmol) and TBDMSCl (500 mg, 3.32 mmol) were added sequentially and the solution was stirred for 5 h followed by addition of 50% sat. aq. NaHCO₃ (50 mL). After extraction with EtOAc (4 x 20 mL), the combined organic layer was washed successively with sat. aq. Na-HCO₃ (20 mL) and H₂O (20 mL), evaporated on celite and purified by dry column vacuum chromatography (3.8 x 3.3 cm) on silica gel eluting with a gradient of 0-10% EtOAc in hexane (v/v) to give the fully silylated azetidinone XIIa (424 mg, 97%) as a colour-less oil.

¹H-NMR (300 MHz, CDCl₃) δ : 7.25-7.21 (4H, m), 7.17 (2H, d, J = 8.1 Hz), 6.98 (2H, t, J = 8.7 Hz), 6.91 (2H, t, J = 8.7 Hz), 6.83 (2H, d, J = 8.1 Hz), 4.66 (1H, t, J = 5.6 Hz), 4.51 (1H, d, J = 2.5 Hz), 3.08-3.02 (1H, m), 1.96-1.78 (4H, m), 0.98 (9H, s), 0.88 (9H, s), 0.20 (6H, s), 0.02 (3H, s), -0.16 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ : 167.27, 163.28, 160.27, 160.04, 157.06, 155.71, 140.58, 140.54, 133.89, 133.86 (C), 129.99, 127.22, 127.11, 126.94, 120.56, 118.24, 118.15, 115.74, 115.44, 114.99, 114.72 (CH), 73.84, 61.08, 60.44 (CH), 38.08 (CH₂), 25.90, 25.68 (CH₃), 24.75 (CH₂), 18.26, 18.24 (C), -4.28, -4.52, -4.83 (CH₃).

44

IR (cm^{-1}) : 2954, 2930, 2858, 1752, 1607, 1510, 1385, 1259, 1223, 1101, 1085, 914, 834, 778. MALDI-MS: [MH-TBDMSOH] + 506.2329 (calcd. 506.2327); [MH] + 638.3289 (calcd. 638.3297); [MNa] + 660.3117 (calcd. 660.3117). Anal. Calcd for $C_{36}H_{49}F_{2}NO_{3}Si_{2}$: C, 67.78; H, 7.74; N, 2.20. Found: C, 67.70; H, 7.60; N, 2.02.

b)

XIIb

LiAlH₄ (57 mg, 1.5 mmol) and AlCl₃ (200 mg, 1.5 mmol) were suspended in anhydrous ether (15 mL), refluxed for 40 min and cooled to 0°C. The fully silylated azetidinone **XIIa** obtained under step 8a) (180.8 mg, 0.283 mmol) dissolved in anhydrous ether (5 mL) was added and after stirring at 0°C for 30 min, H_2O (1 mL) was added dropwise. The suspension was evaporated on celite and purified by dry column vacuum chromatography (3.5 x 3.3 cm) on silica gel eluting with a gradient of 0-50% CH_2Cl_2 in hexane (v/v) to give the desired bicyclic amine **XIIb** (110.8 mg, 63%) as a colourless oil.

¹H-NMR (300 MHz, CDCl₃) δ : 7.18-7.14 (2H, m), 6.95 (2H, t, J = 8.7 Hz), 6.88 (2H, d, J = 8.7 Hz), 6.74 (2H, d, J = 8.1 Hz), 6.68 (1H, dd, J = 2.8, 8.4 Hz), 6.44 (1H, dd, J = 6.5, 8.7 Hz), 6.38 (1H, dd, J = 2.8, 9.6 Hz), 4.48 (1H, dd, J = 5.0, 6.8 Hz), 3.78 (1H, bs), 3.61 (1H, d, J = 7.5 Hz), 3.26 (1H, dd, J = 3.1,

WO 2005/033100

PCT/CH2004/000584

45

11.2 Hz), 2.91 (1H, dd, J = 7.8, 11.5 Hz), 1.91-1.85 (1H, m), 1.68-1.44 (3H, m), 1.16-1.04 (1H, m), 0.99 (9H, s), 0.80 (9H, s), 0.20 (6H, s), 0.06 (3H, s), -0.21 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ : 163.60, 160.36, 157.37, 154.27, 141.53, 141.01, 138.13 (C), 130.07, 127.56, 127.46, 125.58, 125.50, 120.01, 117.27, 116.98, 115.17, 114.89, 114.78, 114.08, 113.79 (CH), 74.64, 48.97 (CH), 44.52 (CH₂), 39.89 (CH), 38.67, 28.28 (CH₂), 26.00, 25.90 (CH₃), 18.38, 18.32 (C), -4.16, -4.43, -4.77 (CH₃). IR (cm⁻¹): 2955, 2930, 2858, 1607, 1506, 1472, 1408, 1361, 1258, 1222, 1170, 1144, 1085, 1006, 915, 837, 808, 779, 735, 667. MALDI-MS (C₃₆H₅₁F₂NO₂Si₂): [MH-TBDMSOH] + 492.2517 (calcd. 492.2534); [M] + 623.3414 (calcd. 623.3426). Anal. Calcd for C₃₆H₅₁F₂NO₂Si₂: C, 69.30; H, 8.24; N, 2.24. Found: C, 69.47; H, 8.32; N, 2.15.

c)

The bicyclic amine **XIIb** obtained under step 8b) (39.8 mg, 0.064 mmol) was dissolved in THF (5 mL), TBAF (0.5 mL, 1M in THF) was added and the solution was stirred for 21 h, evaporated on celite and purified by dry column vacuum chromatography (3.7 x 2.0 cm) on silica gel eluting with a gradient of 0-100% EtOAc in hexane (v/v) to give the desired amine **XII** (27.7 mg, quant.) as a yellowish solid.

¹H-NMR (300 MHz, CDCl₃) δ : 7.19-7.15 (2H, m), 6.97 (2H, t, J = 8.7 Hz), 6.87 (2H, d, J = 8.4 Hz), 6.74-6.66 (3H, m), 6.46 (1H, dd, J = 5.0, 8.7 Hz), 6.38 (1H, dd, J = 2.2, 9.0 Hz), 5.54 (1H, bs), 4.52 (1H, t, J = 6.5 Hz), 3.61 (1H, d, J = 7.2 Hz), 3.26 (1H, dd, J = 3.4, 11.5 Hz), 2.90 (1H, dd, J = 7.5, 11.5 Hz), 1.95-1.86 (1H, m), 1.78-1.68 (2H, m), 1.52-1.41 (1H, m), 1.19-1.06 (1H, m). ¹³C-NMR (75 MHz, CDCl₃) δ : 163.55, 160.30, 157.10, 154.25, 154.00, 140.44, 139.95, 139.90, 137.07 (C), 129.90, 127.46, 127.36, 125.24, 116.99, 116.70, 115.28, 115.26, 115.21, 115.15, 115.00, 114.95, 114.84, 113.91, 113.61 (CH), 73.94, 48.53 (CH), 43.98 (CH₂), 39.73 (CH), 36.43, 27.95 (CH₂). IR (cm⁻¹): 3335, 2925, 2853, 1607, 1511, 1223, 913, 836, 744. MALDI-MS

 $(C_{24}H_{23}F_2NO_2): [MH-H_2O]^+ 378.1661 (calcd.378.1670); [M]^+ 395.1689$ (calcd. 395.1670)

Example 9

XIII

The bicyclic amine **XIIb** obtained in step 8b) (503 mg, 0.806 mmol) was dissolved in THF (15 mL) at 0°C, TBAF (1.5 mL, 1M in THF) was added and the solution was stirred at 0°C for 1.5 h, diluted with EtOAc (50 mL) and washed successively with sat. aq. NaHCO₃ (20 mL) and H₂O (20 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (3.4 x 3.3 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give the corresponding phenol (344.2 mg, 84%) as a light yellow foam.

¹H-NMR (300 MHz, CDCl₃) δ : 7.16 (2H, dd, J= 5.6, 8.1 Hz), 6.95 (2H, t, J = 8.7 Hz), 6.90 (2H, d, J = 8.7 Hz), 6.72 (2H, d, J = 8.7 Hz), 6.72-6.67 (1H, m), 6.48 (1H, dd, J = 4.4, 8.7 Hz), 6.39 (1H, dd, J = 2.7, 9.6 Hz), 4.49 (1H, dd, J = 5.6, 6.8 Hz), 4.40 (1H, bs), 3.61 (1H, d, J = 7.5 Hz), 3.28 (1H, dd, J = 2.7, 11.2 Hz), 2.92 (1H, dd, J = 8.1, 11.2 Hz), 1.93-1.87 (1H, m), 1.73-1.47 (3H, m), 1.20-1.15 (1H, m), 0.81 (9H, s), 0.06 (3H, s), -0.20 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ : 163.16, 159.93, 157.15, 154.03, 141.13, 141.09, 140.43, 140.40, 137.05 (C), 129.95,

47

127.21, 127.11, 125.69, 125.62, 116.92, 116.62, 115.23, 114.98, 114.87, 114.83, 114.55, 113.83, 113.53 (CH), 74.36, 48.77 (CH), 44.49 (CH₂), 39.78 (CH), 38.46, 28.07 (CH₂), 25.81 (CH₃), 18.17 (C), -4.52, -4.90 (CH₃). IR (cm⁻¹): 3338, 2954, 2929, 2857, 1606, 1508, 1475, 1462, 1361, 1251, 1221, 1084, 836, 775, 760. MALDI-MS (C₃₀H₃₇F₂NO₂Si): [MH-TBDMSOH] + 378.1657 (calcd. 378.1670); [M] + 509.2553 (calcd. 509.2562).

The phenol obtained above (79 mg, 0.15 mmol) and 2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O- β -D-glucopyranosyl)- α -D-

glucopyranosyl 1-(2,2,2-trichloroacetimidate) (prepared according to Buijsman, R. C. et al., Bioorg. Med. Chem. 1999, 7, 1881-1890; 267 mg, 0.34 mmol) were then dissolved in anhydrous CH_2Cl_2 (2 mL) at -25°C and $BF_3 \cdot OEt_2$ in CH_2Cl_2 (1:9 (v/v), 0.10 mL, 0.08 mmol) was added. After stirring for 2.5 h at -25 to -20°C, additional $BF_3 \cdot OEt_2$ (0.05 mL, 0.39 mmol) was added and after additional 1 h at -25 to -20°C, sat. aq. NH_4Cl (10 mL) and EtOAc (10 mL) were added. The layers were separated and the aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic layer was washed successively with sat. aq. $NaHCO_3$ (10 mL) and H_2O (10 mL), evaporated on celite and purified by dry column vacuum chromatography (4.5 x 2.0 cm) on silica gel eluting with a gradient of 0-70% EtOAc in hexane (v/v) to give the glycosylated amine (169 mg, 97%) as a white foam.

¹H-NMR (300 MHz, CDCl₃) δ: 7.12 (2H, dd, J= 5.6, 8.7 Hz), 6.94-6.84 (6H, m), 6.66 (1H, dt, J = 2.5, 8.1 Hz), 6.42 (1H, dd, J = 4.4, 8.7 Hz), 6.29 (1H, dd, J = 2.7, 9.6 Hz), 5.29-4.90 (6H, m), 4.54-4.43 (3H, m), 4.37 (1H, dd, J = 4.4, 12.5 Hz), 4.16-4.02 (2H, m), 3.86 (1H, t, J = 9.0 Hz), 3.77-3.64 (2H, m), 3.60 (1H, d, J = 7.5 Hz), 3.23 (1H, dd, J = 2.7, 11.5 Hz), 2.88 (1H, dd, J = 8.1, 11.2 Hz), 2.07-1.96 (21H, m), 1.87-1.75 (1H, m), 1.70-1.38 (3H, m), 1.13-0.97 (1H, m), 0.76 (9H, s), -0.10 (3H, s), -0.25 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ: 170.38, 170.09, 169.67,

WO 2005/033100

48

PCT/CH2004/000584

169.47, 169.20, 168.96, 163.25, 160.01, 156.95, 155.27, 153.85, 141.10, 140.73, 140.10 (C), 129.91, 127.21, 127.11, 124.80, 116.68, 114.83, 114.56, 113.62 (CH), 100.71, 98.80, 76.33, 74.20, 72.81, 72.69, 72.42, 71.89, 71.48, 71.27, 67.63 (CH), 61.84, 61.42 (CH₂), 48.71 (CH), 44.19 (CH₂), 39.61 (CH), 38.27, 27.85 (CH₂), 25.64, 20.67, 20.58, 20.43 (CH₃), 17.96 (C), -4.76, -5.14 (CH₃). IR (cm⁻¹): 2955, 2858, 1756, 1506, 1368, 1223, 1049, 837, 770. MALDI-MS ($C_{56}H_{71}F_{2}NO_{19}Si$): [MNa]⁺ 1150.4235 (calcd. 1150.4255).

The glycosylated amine obtained above (370 mg, 0.328 mmol) was then dissolved in THF (10 mL), TBAF (1.0 mL, 1M in THF) was added and the solution was stirred for 27 h, diluted with EtOAc (40 mL) and washed successively with sat. aq. NaHCO3 (15 mL) and H₂O (15 mL). The organic layer was evaporated and the crude in-[MNa] + 1036.3394 termediate [MALDI-MS $(C_{50}H_{57}F_2NO_{19}):$ 1036.3391)] was dissolved in MeOH/Et3N/THF (12 mL, (v/v/v)), H_2O (10.5 mL) was added dropwise and the solution was stirred for 18 h. sat. aq. NaHCO3 (1 mL) was added dropwise and the suspension was evaporated on celite and purified by dry column vacuum chromatography (4.0 x 3.3 cm) on silica gel eluting with a gradient of 0-25% MeOH in EtOAc (v/v) to give the desired bicyclic amine XIII (80.5 mg, 34%) as a white solid after coevaporation with hexane (20 mL).

¹H-NMR (300 MHz, CD₃OD) δ : 7.20 (2H, dd, J= 5.6, 8.7 Hz), 7.02-6.93 (6H, m), 6.65 (1H, dt, J = 2.5, 8.7 Hz), 6.54 (1H, dd, J = 5.0, 8.7 Hz), 6.23 (1H, dd, J = 2.5, 10.0 Hz), 4.94 (1H, d, J = 7.5 Hz), 4.47-4.43 (2H, m), 3.92 (2H, bs), 3.90 (1H, d, J = 10.6 Hz), 3.72-3.52 (6H, m), 3.43-3.22 (5H, m), 2.86 (1H, dd, J = 8.1, 11.8 Hz), 1.96-1.84 (1H, m), 1.80-1.68 (2H, m), 1.50-1.35 (1H, m), 1.17-1.03 (1H, m). ¹³C-NMR (75 MHz, CD₃OD) δ : 164.71, 161.49, 157.30, 155.12, 142.58, 141.98, 141.95, 140.78 (C), 130.89, 128.83, 128.72, 126.64, 126.56, 117.52, 117.36, 117.09, 115.86, 115.57 (CH), 104.44, 101.98, 80.21, 78.01, 77.76, 76.49,

76.22, 74.83, 74.58, 74.41, 71.29 (CH), 62.39, 61.63 (CH₂), 50.00 (CH), 45.09 (CH₂), 40.95 (CH), 37.38, 29.09 (CH₂). MALDI-MS ($C_{36}H_{43}F_{2}NO_{12}$): [MNa] + 742.2654 (calcd. 742.2651).

Example 10

XIV

The silylated azetidinone phenol VIa obtained in step 2a) (104.0 mg, 0.199 mmol) was dissolved in anhydrous CH_2Cl_2 (10 mL), anhydrous pyridine (0.5 mL) followed by $PhSO_2Cl$ (0.10 mL, 0.78 mmol) were added and the solution was stirred for 19 h. Additional $PhSO_2Cl$ (0.10 mL, 0.78 mmol) was added and the solution was stirred for further 69 h, diluted with EtOAc (50 mL) and washed sequentially with sat. aq. $NaHCO_3$ (20 mL) and H_2O (20 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.2 x 3.3 cm) on silica gel eluting with a gradient of 0-100% CH_2Cl_2 in hexane (v/v) followed by 0.5-1.0% MeOH in CH_2Cl_2 (v/v) to give the corresponding benzene sulfonate (92.0 mg, 70%) as a colourless oil.

R_f (1% MeOH in CH₂Cl₂ (v/v)) 0.72; ¹H-NMR (300 MHz, CDCl₃) δ : 7.83 (2H, d, J = 7.5 Hz), 7.66 (1H, t, J = 7.5 Hz), 7.51 (2H, t, J = 7.5 Hz), 7.25-7.14 (6H, m), 7.00 (2H, d, J = 8.7 Hz), 6.97 (2H, d, J = 8.7 Hz), 6.91 (2H, t, J = 8.7 Hz), 4.66 (1H, dd, J = 4.4, 6.2 Hz), 4.55 (1H, d, J = 1.9 Hz), 3.02-2.96 (1H, m), 1.94-1.75 (4H, m), 0.87 (9H, s), 0.00 (3H, s), -0.16 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ : 166.82, 163.44, 160.51, 157.29, 149.35, 140.54 (C), 136.77 (CH), 135.26, 134.32, 133.56, 129.13 (C), 128.31, 127.27, 127.17, 127.08, 123.15, 118.23, 118.12, 115.93, 115.63,

50

115.09, 114.82, 73.76, 60.53, 60.40 (CH), 37.92 (CH₂), 25.75 (CH₃), 24.59 (CH₂), 18.10 (C), -4.71, -5.03 (CH₃). IR (cm⁻¹): 2953, 2930, 2857, 1752, 1605, 1510, 1450, 1382, 1252, 1221, 1202, 1181, 1155, 1093, 1016, 868, 835, 776, 753, 700, 687. MALDI-MS ($C_{36}H_{39}F_{2}NO_{5}Ssi$): [MH-TBDMSOH] 532.1395 (calcd. 532.1394); [MNa] 686.2185 (calcd. 686.2184).

This benzene sulfonate (90.0 mg, 0.136 mmol) was dissolved in anhydrous THF (2.5 mL, teflon bottle) at 0°C, anhydrous pyridine (0.5 mL) followed by HF-pyridine complex (0.5 mL) were added and the solution allowed slowly to warm to room temperature. After 14 h, the mixture was diluted with ether (20 mL) and washed with sat. aq. NaHCO₃ (3 x 5 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (5.0 x 2.0 cm) on silica gel eluting with a gradient of 0-100% $\rm CH_2Cl_2$ in hexane (v/v) followed by 1-7% MeOH in $\rm CH_2Cl_2$ (v/v) to give β -lactam XIV (69.2 mg, 93%) as a white foam.

 R_f (3% MeOH in CH_2Cl_2 (v/v)) 0.33; 1H -NMR (300 MHz, $CDCl_3$) δ : 7.82 (2H, dd, J = 1.2, 7.5 Hz), 7.67 (1H, tt, J = 1.2, 7.5 Hz), 7.51 (2H, t, J = 7.5 Hz), 7.29-7.22 (4H, m), 7.15 (2H, dd, J = 4.4, 8.7 Hz), 6.99 (2H, t, J = 8.7 Hz), 6.98 (2H, d, J = 8.7 Hz), 6.92 (2H, t, J = 8.7 Hz), 4.68 (1H, dd, J = 5.6, 6.2 Hz), 4.60 (1H, d, J = 1.9 Hz), 3.06-2.98 (1H, m), 2.55 (1H, bs), 2.04-1.84 (4H, m). ^{13}C -NMR (75 MHz, $CDCl_3$) δ : 166.87, 163.56, 160.44, 160.31, 157.22, 149.23, 139.84, 139.79 (C), 136.46 (CH), 135.10, 134.26, 133.37 (C), 129.07, 128.22, 127.26, 127.16, 127.02, 123.07, 118.21, 118.11, 115.93, 115.62, 115.36, 115.07, 72.98, 60.50, 60.32 (CH), 36.54, 25.09 (CH₂). IR (cm⁻¹): 3440, 3069, 3017, 2927, 2862, 1747, 1604, 1510, 1450, 1426, 1378, 1221, 1201, 1180, 1154, 1094, 1016, 868, 835, 753, 700, 687, 668. MALDI-MS ($C_{30}H_{25}F_{2}NO_{5}S$): [MH-H₂O]⁺ 532.1388 (calcd. 532.1394); [MNa]⁺ 572.1302 (calcd. 572.1319).

51

Example 11

ΧV

LiAlH₄ (57 mg, 1.5 mmol) and AlCl₃ (202 mg, 1.5 mmol) were suspended in anhydrous ether (15 mL), refluxed for 30 min and cooled to 0° C. β -Lactam **XIV** obtained in example 10 (62.8 mg, 0.114 mmol) dissolved in anhydrous ether (5 mL) was added and after stirring at 0° C for 20 min, sat. aq. NaHCO₃ (1 mL) was added dropwise. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.8 x 2.0 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give azetidine **XV** (24.5 mg, 40%) as a white foam.

 R_f (1:1 EtOAc/hexane (v/v)) 0.46; ¹H-NMR (300 MHz, CDCl₃) 7.88-7.82 (2H, m), 7.70-7.63 (1H, m), 7.55-7.47 (2H, m), 7.38-7.30(2H, m), 7.24-7.19 (2H, m), 7.05-6.98 (4H, m), 6.83 (2H, t, J = 8.7 Hz), 6.26 (2H, dd, J = 4.4, 9.3 Hz), 4.56 (1H, dd, J =5.0, 7.5 Hz), 4.36 (1H, d, J = 6.8 Hz), 4.09 (1H, dd, J = 6.8, 7.5 Hz), 3.27 (1H, dd, J = 6.8, 7.5 Hz), 2.79 (1H, d, J = 5.6Hz), 2.52 (1H, dd, J = 6.8, 7.5 Hz), 1.89-1.52 (4H, m). ¹³C-NMR $(75 \text{ MHz}, \text{ CDCl}_3)$ δ : 163.65, 160.40, 157.73, 154.61, 148.07, 141.59, 139.94, 135.36 (C), 134.11, 129.24, 129.03, 128.30, 127.28, 127.17, 122.54, 115.45, 115.15, 112.99, 112.90, 73.47, 73.32 (CH), 55.89 (CH₂), 41.74 (CH), 36.30, 29.93 (CH₂). IR (cm^{-1}) : 3411, 2937, 2853, 1604, 1508, 1474, 1450, 1374, 1221, 1198, 1175, 1151, 1093, 1016, 867, 823, 752, 700, 686. MALDI-MS $(C_{30}H_{27}F_{2}NO_{4}S): [MH-H_{2}O]^{+} 518.1596$ (calcd. $518.1601); [M]^{+} 535.1619$ (calcd. 535.1629); [MNa] + 558.1512 (calcd. 558.1527).

52

XVI

The silylated azetidinone phenol VIa obtained in step 2a) (105 mg, 0.201 mmol) was dissolved in anhydrous CH2Cl2 (5 mL), anhydrous pyridine (0.5 mL, 5.0 mmol) and 3-carboxy-4-hydroxybenzene sulfonyl chloride (prepared according to Stewart, J. J. Chem. Soc. 1922, 121, 2555-2561; 223 mg, 0.94 mmol) were added sequentially and the suspension was stirred at room temperature for 63 h. The mixture was evaporated on celite and purified by dry column vacuum chromatography (4.7 x 2.0 cm) on silica gel eluting with a gradient of 0-15% MeOH in CH₂Cl₂ (v/v) to give the corresponding silylated sulfonate (76.2 mg, 53%) as a colourless oil. R_f (20% MeOH in CH_2Cl_2 (v/v)) 0.68; ¹H-NMR (300 MHz, CD_3CN) δ : 10.36 (1H, bs), 8.31 (1H, bs), 7.69 (1H, bs), 7.31-7.13 (8H, m), 7.00 (2H, t, J = 7.5 Hz), 6.89 (2H, t, J = 8.1 Hz), 6.57 (1H, bs), 4.72 (1H, bs), 4.65 (1H, bs), 3.12 (1H, bs), 2.98 (1H, bs), 1.88-1.72 (4H, m), 0.84 (9H, s), 0.01 (3H, s), -0.18 (3H, s). ¹³C-NMR (75 MHz, CD₃CN) δ : 168.91, 167.92, 163.57, 157.89, 150.74, 142.17, 142.14, 137.17, 134.89 (C), 128.57, 128.45, 128.16, 123.34, 119.23, 119.17, 118.18, 116.68, 116.38, 115.71, 115.43, 74.39, 61.14, 60.64 (CH), 38.40 (CH₂), 26.12 (CH_3) , 25.10 (CH_2) , 18.65 (C), -4.53, -4.69 (CH_3) . IR (cm^{-1}) : 3450, 2954, 2930, 2858, 1751, 1696, 1606, 1585, 1510, 1478, 1386, 1339, 1293, 1220, 1194, 1126, 1103, 1087, 1063, 1042, 835, 777, 758. MALDI-MS $(C_{37}H_{39}F_2NO_8SSi)$: $[M-H+2Na]^+$ 768.1851 (calcd. 768.1851).

This silylated sulfonate (74.2 mg, 62.5 mmol) was dissolved in anhydrous THF (2.5 mL, teflon bottle) at 0°C, anhydrous pyridine (0.5 mL) followed by HF·pyridine complex (0.5 mL) were added and the solution allowed slowly to warm to room temperature. After 15 h, sat. aq. NaHCO₃ (15 mL) was added and the suspension was evaporated on celite and purified by dry column vacuum chromatography (4.4 x 2.0 cm) on silica gel eluting with a gradient of 0-25% MeOH in EtOAc (v/v) to give sulfonate XVI (43.6 mg, 70%) as a white solid.

 R_f (1:3 MeOH/EtOAc (v/v)) 0.44; ¹H-NMR (300 MHz, CD₃OD) δ : 8.53 (1H, d, J = 1.9 Hz), 7.99 (1H, dd, J = 2.5, 8.7 Hz), 7.48 (1H, d, J = 8.7 Hz), 7.35-7.28 (6H, m), 7.07-6.97 (5H, m), 4.93 (1H, d, J = 2.5 Hz), 4.62 (1H, dd, J = 5.0, 6.2 Hz), 3.17-3.08 (1H, m), 1.97-1.84 (4H, m). ¹³C-NMR (75 MHz, CD₃OD) δ : 169.19, 164.04, 151.43, 142.04, 142.01, 138.00 (C), 137.35 (CH), 134.92 (C), 129.46, 128.72, 128.62, 128.44, 123.54, 119.86, 119.76, 118.63, 116.82, 116.51, 115.98, 115.68 (CH), 112.37 (C), 73.73, 61.65, 61.39 (CH), 37.49, 26.18 (CH₂). MALDI-MS (C₃₁H₂₅F₂NO₈S): [M-H+2Na]⁺ 654.1000 (calcd. 654.0986).

Example 13

a)

XVIIa

54

The silylated azetidinone phenol VIa obtained in step 2a) (80.3 mg, 0.153 mmol) and alcohol XVIIa (prepared according to Spak, S. J.; Martin, O. R. Tetrahedron 2000, 56, 217-224; 101.5 mg, 0.103 mmol) were dissolved in anhydrous THF (10 mL) at 0°C, Bu₃P (50 mg, 0.20 mmol) and 1,1'-(azodicarbonyl)dipiperidine (39.5 mg, 0.17 mmol) were added sequentially and the suspension was allowed to warm to ambient temperature over several hours. After stirring at room temperature for 26 h, EtOAc/hexane (1:4 (v/v), 30 mL) was added and the suspension was filtered through celite (2 x 10 mL EtOAc/hexane (1:4 (v/v)) washings). The filtrate was evaporated on celite and purified by dry column vacuum chromatography (4.5 x 2.0 cm) on silica gel eluting with a gradient of 0-25% EtOAc in hexane (v/v) to give a 1:1 mixture of the corresponding C-glycoside and unreacted phenol VIa (49.7 mg) as a white foam.

 R_f (1:1 EtOAc/hexane (v/v)) 0.64; 13 C-NMR (75 MHz, CDCl₃) δ : 167.39, 163.27, 160.31, 158.82, 157.09, 140.54, 140.49, 139.05, 138.37, 138.29, 138.19, 137.85, 133.78, 133.73, 129.40, 128.96, 128.23, 128.12, 128.04, 127.94, 127.86, 127.73, 127.63, 127.57, 127.49, 127.41, 127.20, 127.10, 126.87, 118.30, 118.19, 116.01, 115.78, 115.49, 115.30, 114.99, 114.71, 102.41, 85.35, 84.84, 82.70, 79.29, 78.01, 77.82, 77.19, 75.64, 75.25, 75.10, 75.02, 74.96, 74.81, 73.84, 73.26, 68.99, 68.15, 67.49, 61.07, 60.44, 38.09, 25.90, 24.72, 18.25, -4.53, -4.83. MALDI-MS $(C_{92}H_{99}F_2NO_{13}Si)$: [MNa] $^+$ 1514.6763 (calcd. 1514.6751).

This mixture of the C-glycoside and phenol VIa (49.7 mg) was dissolved in EtOH/EtOAc (10 mL, 1:1 (v/v)), $Pd(OH)_2/C$ (20% (w/w), 31 mg) was added and the suspension was evacuated 4 times with H_2 and stirred under an H_2 -atmosphere for 3 h. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.6 x 2.0 cm) on silica gel eluting with a gradient of

55

0-20% MeOH in CH_2Cl_2 (v/v) to give the corresponding debenzylated C-qlycoside (18.7 mg, 21% from **VIa**) as a colourless oil.

 R_f (20% MeOH in CH_2Cl_2 (v/v)) 0.44; 1H -NMR (300 MHz, CD_3OD) δ : 7.31-7.23 (6H, m), 7.04-6.94 (6H, m), 4.71 (1H, d, J = 1.9 Hz), 4.41 (1H, d, J = 7.5 Hz), 4.12 (1H, dd, J = 5.3, 10.9 Hz), 3.91-3.81 (3H, m), 3.66 (1H, d, J = 5.6, 11.8 Hz), 3.57-3.47 (3H, m), 3.40-3.20 (7H, m), 3.07 (1H, t, J = 5.9 Hz), 1.92-1.78 (4H, m), 0.87 (9H, s), 0.02 (3H, s), -0.18 (3H, s). ^{13}C -NMR (75 MHz, CD_3OD) δ : 169.71, 160.66, 145.96, 142.43, 131.16, 131.05, 128.89, 128.80, 128.62, 120.00, 119.89, 116.83, 116.54, 116.41, 116.02, 115.74, 115.58, 104.65, 80.78, 80.43, 79.64, 78.16, 77.90, 75.13, 74.99, 71.43, 62.50, 62.08, 61.29, 38.96, 26.38, 25.75, 19.06, -4.40. MALDI-MS ($C_{43}H_{57}F_2NO_{13}Si$): [MNa] * 884.3668 (calcd. 884.3465).

This debenzylated *C*-glycoside (18.3 mg, 0.021 mmol) was dissolved in anhydrous THF (2.5 mL, teflon bottle) at 0°C, anhydrous pyridine (0.50 mL) followed by HF·pyridine complex (0.50 mL) were added and the solution was stirred for 17 h. NaHCO₃ (s) was added and the suspension was evaporated on celite and purified by dry column vacuum chromatography (4.6 x 2.0 cm) on silica gel eluting with a gradient of 0-20% MeOH in CH₂Cl₂ (v/v) to give the desired *C*-glycoside **XVII** (10.3 mg, 65%) as a white solid.

R_f (20% MeOH in CH_2Cl_2 (v/v)) 0.31; ¹H-NMR (300 MHz, CD_3OD) δ : 7.33-7.24 (6H, m), 7.05-6.94 (6H, m), 4.78 (1H, d, J = 1.9 Hz), 4.60 (1H, t, J = 4.4 Hz), 4.41 (1H, d, J = 7.5 Hz), 4.30 (1H, d, J = 10.0 Hz), 4.12 (1H, dd, J = 5.0, 10.6 Hz), 3.91-3.84 (3H, m), 3.66 (1H, d, J = 5.6, 11.8 Hz), 3.57-3.49 (3H, m), 3.40-3.20 (6H, m), 3.10-3.06 (1H, m), 1.97-1.82 (4H, m). ¹³C-NMR (75 MHz, CD_3OD) δ : 169.52, 164.87, 160.42, 142.07, 133.18 (C), 131.03, 130.87, 128.68, 128.59, 128.47, 123.36, 119.86, 119.74, 116.69, 116.38, 116.25, 116.22, 115.96, 115.88, 115.68, 104.54, 80.71, 80.36, 79.58, 78.11, 77.85, 74.94, 73.70, 71.38 (CH), 69.02,

56

62.47 (CH₂), 62.09 (CH₂+CH), 61.20 (CH), 37.54, 26.18 (CH₂). MALDI-MS ($C_{37}H_{43}F_{2}NO_{13}$): [MNa]⁺ 770.2589 (calcd. 770.2600).

Example 14

XVIII

a)

XVIIIa

Alcohol XVIIa (prepared according to Spak, S. J.; Martin, O. R. Tetrahedron 2000, 56, 217-224; 895.3 mg, 0.907 mmol) was dissolved in anhydrous CH_2Cl_2 (10 mL), anhydrous pyridine (1.0 mL) followed by MsCl (0.20 mL, 2.6 mmol) were added and after stirring for 1 h, sat. aq. $NaHCO_3$ (40 mL) was added. The layers were separated and the aqueous layer extracted with EtOAc (3 x 20 mL). The combined organic layer was washed successively with sat. aq. $NaHCO_3$ (20 mL) and H_2O (20 mL), evaporated on celite and purified by dry column vacuum chromatography (4.2 x 3.3 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give the corresponding mesylate (830.7 mg, 86%) as a white solid.

 $R_{\rm f}$ (1:1 EtOAc/hexane (v/v)) 0.67; ¹H-NMR (300 MHz, CDCl₃) δ : 7.49-7.24 (35H, m), 5.31 (1H, d, J = 11.2 Hz), 5.00 (1H, d, J =

57

11.2 Hz), 4.98-4.79 (6H, m), 4.66-4.36 (9H, m), 4.09 (1H, t, J = 9.3 Hz), 3.90 (1H, dd, J = 2.8, 10.9 Hz), 3.83 (1H, d, J = 10.0 Hz), 3.75-3.62 (5H, m), 3.55-3.39 (5H, m), 2.97 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ : 138.97, 138.37, 138.21, 138.04, 137.61 (C), 128.37, 128.29, 128.18, 128.08, 127.93, 127.84, 127.76, 127.38, 127.34, 127.24, 102.51, 84.86, 82.64, 78.70, 77.94, 76.84, 76.53, 76.38, 75.57 (CH), 75.22, 75.09 (CH₂), 74.96, 74.78 (CH₂, CH), 73.21, 73.02, 69.22, 68.89, 67.76 (CH₂), 37.74 (CH₃). IR (cm⁻¹): 3063, 3030, 2867, 1497, 1454, 1358, 1277, 1209, 1174, 1150, 1092, 1071, 1028, 984, 922, 812, 737, 698, 527. MALDI-MS (C₆₃H₆₈O₁₃S): [MNa]⁺ 1087.4284 (calcd. 1087.4278). Anal. Calcd for C₆₃H₆₈O₁₃S: C, 71.03; H, 6.43. Found: C, 70.94; H, 6.62.

Subsequently, this mesylate (825 mg, 0.774 mmol) was dissolved in EtOH (20 mL), KOSCMe (278 mg, 2.43 mmol), iPrOH (10 mL) and THF (10 mL) were added and the orange solution was stirred at reflux for 3 h (orange precipitate). Additional KOSCMe (512 mg, 4.48 mmol) was added and the suspension was stirred at reflux for 16 h. After cooling, 50% sat. aq. NaHCO $_3$ (100 mL) was added and the suspension was extracted with ether (4 x 30 mL). The combined organic layer was washed successively with sat. aq. NaHCO $_3$ (50 mL) and H $_2$ O (50 mL), evaporated on celite and purified by dry column vacuum chromatography (4.2 x 3.3 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give the corresponding thioacetate (637 mg, 79%) as a light orange solid.

 R_f (1:3 EtOAc/hexane (v/v)) 0.45; $^1\text{H-NMR}$ (300 MHz, CDCl₃) δ : 7.43-7.19 (35H, m), 5.22 (1H, d, J=11.2 Hz), 4.92 (1H, d, J=11.2 Hz), 4.88 (1H, d, J=11.2 Hz), 4.87-4.71 (5H, m), 4.62 (1H, d, J=12.5 Hz), 4.60-4.43 (5H, m), 4.41 (1H, d, J=11.8 Hz), 4.06 (1H, t, J=9.3 Hz), 3.86 (1H, dd, J=3.7, 11.2 Hz), 3.75 (1H, dd, J=1.6, 10.9 Hz), 3.69-3.55 (5H, m), 3.51-3.31 (6H, m), 3.05 (1H, dd, J=6.8, 13.7 Hz), 2.34 (3H, s). $^{13}\text{C-NMR}$

WO 2005/033100

PCT/CH2004/000584

58

(75 MHz, CDCl₃) δ : 195.04, 139.19, 138.53, 138.30, 138.24, 138.17, 137.96 (C), 128.33, 128.26, 128.20, 128.04, 127.79, 127.71, 127.63, 127.55, 127.47, 127.29, 127.19, 102.40, 85.12, 84.88, 82.71, 79.85, 79.30, 78.05, 77.87 (CH), 75.62, 75.18 (CH₂), 75.09 (CH), 74.94, 74.81, 73.26, 73.21, 68.96, 67.86, 31.12 (CH₂), 30.49 (CH₃). IR (cm⁻¹): 3030, 2868, 1692, 1496, 1454, 1358, 1210, 1067, 1028, 773, 735, 698, 626. MALDI-MS (C₆₄H₆₈O₁₁S): [MNa] [†] 1067.4365 (calcd. 1067.4380). Anal. Calcd for C₆₄H₆₈O₁₁S: C, 73.54; H, 6.56. Found: C, 73.50; H, 6.60.

The thioacetate received above (631 mg, 0.604 mmol) was suspended in AcOH (10 mL), KOAc (933 mg, 9.5 mmol) followed by Oxone (2KHSO $_5$ ·KHSO $_4$ ·K $_2$ SO $_4$, 1.179 g, 2.55 mmol) were added and after stirring for 18 h, sat. aq. Na $_2$ CO $_3$ (50 mL) and H $_2$ O (50 mL) were carefully added. After extraction with CHCl $_3$ (4 x 25 mL), the combined organic layer was washed with sat. aq. Na $_2$ CO $_3$ (25 mL), evaporated on celite and purified by dry column vacuum chromatography (4.1 x 3.3 cm) on silica gel eluting with a gradient of 0-20% MeOH in CH $_2$ Cl $_2$ (v/v) to give the corresponding sulfinate salt (622 mg, 96%) as a colourless oil.

 R_f (10% MeOH in CH_2Cl_2 (v/v)) 0.29; 1H -NMR (300 MHz, $CDCl_3$) δ : 7.40-7.14 (35H, m), 5.19-4.34 (15H, m), 4.17-3.22 (15H, m). ^{13}C -NMR (75 MHz, $CDCl_3$) δ : 138.97, 138.32, 138.21, 138.06, 137.88, 137.84, 128.70, 128.36, 128.18, 128.05, 127.86, 127.76, 127.63, 127.57, 127.44, 127.29, 127.20, 126.94, 84.53, 84.45, 82.01, 79.48, 77.96, 77.75, 76.06, 76.01, 75.46, 74.94, 74.79, 74.67, 74.57, 73.28, 73.08, 73.02, 53.42. IR (cm^{-1}): 3478, 3063, 3030, 2870, 1497, 1454, 1361, 1315, 1210, 1174, 1069, 1048, 1028, 736, 698, 621. MALDI-MS ($C_{62}H_{65}NaO_{13}S$): [MH]* 1073.4098 (calcd. 1073.4122); [MNa]* 1095.3926 (calcd. 1095.3941).

Finally, the obtained sulfinate salt (334 mg, 0.311 mmol) was dissolved in anhydrous acetonitrile/ CH_2Cl_2 (4 mL, 1:1 (v/v)) at

59

 0° C, Ph_3P (264 mg, 1.01 mmol) and thionyl chloride (0.10 mL, 1.37 mmol) were added sequentially at 0° C and the suspension was stirred at room temperature for 6 h. EtOAc/hexane (1:4 (v/v), 30 mL) was added, the suspension was filtered through a short pad of silica gel (4 x 5 mL EtOAc/hexane (1:3 (v/v)) washings) and the filtrate was evaporated and dried shortly under vacuum to give the desired sulfonyl chloride XVIIIa (220 mg, 66%) as a light yellow foam.

 R_f (1:3 EtOAc/hexane (v/v)) 0.38; 1H -NMR (300 MHz, CDCl₃) \bar{o} : 7.50-7.26 (35H, m), 5.30 (1H, d, J = 11.2 Hz), 4.98 (1H, d, J = 10.6 Hz), 4.96-4.81 (5H, m), 4.79 (1H, d, J = 10.6 Hz), 4.67-4.50 (6H, m), 4.48 (1H, d, J = 11.8 Hz), 4.23-4.15 (1H, m), 3.98-3.91 (2H, m), 3.85-3.57 (8H, m), 3.51-3.38 (3H, m), 3.30 (1H, t J = 9.0 Hz). ^{13}C -NMR (75 MHz, CDCl₃) \bar{o} : 138.77, 138.45, 138.17, 138.11, 137.78, 137.27 (C), 128.63, 128.38, 128.31, 128.18, 128.12, 127.94, 127.78, 127.70, 127.63, 127.55, 127.42, 127.29, 102.32, 84.98, 84.80, 82.66, 79.23, 77.95, 77.82, 75.78 (CH), 75.60, 75.38 (CH₂), 75.12 (CH), 74.99, 74.78, 74.70 (CH₂), 74.21 (CH), 73.24, 68.95, 67.35, 66.79 (CH₂). IR (cm⁻¹): 3089, 3063, 3030, 2868, 1496, 1454, 1362, 1313, 1280, 1209, 1167, 1091, 1067, 1028, 913, 771, 736, 698, 601. MALDI-MS ($C_{62}H_{65}ClO_{12}S$): [MNa] + 1091.3767 (calcd. 1091.3783).

The sulfonyl chloride **XVIIIa** (271 mg, 0.253 mmol) was dissolved in anhydrous CH_2Cl_2 (3 mL), anhydrous pyridine (0.5 mL) followed by the silylated azetidinone phenol **VIa** obtained in step 2a) (75.7 mg, 0.145 mmol) were added and the solution was stirred for 38 h, diluted with EtOAc (50 mL) and washed sequentially with sat. aq. $NaHCO_3$ (15 mL) and H_2O (15 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.5 x 3.3 cm) on silica gel eluting with a gradient of 0-20% EtOAc in toluene (v/v) to give the corresponding sulfonate mixed with unreacted phenol **VIa** (166 mg, 4:1 mixture) as

a white foam.

WO 2005/033100

 R_f (1:1 EtOAc/hexane (v/v)) 0.73; ¹H-NMR (300 MHz, CDCl₃) δ : 7.49-7.17 (41H, m), 7.06 (2H, d, J = 8.7 Hz), 7.02 (2H, t, J =8.1 Hz), 6.96 (2H, d, J = 8.7 Hz), 5.31 (1H, d, J = 11.2 Hz), 5.01-4.74 (7H, m), 4.65-4.45 (8H, m), 4.21 (1H, t, J = 9.3 Hz), 4.02-3.96 (2H, m), 3.86-3.60 (6H, m), 3.53-3.47 (4H, m), 3.33 (1H, d, J = 9.3 Hz), 3.26 (1H, t, J = 9.0 Hz), 3.19 (1H, d, J =9.3 Hz), 3.06-3.00 (1H, m), 2.06-1.84 (4H, m), 0.96 (9H, s), 0.10 (3H, s), -0.07 (3H, s). $^{13}C-NMR$ (75 MHz, $CDCl_3$) δ : 166.70, 160.35, 160.00, 156.27, 149.33, 140.35, 140.31, 138.63, 138.26, 138.00, 137.90, 137.59, 137.45, 137.29, 136.51, 133.47 (C), 128.82, 128.73, 128.34, 128.19, 128.08, 127.98, 127.85, 127.66, 127.56, 127.45, 127.30, 127.25, 127.12, 127.01, 125.10, 123.32, 118.11, 118.01, 115.91, 115.60, 115.00, 114.93, 114.72, 102.39, 84.93, 84.80, 82.56, 78.82, 78.55, 77.95, 75.99 (CH), 75.60, 75.31 (CH₂), 75.15 (CH), 74.96, 74.76 (CH₂), 74.23, 73.77 (CH), 73.21, 73.08, 68.97, 67.62 (CH₂), 61.02, 60.57, 60.39 (CH), 51.26, 38.02 (CH₂), 25.85 (CH₃), 24.67 (CH₂), 18.19 (C), -4.56, -4.87 (CH₃). ¹⁹F-NMR (282 MHz, CDCl₃) δ : -114.94 (1F, septet, J = 4.3 Hz), -117.10 (1F, septet, J = 4.3Hz). MALDI-MS $(C_{92}H_{99}F_2NO_{15}SiS): [MNa]^+ 1578.6365 (calcd. 1578.6370).$

Subsequently, this sulfonate (166 mg 4:1 mixture) was dissolved in EtOH (5 mL), $Pd(OH)_2/C$ (20% (w/w), 94 mg) was added and the suspension was evacuated 4 times with H_2 and stirred under an H_2 -atmosphere for 11.5 h. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.3 x 2.0 cm) on silica gel eluting with a gradient of 0-10% MeOH in CH_2Cl_2 (v/v) to give the corresponding debenzylated β -lactam (69.5 mg, 52% from phenol **VIa**) as a colourless oil.

R_f (20% MeOH in CH_2Cl_2 (v/v)) 0.46; ¹H-NMR (300 MHz, CD_3OD) δ : 7.46-7.38 (4H, m), 7.31-7.23 (4H, m), 7.04-6.95 (4H, m), 4.75-4.68 (1H, m), 4.44 (1H, d, J = 8.1 Hz), 3.92-3.80 (5H, m), 3.69-

61

3.18 (11H, m), 3.10-3.05 (1H, m), 1.95-1.75 (4H, m), 0.86 (9H, s), 0.01 (3H, s), -0.19 (3H, s). 13 C-NMR (75 MHz, CD₃OD) δ : 169.31, 169.21, 161.76, 158.91, 150.96, 142.28, 138.45, 135.01, 134.98, 131.06, 130.95 (C), 128.83, 124.50, 119.92, 119.83, 116.99, 116.68, 116.10, 116.04, 115.81, 115.74, 104.54, 80.33, 80.10, 78.11, 77.81, 77.72, 76.30, 75.13, 74.89, 73.61, 71.38 (CH), 62.47, 61.63 (CH₂), 61.56, 61.47 (CH), 53.26, 38.83 (CH₂), 26.38 (CH₃), 25.75 (CH₂), 19.04 (C), -4.40, -4.70 (CH₃). 19 F-NMR (282 MHz, CD₃OD) δ : -117.94 (1F, septet, J = 4.3 Hz), -120.10 (1F, septet, J = 4.3 Hz). MALDI-MS (C₄₃H₅₇F₂NO₁₅SiS): [MNa]⁺ 948.3088 (calcd. 948.3084).

This debenzylated β -Lactam (59.5 mg, 0.073 mmol) was dissolved

in anhydrous THF (2.0 mL, teflon bottle), anhydrous pyridine (0.40 mL) followed by HF.pyridine complex (0.40 mL) were added and the solution was stirred for 14 h. Sat. aq. NaHCO3 (5 mL) was added and the suspension was evaporated on celite and purified by dry column vacuum chromatography (4.4 x 2.0 cm) on silica gel eluting with a gradient of 10-20% MeOH in CH_2Cl_2 (v/v) to give the desired β -lactam **XVIII** (38.1 mg, 64%) as a white solid. R_f (10% MeOH in CH_2Cl_2 (v/v)) 0.17 (eluted thrice); 1H -NMR (300 MHz, CD₃OD) δ : 7.45 (2H, t, J = 9.3 Hz), 7.40 (2H, d, J = 8.7 Hz), 7.33-7.24 (4H, m), 7.02 (2H, t, J=8.1 Hz), 6.98 (2H, d, J= 8.7 Hz), 4.90 (1H, d, J = 1.9 Hz), 4.60 (1H, dd, J = 5.0, 6.2 Hz), 4.43 (1H, d, J = 7.5 Hz), 3.92-3.79 (5H, m), 3.69-3.49 (4H, m), 3.44-3.18 (6H, m), 3.12-3.06 (1H, m), 1.99-1.82 (4H, m). $^{13}C-$ NMR (75 MHz, CD₃OD) δ : 169.31, 165.08, 162.17, 161.85, 158.96, 150.98, 142.15, 138.51, 135.01 (C), 128.88, 128.76, 124.46, 119.97, 119.86, 116.99, 116.68, 116.13, 115.84, 104.54, 80.35, 80.06, 78.11, 77.81, 77.71, 76.31, 74.91, 73.77, 73.63, 71.39 (CH), 62.45, 61.50 (CH₂), 61.42 (CH), 53.26, 37.45, 26.12 (CH₂). 19 F-NMR (282 MHz, CD₃OD) δ : -118.08 (1F, septet, J = 4.3 Hz), -120.21 (1F, septet, J = 4.3 Hz). MALDI-MS ($C_{37}H_{43}F_2NO_{15}S$): [MNa]⁺

834.2223 (calcd. 834.2219).

Example 15

a)

A 50 mL Schlenk flask was charged with $Zn(OTf)_2$ (12.647 g, 34.79 mmol) and heated to 120°C under high-vacuum (0.2 Torr) for 3.5 h. After cooling, (+)-N-methylephedrine (6.595 g, 36.79 mmol) was added and the flask was purged with Ar for 15 min. Anhydrous toluene (14 mL) followed by Et_3N (3.874 g, 38.3 mmol) were added and after 3 h stirring, benzyl propargyl ether (prepared according to Ren, X. F.; Turos, E.; Lake, C. H.; Churchill, M. R. J. Org. Chem. 1995, 60, 6468-6483; 5.556 g, 38.00 mmol) was added in one portion. After 20 min stirring, the mixture was transferred to a precooled acetone bath (8°C), stirred for 5 min and p-FC₆H₄CHO (3.632 g, 29.26 mmol) was added in one portion. After 15 h stirring at 9 to 12°C, the suspension was diluted with EtOAc

(125 mL) and washed with sat. aq. NH_4Cl (2 x 30 mL) and brine (30 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (5.4 x 5.5 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give propargyl alcohol XIXa (5.896 g, 75%) as a light yellow oil. Enantiomeric excess as determined by HPLC analysis: 96% ee; Rt 20 min (R-XIXa), 28 min (S-XIXa) (Chiracel OD-H 25 cm, 6% iPrOH in hexane, flow 1.0 mL/min, 254 nm). R_f (1:3 EtOAc/hexane (v/v)) 0.28; ; $^{1}\text{H-NMR}$ (300 MHz, CDCl₃) δ : 7.50 (2H, dd, J = 5.6, 8.7 Hz), 7.38-7.32 (5H, m), 7.06 (2H, t, J = 8.7 Hz), 5.48 (1H, s), 4.60 (2H, s), 4.26 (2H, s), 2.84 (1H, s). $^{13}\text{C-NMR}$ (75 MHz, CDCl₃) δ: 164.01, 160.75, 136.95, 136.04 (C), 128.30, 128.21, 127.92, 127.81, 115.43, 115.13 (CH), 86.13, 82.62 (C), 71.74 (CH₂), 63.74 (CH), 57.35 (CH₂). $^{19}\text{F-NMR}$ (282 MHz, CDCl₃) δ : -113.28 (1F, septet, J = 4.3 Hz). IR (cm⁻¹): 3390, 3066, 3032, 2859, 1604, 1508, 1455, 1413, 1386, 1355, 1224, 1158, 1121, 1096, 1072, 1014, 842, 772, 744, 699, 592, 561, 498. MALDI-MS $(C_{17}H_{15}FO_2)$: $[MNa]^{+}$ 293.0947 (calcd. 293.0954). Anal. Calcd for $C_{17}H_{15}FO_{2}$: $C_{17}H_{15}FO_{17}H_{15}H_{15}FO_{17}H_{15}H_$ 75.54; H, 5.59. Found: C, 75.39; H, 5.62.

Subsequently this propargyl alcohol (4.108 g, 15.20 mmol) was dissolved in anhydrous DMF (50 mL), imidazole (2.123 g, 31.1 mmol) and TBDMSC1 (3.590 mg, 23.8 mmol) were added sequentially and the solution was stirred for 3.5 h followed by addition of 50% sat. aq. NaHCO₃ (150 mL). After extraction with ether (4 x 50 mL), the combined organic layer was washed successively with sat. aq. NaHCO₃ (50 mL) and H₂O (50 mL), evaporated and dried shortly under high vacuum. The residue was dissolved in EtOH (40 mL), Na₂CO₃ (3.229 g, 30.5 mmol) and Pd/C (10% (w/w), 223 mg) were added and the suspension was evacuated 4 times with H₂ and stirred under an H₂-atmosphere for 19 h. The suspension was diluted with 10% EtOAc/hexane (250 mL (v/v)) and filtered through a short pluq of silica qel (2 x 25 mL 20% EtOAc/hexane washings

64

(v/v)), evaporated and dried shortly under high vacuum. The residue was dissolved in EtOH (40 mL), Pd/C (10% (w/w), 142 mg) was added and the suspension was evacuated 4 times with H₂ and stirred under an H₂-atmosphere for 1 h. Additional Pd/C (10% (w/w), 190 mg) was added and the suspension was evacuated 4 times with H₂ and stirred under an H₂-atmosphere for 1.25 h. The suspension was evaporated on celite and purified by dry column vacuum chromatography (5.2 x 5.5 cm) on silica gel eluting with a gradient of 0-25% EtOAc in hexane (v/v) to give the corresponding alcohol (3.643 g, 80%) as a light yellow oil.

 R_f (1:3 EtOAc/hexane (v/v)) 0.37; 1H -NMR (300 MHz, CDCl₃) δ : 7.24 (2H, dd, J = 5.6, 8.7 Hz), 6.97 (2H, t, J = 8.7 Hz), 4.69 (1H, dt, J = 1.2, 5.0 Hz), 3.59 (2H, dt, J = 1.2, 6.2 Hz), 2.18 (1H, bs), 1.77-1.45 (4H, m), 0.87 (9H, s), 0.02 (3H, s), -0.15 (3H, s). 13 C-NMR (75 MHz, CDCl₃) δ : 163.37, 160.13, 140.96, 140.91 (C), 127.32, 127.23, 114.94, 114.64, 74.16 (CH), 62.76, 37.19, 28.47 (CH₂), 25.76 (CH₃), 18.15 (C), -4.71, -5.05 (CH₃). IR (cm⁻¹): 3339, 2954, 2930, 2885, 2858, 1606, 1510, 1472, 1463, 1362, 1252, 1223, 1156, 1092, 1060, 984, 890, 836, 776, 668, 560. MALDI-MS ($C_{16}H_{27}FO_2Si$): [MNa] $^+$ 321.1643 (calcd. 321.1662). Anal. Calcd for $C_{16}H_{27}FO_2Si$: C, 64.39; H, 9.12. Found: C, 64.36; H, 9.15.

The alcohol obtained above was dissolved in CH_2Cl_2 (50 mL), Dess-Martin periodinane (5.658 g, 13.3 mmol) was added and the milky solution was stirred at room temperature for 1.5 h. Sat. aq. Na_2SO_3 (100 mL) was added and the layers were swirled until the solid had dissolved. The layers were separated and the aqueous phase was extracted with CH_2Cl_2 (2 x 40 mL). The combined organic phase was evaporated on celite and purified by dry column vacuum chromatography (5.1 x 5.5 cm) on silica gel eluting with a gradient of 0-10% EtOAc in hexane (v/v) to give the corresponding aldehyde XIXb (2.093 g, 80%) as a light yellow oil.

65

R_f (1:3 EtOAc/hexane (v/v)) 0.63; 1 H-NMR (300 MHz, CDCl₃) δ : 9.73 (1H, d, J = 1.5 Hz), 7.25 (2H, dd, J = 5.6, 8.7 Hz), 6.99 (2H, t, J = 9.0 Hz), 4.74 (1H, dt, J = 5.0, 6.8 Hz), 2.52-2.35 (2H, m), 2.06-1.88 (2H, m), 0.88 (9H, s), 0.02 (3H, s), -0.16 (3H, s). 13 C-NMR (75 MHz, CDCl₃) δ : 201.91 (CH), 163.35, 160.10, 140.13 (C), 127.20, 127.10, 115.04, 114.75, 73.03 (CH), 39.69, 33.11 (CH₂), 25.85 (CH₃), 18.21 (C), -4.61, -4.95 (CH₃). IR (cm⁻¹): 2955, 2938, 2888, 2858, 2720, 1727, 1606, 1509, 1472, 1464, 1412, 1390, 1362, 1254, 1223, 1156, 1090, 1014, 837, 776, 670, 540. Anal. Calcd for $C_{16}H_{25}FO_{2}Si$: C, 64.82; H, 8.50. Found: C, 64.95; H, 8.36.

LiCl (140.8 mg, 3.32 mmol) was heated shortly with a heat gun under high-vacuum and after cooling, anhydrous CH₃CN (5 mL), phosphonate XIXc (prepared according to Melekhov, A.; Fallis, A. G. Tetrahedron Lett. 1999, 40, 7867-7870; 660 mg, 1.68 mmol) and DBU (221 mg, 1.45 mmol) were added sequentially. After 3 min stirring, the aldehyde XIXb (407.3 mg, 1.37 mmol) was added and the suspension was stirred at room temperature for 2.5 h followed by addition of 50% sat. aq. NaHCO3 (60 mL). After extraction with ether/hexane (1:1 (v/v), 4 x 25 mL), the combined organic layer was washed with brine (25 mL), evaporated on celite and purified by dry column vacuum chromatography (4.6 x 3.3 cm) on silica gel eluting with a gradient of 0-20% EtOAc in hexane (v/v) to give olefin **XIXd** (520.7 mg, 71%) as a colourless oil. R_f (1:3 EtOAc/hexane (v/v)) 0.43; 1H -NMR (300 MHz, CDCl₃) δ : 7.25 (2H, dd, J = 5.6, 8.7 Hz), 7.10-6.94 (3H, m), 6.53 (1H, d, J = 5.6)14.9 Hz), 4.65 (1H, dd, J = 5.0, 7.5 Hz), 3.91 (1H, dd, J = 5.6, 6.8 Hz), 3.50 (1H, d, J = 13.7 Hz), 3.42 (1H, d, J = 13.7 Hz), 2.30-2.23 (2H, m), 2.09-2.02 (2H, m), 1.90-1.70 (5H, m), 1.43-1.30 (2H, m), 1.15 (3H, s), 0.95 (3H, s), 0.85 (9H, s), 0.01 (3H, s), -0.20 (3H, s). 13 C-NMR (75 MHz, CDCl₃) δ : 163.88, 163.39, 160.14, 150.06, 140.63 (C), 127.35, 127.26, 120.91,

114.98, 114.69, 73.24, 64.99 (CH), 53.04 (CH₂), 48.33, 47.67 (C), 44.58 (CH), 38.61, 38.39, 32.71, 28.32, 26.40 (CH₂), 25.72, 20.72, 19.78 (CH₃), 18.04 (C), -4.74, -5.10 (CH₃). IR (cm⁻¹): 2956, 2885, 2859, 1684, 1640, 1605, 1509, 1472, 1414, 1374, 1332, 1295, 1250, 1220, 1165, 1134, 1083, 1049, 995, 970, 860, 836, 774, 544. MALDI-MS ($C_{28}H_{42}FNO_4SSi$): [MNa]⁺ 558.2479 (calcd. 558.2486). Anal. Calcd for $C_{28}H_{42}FNO_4SSi$: C, 62.77; H, 7.90; N, 2.61. Found: C, 62.84; H, 7.78; N, 2.58.

66

Olefin XIXd was dissolved in anhydrous toluene (2.0 mL), TMSCHN₂ (2 M in hexanes, 1.50 mL, 3.0 mmol) was added and the solution was stirred at room temperature for 64 h. After evaporation, the residue was dissolved in CH_2Cl_2 (10 mL), TFA (202 mg, 1.77 mmol) was added and the solution was stirred for 20 min. Sat. aq. Na- HCO_3 (1.5 mL) was added and the mixture was evaporated on celite and purified by dry column vacuum chromatography (4.5 x 3.3 cm) on silica gel eluting with a gradient of 0-40% EtOAc in hexane (v/v) to give the corresponding pyrazoline (468 mg, 84%) as a light yellow foam.

 R_f (1:3 EtOAc/hexane (v/v)) 0.25; 1H -NMR (300 MHz, CDCl₃) δ : 7.21 (2H, dd, J = 5.6, 8.7 Hz), 6.95 (2H, t, J = 8.7 Hz), 6.60 (1H, s), 6.16 (1H, d, J = 5.6 Hz), 4.65 (1H, t, J = 5.0 Hz), 4.33 (1H, dd, J = 5.9, 9.7 Hz), 3.87 (1H, dd, J = 5.0, 7.5 Hz), 3.67-3.62 (1H, bs), 3.53 (1H, d, J = 13.7 Hz), 3.44 (1H, d, J = 13.7 Hz), 2.15-1.99 (2H, m), 1.91-1.86 (3H, m), 1.66-1.51 (3H, m), 1.47-1.21 (3H, m), 1.14 (3H, s), 0.95 (3H, s), 0.86 (9H, s), 0.01 (3H, s), -0.17 (3H, s). ^{13}C -NMR (75 MHz, CDCl₃) δ : 167.96, 163.12, 159.89 (C), 146.91 (CH), 140.52, 140.49 (C), 127.15, 127.05, 114.83, 114.54, 73.37, 66.44, 65.09 (CH), 52.81 (CH₂), 48.91 (C), 48.04 (CH), 47.79 (C), 44.33 (CH), 37.98, 37.79, 32.55, 26.76, 26.45 (CH₂), 25.82, 20.68, 19.84 (CH₃), 18.16 (C), -4.64, -4.90 (CH₃). TR (cm⁻¹): 3360, 2955, 2857, 1700, 1604, 1509, 1472, 1390, 1329, 1273, 1250, 1236, 1221, 1166, 1134,

67

1086, 1066, 994, 939, 836, 775, 694, 542. MALDI-MS $(C_{29}H_{44}FN_3O_4SSi)$: [MNa]⁺ 600.2691 (calcd. 600.2704). Anal. Calcd for $C_{29}H_{44}FN_3O_4SSi$: C, 60.28; H, 7.67; N, 7.27. Found: C, 60.25; H, 7.83; N, 7.16.

This pyrazoline (409.8 mg, 0.709 mmol), $Cu(OAc)_2$ (296 mg, 1.63 mmol) and $(p-FC_6H_4)_3Bi$ (prepared according to Banfi, A.; Bartoletti, M.; Bellora, E.; Bignotti, M.; Turconi, M. Synthesis 1994, 775-776; 950 mg, 1.92 mmol) were dissolved in anhydrous CH_2Cl_2 (5 mL), anhydrous Et_3N (165 mg, 1.63 mmol) was added and the dark green suspension was stirred at room temperature for 12.5 h. After evaporation on celite the residue was purified by dry column vacuum chromatography (4.5 x 3.3 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give N-arylated pyrazoline XIXe (320.8 mg, 63%) as a light yellow foam.

 R_f (1:3 EtOAc/hexane (v/v)) 0.33; ¹H-NMR (300 MHz, CDCl₃) δ : 7.24 (2H, dd, J = 5.3, 8.4 Hz), 7.01-6.94 (4H, m), 6.89 (2H, t, J =8.7 Hz), 6.68 (1H, d, J = 1.9 Hz), 5.05 (1H, d, J = 3.7 Hz), 4.62 (1H, t, J = 5.3 Hz), 3.85 (1H, dd, J = 4.4, 7.5 Hz), 3.59 (1H, d, J = 14.3 Hz), 3.58 (1H, d, J = 14.3 Hz), 3.41-3.35 (1H, d, J = 14.3 Hz)m), 1.98-1.78 (5H, m), 1.72-1.60 (3H, m), 1.41-1.23 (3H, m), 1.21 (3H, s), 0.98 (3H, s), 0.88 (9H, s), 0.04 (3H, s), -0.17 (3H, s). 13 C-NMR (75 MHz, CDCl₃) δ : 169.54, 163.38, 160.14, 158.46, 155.30 (C), 142.10 (CH), 140.75 (C), 127.32, 127.22, 115.71, 115.40, 114.96, 114.67, 114.22, 114.12, 73.99, 65.48, 64.93 (CH), 53.02 (CH, CH₂), 49.05, 47.77 (C), 44.31 (CH), 37.98, 36.95, 32.76, 27.79, 26.25 (CH_2), 25.75, 20.37, 19.77 (CH_3), 18.07 (C), -4.77, -5.01 (CH₃). ¹⁹F (282 MHz, CDCl₃) δ : -116.27(1F, m), -125.73 (1F, septet, J = 4.3 Hz). IR (cm^{-1}) : 2957, 2857, 1699, 1606, 1510, 1471, 1413, 1362, 1334, 1268, 1250, 1221, 1166, 1136, 1113, 1088, 1063, 987, 836, 776, 759, 538. MALDI-MS $(C_{35}H_{47}F_2N_3O_4SSi): [MH-TBDMSOH]^+ 540.2127 (calcd. 540.2132); [MNa]^+$

68

694.2909 (calcd. 694.2922). Anal. Calcd for $C_{35}H_{47}F_2N_3O_4SSi$: C, 62.56; H, 7.05; N, 6.25. Found: C, 62.37; H, 7.05; N, 6.03.

The N-arylated pyrazoline XIXe (101.5 mg, 0.151 mmol) was dissolved in anhydrous THF (5 mL) -78° C, LiAlH₄ (33 mg, 0.87 mmol) was added and the suspension was stirred at -78° C for 4.5 h. Sat. aq. NaHCO₃ (1 mL) was added and the mixture was evaporated on celite and purified twice by dry column vacuum chromatography (4.6 x 2.0 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give the corresponding alcohol (52.7 mg, 76%) as a light yellow oil.

 R_f (1:3 EtOAc/hexane (v/v)) 0.23; 1H -NMR (300 MHz, CDCl₃) δ : 7.23 (2H, dd, J = 5.6, 8.7 Hz), 7.04-6.92 (6H, m), 6.67 (1H, d, J =1.2 Hz), 4.64 (1H, t, J = 5.9 Hz), 3.81 (1H, dd, J = 4.0, 11.5 Hz), 3.68-3.58 (2H, m), 3.12 (1H, dd, J = 6.2, 6.8 Hz), 1.86 (1H, bs), 1.77-1.67 (2H, m), 1.58-1.48 (2H, m), 0.86 (9H, s), 0.00 (3H, s), -0.17 (3H, s). 13 C-NMR (75 MHz, CDCl₃) δ : 163.47, 160.22, 158.83, 155.68 (C), 144.84 (CH), 142.35, 140.67, 140.62 (C), 127.26, 127.16, 115.75, 115.46, 115.11, 115.06, 114.96, 114.83, 73.76, 66.81 (CH), 62.37 (CH₂), 50.05 (CH), 37.72, 28.28 (CH_2) , 25.75 (CH_3) , 18.12 (C), -4.67, -5.01 (CH_3) . ¹⁹F (282 MHz, $CDCl_3$) δ : -115.25 (1F, septet, $J = 4.3 \, \text{Hz}$), -124.25 (1F, septet, J = 4.3 Hz). IR (cm⁻¹): 3401, 2953, 2930, 2885, 2858, 1672, 1605, 1509, 1472, 1463, 1416, 1362, 1296, 1252, 1223, 1156, 1006, 979, 938, 861, 835, 776, 666, 608, 554. MALDI-MS $(C_{25}H_{34}F_2N_2O_2Si): [MH-CH_2O] 429.2175 (calcd. 429.2174); [M-H]^+$ 459.2279 (calcd. 459.2279).

Subsequently this alcohol (70.8 mg, 0.154 mmol) was dissolved in anhydrous CH_2Cl_2 (5 mL), anhydrous Et_3N (0.50 mL, 3.9 mmol), DMAP (6.8 mg, 0.056 mmol) and TsCl (69 mg, 0.36 mmol) were added and the solution was stirred at room temperature for 12.5 h, evaporated on celite and purified by dry column vacuum chromatography

WO 2005/033100

 $(4.4 \times 2.0 \text{ cm})$ on silica gel eluting with a gradient of 0-20% EtOAc in hexane (v/v) to give the corresponding tosylate (78.4 mg, 83%) as a colourless oil.

 R_f (1:3 EtOAc/hexane (v/v)) 0.44; ¹H-NMR (300 MHz, CDCl₃) δ : 7.68 (2H, d, J = 8.7 Hz), 7.25 (4H, t, J = 8.1 Hz), 6.99 (2H, t, J =8.7 Hz), 6.92-6.80 (4H, m), 6.64 (1H, d, J = 1.2 Hz), 4.65 (1H, dd, J = 4.4, 6.8 Hz), 4.12 (1H, dd, J = 2.5, 9.3 Hz), 3.92-3.81(2H, m), 3.08-3.01 (1H, m), 2.42 (3H, s), 1.80-1.43 (4H, m), $0.87 \text{ (9H, s)}, 0.01 \text{ (3H, s)}, -0.17 \text{ (3H, s)}. ^{13}\text{C-NMR} \text{ (75 MHz,}$ $CDCl_3$) δ : 163.49, 160.24, 158.59, 155.43, 145.16 (C), 143.40 (CH), 140.54, 132.21 (C), 129.84, 127.82, 127.32, 127.21, 115.79, 115.48, 115.12, 114.83, 114.31, 114.22, 73.50 (CH), 67.45 (CH₂), 62.42, 50.74 (CH), 37.35, 27.87 (CH₂), 25.77, 21.59 (CH₃), 18.10 (C), -4.67, -5.01 (CH₃). ¹⁹F (282 MHz, CDCl₃) δ : -116.01 (1F, m), -125.40 (1F, septet, J = 4.3 Hz). IR (cm⁻¹): 3055, 3034, 2953, 2930, 2886, 2857, 1603, 1509, 1472, 1463, 1365, 1307, 1294, 1252, 1223, 1190, 1177, 1156, 1096, 979, 862, 835, 775, 666, 608, 555. MALDI-MS $(C_{32}H_{40}F_2N_2O_4SSi)$: [MH-TBDMSOH]⁺ 483.1559 (calcd. 483.1554); [MNa] + 637.2330 (calcd. 637.2344).

The tosylate received above was dissolved in anhydrous DMF (2.5 mL), hydroquinone (263 mg, 2.39 mmol) and Cs_2CO_3 (102.1 mg, 0.313 mmol) were added and the suspension was stirred at $80^{\circ}C$ for 12 h. EtOAc (30 mL) was added and the organic phase was washed with sat. aq. NaHCO₃ (10 mL) and H₂O (10 mL), evaporated on celite and purified by dry column vacuum chromatography (4.5 x 2.0 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give the corresponding phenol XIXf (70.9 mg, 86%) as a colourless oil.

 R_f (1:3 EtOAc/hexane (v/v)) 0.33; 1H -NMR (300 MHz, CDCl₃) δ : 7.24 (2H, dd, J = 5.3, 8.4 Hz), 7.06-6.93 (6H, m), 6.75-6.68 (5H, m), 4.67 (1H, dd, J = 4.4, 6.8 Hz), 4.10-3.98 (2H, m), 3.74 (1H, dd, J = 1.2, 7.5 Hz), 3.17-3.11 (1H, m), 1.86-1.54 (4H, m), 0.88

(9H, s), 0.02 (3H, s), -0.15 (3H, s). 13 C-NMR (75 MHz, CDCl₃) δ : 163.32, 160.08, 158.48, 155.35, 152.31, 149.86 (C), 143.85 (CH), 141.52, 141.49, 140.63 (C), 127.23, 127.12, 115.99, 115.73, 115.51, 115.44, 115.04, 114.75, 114.67, 114.57, 73.78 (CH), 67.79 (CH₂), 63.88, 51.51 (CH), 37.77, 28.38 (CH₂), 25.89 (CH₃), 18.25 (C), -4.46, -4.80 (CH₃). 19 F (282 MHz, CDCl₃) δ : -115.31 (1F, m), -124.71 (1F, septet, J = 4.3 Hz). IR (cm⁻¹): 3350, 3056, 2953, 2930, 2885, 2858, 1605, 1509, 1472, 1462, 1362, 1297, 1226, 1156, 1100, 1086, 1050, 1006, 939, 828, 776, 667, 609, 553, 518. MALDI-MS (C₃₁H₃₈F₂N₂O₃Si): [MH-TBDMSOH] 421.1720 (calcd. 421.1728); [MH] 553.2677 (calcd. 553.2698); [MNa] 575.2505 (calcd. 575.2517).

70

The phenol XIXf (18.4 mg, 0.0333 mmol) was dissolved in anhydrous THF (1.0 mL, teflon bottle) at 0°C, anhydrous pyridine (0.20 mL) followed by HF pyridine complex (0.20 mL) were added and the solution was allowed to warm to room temperature over several h and stirred at room temperature for 22 h. Ether (20 mL) was added and the solution was washed with sat. aq. NaHCO $_3$ (2 x 5 mL), evaporated on celite and purified by dry column vacuum chromatography (4.5 x 2.0 cm) on silica gel eluting with a gradient of 0-60% EtOAc in hexane (v/v) to give the desired diol XIX (14.4 mg, 99%) as a colourless oil.

R_f (1:1 EtoAc/hexane (v/v)) 0.27; 1 H-NMR (300 MHz, CDCl₃) δ : 7.29 (2H, dd, J = 5.3, 8.4 Hz), 7.06-6.93 (6H, m), 6.75-6.67 (5H, m), 4.70 (1H, t, J = 6.5 Hz), 4.09-4.03 (2H, m), 3.72 (1H, t, J = 10.0 Hz), 3.18 (1H, dd, J = 4.4, 6.2 Hz), 1.99-1.50 (4H, m). 13 C-NMR (75 MHz, CDCl₃) δ : 163.72, 160.47, 155.31, 152.26, 149.95 (C), 143.53 (CH), 141.41, 139.78 (C), 127.41, 127.29, 116.01, 115.77, 115.51, 115.23, 114.54, 114.42, 73.49 (CH), 67.60 (CH₂), 63.67, 51.35 (CH), 35.89, 28.70 (CH₂). 19 F (282 MHz, CDCl₃) δ : -114.89 (1F, septet, J = 4.3 Hz), -124.64 (1F, septet, J = 4.3 Hz). IR (cm⁻¹): 3320, 2927, 1604, 1508, 1453, 1366, 1225, 1157,

1102, 1044, 910, 826, 733, 609. MALDI-MS $(C_{25}H_{24}F_2N_2O_3)$: $[MH-H_2O]^+$ 421.1717 (calcd. 421.1728); $[M]^+$ 438.1755 (calcd. 438.1755); $[MH]^+$ 439.1825 (calcd. 439.1833); $[MNa]^+$ 461.1650 (calcd. 461.1653).

Example 16

The phenol XIXf obtained in step 15a) (28.4 mg, 0.0514 mmol) was dissolved in anhydrous CH_2Cl_2 (2 mL), anhydrous pyridine (0.10 mL, 1.3 mmol) and MsCl (0.05 mL, 0.51 mmol) were added and the solution was stirred at room temperature for 22.5 h, evaporated on celite and purified by dry column vacuum chromatography (4.5 x 2.0 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give the corresponding mesylate (29.2 mg, 90%) as a colourless oil.

 R_f (1:1 EtOAc/hexane (v/v)) 0.64; 1H -NMR (300 MHz, CDCl₃) δ : 7.26-7.17 (6H, m), 7.06-6.94 (6H, m), 6.83 (2H, d, J = 9.3 Hz), 6.71 (1H, d, J = 1.2 Hz), 4.66 (1H, dd, J = 4.4, 6.8 Hz), 4.11 (1H, dd, J = 4.0, 9.0 Hz), 4.04 (1H, dt, J = 4.4, 7.5 Hz), 3.81 (1H, dd, J = 7.5, 8.7 Hz), 3.11 (3H, s), 3.19-3.08 (1H, m), 1.85-1.52 (4H, m), 0.87 (9H, s), 0.01 (3H, s), -0.16 (3H, s). ^{13}C -NMR (75 MHz, CDCl₃) δ : 160.25, 158.65, 157.92, 157.23, 155.50 (C), 143.67 (CH), 142.93, 141.52, 140.67 (C), 127.30, 127.19, 123.18, 115.85, 115.56, 115.45, 115.14, 114.85, 114.64, 114.53, 73.76 (CH), 67.53 (CH₂), 63.54, 51.60 (CH), 37.75 (CH₂), 37.09 (CH₃), 28.29 (CH₂), 25.78 (CH₃), 18.13 (C), -4.63, -4.98 (CH₃). ^{19}F (282 MHz, CDCl₃) δ : -116.00 (1F, m), -125.47 (1F, septet, J = 4.3 Hz). IR (cm⁻¹): 2930, 2857, 1605, 1508, 1472, 1369, 1299, 1251, 1223, 1197, 1168, 1152, 1086, 1009, 970, 868, 836, 776,

72

609, 527. MALDI-MS $(C_{32}H_{40}F_2N_2O_5Ssi)$: [MH-TBDMSOH]⁺ 499.1504 (calcd. 499.1503); [MNa]⁺ 653.2298 (calcd. 653.2293).

This mesylate (29.0 mg, 0.0460 mmol) was dissolved in anhydrous THF (1.0 mL, teflon bottle) at 0°C, anhydrous pyridine (0.20 mL) followed by HF pyridine complex (0.20 mL) were added and the solution was allowed to warm to room temperature over several h and stirred at room temperature for 10 h. Ether (20 mL) was added and the solution was washed with sat. aq. NaHCO $_3$ (2 x 5 mL), evaporated on celite and purified by dry column vacuum chromatography (4.6 x 2.0 cm) on silica gel eluting with a gradient of 0-90% EtOAc in hexane (v/v) to give the desired mesylate **XX** (23.0 mg, 97%) as a colourless oil.

 R_f (1:1 EtOAc/hexane (v/v)) 0.18; ¹H-NMR (300 MHz, CDCl₃) δ : 7.30 (2H, dd, J = 5.6, 8.7 Hz), 7.18 (2H, d, J = 9.3 Hz), 7.06-6.94(6H, m), 6.83 (2H, d, J = 9.3 Hz), 6.73 (1H, d, J = 1.2 Hz), 4.70 (1H, dd, J = 5.6, 6.8 Hz), 4.14-4.07 (2H, m), 3.84-3.77 (1H, m), 3.19-3.14 (1H, m), 3.10 (3H, s), 1.94 (1H, bs), 1.92-1.54 (4H, m). 13 C-NMR (75 MHz, CDCl₃) δ : 163.72, 160.47, 158.50, 157.04, 155.35 (C), 143.35 (CH), 142.82, 141.30, 141.26, 139.84 (C), 127.36, 127.26, 123.11, 115.81, 115.52, 115.41, 115.25, 114.52, 114.42, 73.44 (CH), 67.37 (CH₂), 63.44, 51.43 (CH), 37.20 (CH₃), 35.97, 28.73 (CH₂). ¹⁹F (282 MHz, CDCl₃) δ : -114.06 (1F, m), -124.49 (1F, septet, J = 4.3 Hz). IR (cm⁻¹): 3550, 3404, 2936, 1604, 1508, 1366, 1299, 1249, 1223, 1196, 1168, 1151, 1039, 970, 913, 870, 835, 743, 528. MALDI-MS $(C_{26}H_{26}F_2N_2O_5S)$: [MH- H_2O] + 499.1500 (calcd. 499.1503); [M] ⁺ 516.1536 (calcd. 516.1504); [MH] * 517.1606 (calcd. 517.1609); [MNa] * 539.1428 (calcd. 539.1428).

Example 17

To a solution of acid XXIa (prepared according to B. A. Shinkre, V. G. Puranik, B. M. Bhawal, A. Deshmukh, Tetrahedron: Asymmetry **2003**, 14, 453; 30.0 g, 102 mmol, 1.11 equiv) in CH_2Cl_2 (600 ml) is added triethylamine (64.0 ml, 461 mmol, 5.00 equiv) followed by imine XXIb (prepared according to T. Kambara, K. Tomioka, J. Org. Chem. 1999, 64, 9282; 28.1 g, 92.1 mmol, 1.00 equiv). The solution is cooled to -20 °C and triphospene (16.4 g, 55.8 mmol, 0.600 equiv) is added in 50 ml CH₂Cl₂ over a period of 20 min. The solution is warmed to 23 °C over a period of 8 h and stirred for additional 10 h at this temperature. The solution is poured onto 600 ml ice water and 200 ml CH2Cl2. The aqueous phase is extracted with CH_2Cl_2 (3 * 100 ml). The combined organic phases are washed with brine, dried (Na2SO4) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (3/2 to 1/2 gradient) and then chromatography on silica gel eluting with EtOAc/ CH_2Cl_2 (7/1 to 3/1 gradient) to afford β -lactam **XXIc** as a colorless solid in 40 % yield along with 35 % yield of the undesired diastereomer.

74

mp: 132 °C. R_{f} = 0.38 (hexane/ ethyl acetate 1/1). α_{D} = +77°, (CHCl₃, c = 1.075, 30.5 °C). ¹H-NMR (300 MHz, CDCl₃): δ 7.46-7.07 (m, 16 H), 6.92-6.84 (m, 2 H), 5.34 (d, J = 5.3 Hz, 1 H), 5.06 (s, 2 H), 4.95 (d, J = 5.3 Hz, 1 H), 4.60 (d, J = 2.5 Hz), 3.23 - 3.14 (m, 1 H), 2.90 (s, 3 H), 1.70 (s, 3 H), 0.83 (d, J = 6.2 Hz). ¹³C-NMR (75 MHz, CDCl₃),: δ 165.4, 165.0, 159.3 (J = 244 Hz), 159.1, 137.1 (J = 5 Hz), 133.7, 129.9, 128.9, 128.6, 128.3, 128.0, 127.7, 125.7, 119.0 (J = 8 Hz), 116.0 (J = 23 Hz), 115.1, 100.1, 76.9, 71.2, 70.1, 62.2, 59.0, 33.8, 23.6, 12.4. IR (thin film): 2938, 1756, 1667, 1612, 1511, 1382, 1223, 1177, 1112, 1092, 834, 734. HRMS (EI): Calcd' for ($C_{35}H_{33}FN_{2}O_{5}^{+}$), 580.2374, found, 580.2369.

To a solution of β -lactam XXIc (17.0 g, 29.0 mmol, 1.00 equiv) in THF (242 ml) and water (48 ml) is added p-toluenesulfonic acid hydrate (55.7 g, 293 mmol, 10.0 equiv). The solution is heated to reflux for 5 h. The solution is concentrated to an approximate volume of 60 ml and then poured onto EtOAc (150 ml) and water (250 ml). The aqueous phase is extracted with EtOAc (4 * 100 ml). The combined organic phases are washed with brine, dried (Na₂SO₄) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (3/2 to 2/3 gradient) to afford the corresponding 3-hydroxy- β -lactam as a colorless solid in 51 % yield.

mp: 168 °C. R_f = 0.26 (hexane/ ethyl acetate 3/2). α_D = -129°, (acetone, c = 1.22, 29.5 °C). 1 H-NMR (300 MHz, acetone): δ 7.50-7.47 (m, 2 H), 7.42-7.29 (m, 5 H), 7.10-7.01 (m, 4 H), 5.33 (d, J = 5.3 Hz, 1 H), 5.27 (dd, J = 7.2 Hz, 5.3 Hz, 1 H), 5.11 (s, 2 H), 5.07 (d, J = 7.2 Hz, 1 H). 13 C-NMR (75 MHz, acetone),: δ 166.5, 159.2, 159.0 (J = 241 Hz), 137.7, 134.7, 129.6, 128.6, 128.0, 127.8, 118.9 (J = 8 Hz), 115.8 (J = 23 Hz), 114.8, 78.0, 69.8, 62.3. IR (thin film): 3120, 1756, 1667, 1612, 1511, 1382,

75

1223, 1177, 1112, 1092, 834, 734. HRMS (EI): Calcd' for $(C_{22}H_{18}FNO_3^+)$, 363.1271, found, 363.1268. Anal. Calcd. for $C_{22}H_{18}FNO_3$: C, 72.72; H, 4.99; N, 3.85; found: C, 77.73; H, 5.20; N, 3.91.

To a suspension of this 3-hydroxy- β -lactam (2.00 g, 5.50 mmol, 1.00 equiv) in methanol (55.0 ml) is added sodium methoxide (1.49 g, 27.5 mmol, 5.00 equiv). The suspension is stirred at 23 °C for 2 h. To the forming solution is added NH₄Cl_(s) and the suspension is concentrated in vacuo. To the solid is added EtOAc (50 ml) and water (50 ml). The aqueous phase is extracted with EtOAc (3 * 20 ml). The combined organic phases are washed with brine, dried (Na₂SO₄) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (3/2 to 1/1 gradient) to afford the corresponding amino alcohol as a colorless solid in 89 % yield.

mp: 103 °C. R_f = 0.45 (hexane/ ethyl acetate 3/2). α_D = +13.9°, (CH₂Cl₂, c = 1.10, 25.3 °C. ¹H-NMR (300 MHz, CDCl₃): δ 7.44-7.24 (m, 4 H), 6.97-6.91 (m, 2 H), 6.84-6.76 (m, 2 H), 6.53-6.46 (m, 2 H), 5.02 (s, 2 H), 4.81 (s, 1 H), 4.60 (s, 1 H), 4.46 (m, 1 H), 3.79 (s, 3 H), 3.07 (d, J = 3.7 Hz, 1 H). ¹³C-NMR (75 MHz, CDCl₃),: δ 158.2, 155.8 (J = 233 Hz), 142.5, 136.8, 131.0, 128.5, 127.9, 127.9, 127.4, 155.5 (J = 22 Hz), 114.9, 114.8, 74.6, 70.0, 59.1, 53.1, 114.8, 78.0, 69.8, 62.3. IR (thin film): 3390, 1737, 1610, 1510, 1221, 1113, 823. MS (EI): 306.1748 (2.54 %), 186.2356 (18.8 %, 91.0908 (100 %). Anal. Calcd. for $C_{23}H_{22}FNO_4$: C, 69.86; H, 5.61; N, 3.54; found: C, 69.88; H, 5.78; N, 3.54.

To a solution of the amino alcohol received above (1.92 g, 4.86 mmol, 1.00 equiv) in CH_2Cl_2 (24.0 ml) is added diisopropylethylamine (2.54 ml, 14.6 mmol, 3.00 equiv) and 4-N,N-dimethylaminopyridine (59.0 mg, 0.486 mmol, 0.10 equiv). The solution is cooled to -78 °C and triphosgene (1.44 g, 4.86 mmol,

76

1.00 equiv) in CH_2Cl_2 (4.0 ml) is added over a period of 5 min. The solution is warmed to 23 °C over 8 h and stirred at this temperature for additional 5 h. To this solution is added water (50 ml) and concentrated aqueous ammonium hydroxide solution (3 ml). The aqueous phase is extracted with CH_2Cl_2 (3 * 20 ml). The combined organic phases are washed with brine, dried (Na_2SO_4) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (2/1 to 1/1 gradient) to afford methyl ester **XXId** as a colourless solid in 82 % yield.

mp: 118 °C. R_f = 0.54 (hexane/ ethyl acetate 3/2). α_D = +18°, (CHCl₃, c = 1.10, 29.3 °C). ¹H-NMR (300 MHz, CDCl₃): δ 7.40-7.32 (m, 7 H), 7.29-7.22 (m, 2 H), 6.98-6.93 (m, 4 H), 5.33 (d, J = 4.4 Hz, 1 H), 5.03 (s, 2 H), 4.73 (d, J = 4.4 Hz, 1 H), 3.89 (s, 3 H). ¹³C-NMR (75 MHz, CDCl₃),: δ 168.9, 160.1 (d, J = 244 Hz), 159.7, 154.3, 136.7, 132.7, 129.5, 128.9, 128.4, 127.8, 127.7, 123.2 (d, J = 8 Hz), 116.1 (d, J = 22 Hz), 116.0, 77.9, 70.3, 36.6, 53.5. IR (thin film): 1769, 1552, 1388, 1227, 1099, 834. HRMS (MALDI): Calcd' for ($C_{24}H_{20}FNO_5Na^+$), 444.1224, found, 444.1224. Anal. Calcd. for $C_{24}H_{20}FNO_5$: C, 68.40; H, 4.78; N, 3.32; found: C, 68.18; H, 4.91; N, 3.38.

To a suspension of methyl ester XXId (1.68 g, 3.99 mmol, 1.00 equiv) in ethanol (27.0 ml) is added at 23 °C sodium cyanoborohydride (226 mg, 5.98 mmol, 1.50 equiv). The suspension is stirred for 2 h at this temperature at which point all solids were dissolved. To this solution is added $NH_4Cl_{(s)}$ and the volume is concentrated in vacuo to 5 ml. To this suspension is added water (50 ml) and EtOAc (50 ml). The aqueous phase is extracted with EtOAc. The combined organic phases are washed with brine, dried (Na_2SO_4) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (1/1 to 2/3 gradient) to afford the corresponding alcohol

77

as a colorless solid in 92 % yield.

mp: 143 °C. R_f = 0.40 (hexane/ ethyl acetate 2/3). α_D = -16°, (CHCl₃, c = 1.54, 32.4 °C). ¹H-NMR (300 MHz, CDCl₃): δ 7.42-7.19 (m, 9 H), 6.97-6.90 (m, 4 H), 5.26 (d, J = 6.5 Hz, 1 H), 5.02 (s, 2 H), 4.39 (m, 1 H), 3.99 (d, J = 12.5 Hz, 1 H), 3.74 (d, J = 12.5 Hz, 1 H), 2.77 (s, 1 H). ¹³C-NMR (75 MHz, CDCl₃),: δ 159.7 (d, J = 245 Hz), 159.0, 136.4, 132.7, 129.4, 128.5, 128.0, 127.9, 127.4, 123.6 (d, J = 8 Hz), 115.6 (d, J = 22 Hz), 115.6, 82.0, 70.1, 61.6, 61.2. IR (thin film): 3418, 2930, 2871, 1748, 1611, 1512, 1394, 1234. HRMS (EI): Calcd' for ($C_{23}H_{20}FNO_4$ *), 393.1376, found, 393.1389. Anal. Calcd. for $C_{23}H_{20}FNO_4$: C, 70.22; H, 5.12; N, 3.56; found: C, 70.26; H, 5.21; N, 3.61.

To a solution of oxalylchloride (508 mg, 4.00 mmol, 2.00 equiv) in CH₂Cl₂ (15.0 ml) is added at -78 °C dimethylsulfoxide (0.355 ml, 5.00 mmol, 2.50 equiv). After 10 min at -78 °C is added the alcohol received above (787 mg, 2.00 mmol, 1.00 equiv) in CH₂Cl₂ (15.0 ml) over a period of 5 min. After additional 5 min at this temperature triethylamine (1.14 ml, 8.00 mmol, 8.00 equiv) is 1-(4-Fluoro-phenyl)-2-(triphenyl- λ^5 -After min 5 phosphanylidene)-ethanone is added and the resulting suspension is warmed to 20 °C and stirred for additional 30 min. To the solution is added saturated aqueous Na₂HCO₃ solution. The aqueous phase is extracted with CH2Cl2. The combined organic phases are washed with brine, dried (Na₂SO₄) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (2/1 to 1/1 gradient) to afford the corresponding enone as a colorless solid in 89 % yield.

mp: 152 °C. R_f = 0.56 (hexane/ ethyl acetate 3/2). α_D = +100°, (CHCl₃, c = 0.60, 25.6 °C). ¹H-NMR (300 MHz, CDCl₃): δ 8.06-7.99 (m, 2 H), 7.42-7.06 (m, 14 H), 7.00-6.92 (m, 4 H), 5.05-5.00 (m, 4 H). ¹³C-NMR (75 MHz, CDCl₃),: δ 187.1, 165.9 (d, J = 254 Hz), 159.8 (d, J = 243 Hz), 159.4, 154.8, 140.0, 136.2, 133.2, 132.3,

78

131.4 (d, J = 9 Hz), 128.6, 128.1, 128.1, 127.9, 127.4, 125.8, 123.5 (d, J = 9 Hz), 115.9 (d, J = 24 Hz), 115.8 (d, J = 24 Hz), 115.8, 80.5, 70.2, 66.0. IR (thin film): 1760, 1675, 1597, 1511, 1385, 1227. HRMS (MALDI): Calcd' for ($C_{31}H_{23}F_2NO_4Na^+$), 534.1493, found, 534.1482. Anal. Calcd. for $C_{31}H_{23}F_2NO_4$: C, 72.79; H, 4.53; N, 2.74; found: C, 72.51; H, 4.78; N, 2.73.

To this enone (910 mg, 1.78 mmol, 1.00 equiv) in ethanol (15.0 ml) is added at 23 °C palladium on carbon (10 %) (100 mg). The suspension is vigorously stirred under 1 atm of hydrogen gas for 3 h. The suspension is filtered through a pad of celite eluting with EtOAc concentrated and the residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (2/1 to 1/1 gradient). A portion of the resulting benzyl ether (310 mg, 0.604 mmol, 1.00 equiv) is dissolved in CH₂Cl₂ and cooled to -20 (R)-3,3-diphenyl-1-methyltetrahydro-3H-pyrrolooxazaborole2-methyl-oxazaborolidin (solution in toluene (0.5 M) 0.600 ml, 0.302 mmol, 0.50 equiv) is added followed by borane dimethylsulfide complex (0.080 ml, 0.905 mmol, 1.50 equiv). The solution is stirred at -20 °C for 2 h, then warmed to 0 °C and quenched with methanol. To the solution is added saturated aqueous Na₂HCO₃ solution and CH₂Cl₂. The aqueous phase is extracted with CH2Cl2. The combined organic phases are washed with brine, dried (Na2SO4) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (3/2 to 1/1 gradient). A portion of the resulting alcohol (53 mg, 0.10 mmol, 1.0 equiv) is dissolved in ethanol and palladium on carbon (10 mg) is added. The suspension is vigorously stirred under an atmosphere of hydrogen for 2.5 h. The suspension is filtered through a plug of celite eluting with EtOAc. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (1/1 to 1/2 gradient) to afford the desired oxazolidinone XXI as a colorless solid in 57 % yield

79

from the starting enone.

mp: 98 °C. R_f = 0.41 (hexane/ ethyl acetate 2/3). α_D = -1°, (CHCl₃, C = 0.84, 27.6 °C). ¹H-NMR (300 MHz, acetone d_6): δ 7.47-7.35 (m, 4 H), 7.29-7.24 (m, 2 H), 7.09-6.97 (m, 4 H), 6.85-6.79 (m, 2 H), 5.15 (d, J= 6.7 Hz, 1H), 4.76-4.68 (m, 1 H), 4.43-4.34 (m, 2 H), 2.02-1.76 (m, 4 H). ¹³C-NMR (75 MHz, acetone d_6): δ 162.0 (d, J = 243 Hz), 159.5 (d, J = 242 Hz), 157.9, 155.3, 142.2 (d, J = 3 Hz), 134.3 (d, J = 2 Hz), 129.1, 128.7, 127.8 (d, J = 8 Hz), 123.8 (d, J = 9 Hz), 116.1, 115.2 (d, J = 23 Hz), 114.9 (d, J = 21 Hz), 82.4, 72.3, 65.6, 35.0, 30.3. IR (thin film): 3316, 2925, 1726, 1603, 1511, 1224, 835. HRMS (MALDI): Calcd' for ($C_{24}H_{21}F_2NO_4Na^+$), 448.1337, found, 448.1326.

Example 18

The compounds of the invention and ezetimibe (commercially obtained or prepared according to Wu, G. Z. et al., J. Org. Chem. 1999) together with the glucuronide (the metabolite of ezetimibe, prepared according to Vaccaro, W. D.; Davis, H. R. Bioorg. Med. Chem. Lett. 1998, 8, 313-318) as appropriate reference compounds were evaluated by well-established methods to determine their inhibition of cholesterol uptake in rabbit brush border membrane vesicles (BBMV) (Table 1). Briefly, the scavenger receptor-mediated uptake of radiolabelled cholesterol ester from the loaded donor particles into the BBMV bilayer was measured in the presence of various compounds of the invention and appropriate reference compounds (Hauser, H. et al., Biochemistry 1998, 37, 17843-17850; Werder, M. et al., Biochemistry 2001, 40, 11643-11650; Boffelli, D. et al., FEBS Lett. 1997, 411, 7-11.)

Table 1:

Compound	applied in donor SUV
	(9 mol%)
	Inhibition in (%)
Ezetimibe	16 ± 4
Glucuronide	19 ± 4
VI	30 ± 4
VII	22 ± 2
VIII	15 ± 3
IXb	20 ± 5
IX	27 ± 4
X	15 ± 3
XI	20 ± 5
XIV	26 ± 3
XV	19 ± 3
XVI	21 ± 5
XVII	28 ± 4
XVIII	41 ± 4
XXI	19 ± 2

81

Claims

1. A compound according to formula I

$$P_1$$
 P_2 P_3 P_4 P_4

wherein

P represents -N< or -C=,

X represents independently of each other $-CH_2-$, CR_1 (sp₂-hybridised), O, -NH-, =N-, -CO- or -CS-, wherein R_1 represents H or NR_2 , wherein R_2 represents H or lower alkyl, which optionally is linked to Z such that a bicyclic structure is formed;

n represents 1 or 2,

 $R_a \qquad \text{represents H, lower alkyl, } -OR_3, -O(CO)R_3, -O(CO)OR_3, -O(CO)NR_3R_4, -NR_3R_4, -NR_3(CO)R_4, -COOR_3, -CONR_3R_4, -CH=CHCOOR_3, -CF_3, -CN, -NO_2, SO_3H, PO_3H or halogen, wherein <math>R_3$ and R_4 represent H or lower alkyl,

 R_b represents H, OH, $-OSO_2Me$, $-OSO_2W$ wherein W represents optionally substituted aryl or heteroaryl, $-OCO(CHOH)_2COOR_5$ wherein R_5 represents H or lower alkyl; or represents the formula $-Sp_3-R_6$, wherein Sp_3 represents a covalent bond, -O-, $-OCH_2-$, $-OSO_2CH_2-$, $-OSO_2-$, $-OSO_2-$ (p) C_6H_4O- and R_6 represents one of carbohydrate structures A-D:

PCT/CH2004/000584

82

$$R_{7}O_{11}OR_{9}OR_{8}OR_{11}OR_{7}OR_{8}OR_{8}OR_{8}OR_{8}OR_{12}OR_{13}OR_{7}OR_{14}OR_{9}OR_{14}OR_{15}OR_{14}OR_{15}OR_{1$$

wherein

 R_7 , R_8 , R_9 , R_{11} , R_{12} , R_{13} and R_{14} represent independently of each other H, lower alkyl, aryl(lower alkyl), -CO-lower alkyl, -CO-aryl, $-SO_3^-$ or $-PO_3^-$,

 R_{10} represents $-CH_2OR_{16}$ or $-COOR_{17}$, and

 R_{15} represents $-CH_2OR_{16}$, $-COOR_{17}$, $-CH_2NH_2$, $-CH_2OPO_3$ or $-CH_2OSO_3$, wherein R_{16} and R_{17} independently of each other represent H, lower alkyl, aryl(lower alkyl), -CO-lower alkyl, -CO-aryl, $-SO_3$ or $-PO_3$,

Z represents optionally substituted anyl or heteroaryl,

represents a spacer unit, such as a straight-chain or branched lower alkyl group $-(CH_2)_p$ -, wherein p is from 2-6, which is unsubstituted, mono or poly-substituted by -OH, $-OR_{18}$, halogen or cyano group, wherein one or more -CH₂- groups may independently be replaced by -O-, -CO-, -CO-O-, -O-CO-, -NR₁₉-, -NR₁₉-CO-, -CO-NR₁₉-, -CH=CH-, -C=C-and wherein R₁₈ and R₁₉ represent a hydrogen atom or lower alkyl;

Sp₂ represents an optional spacer unit, such as a covalent bond or a straight-chain or branched lower alkyl group -

83

 $(CH_2)_{q}$ -, wherein q is from 1-6, which is unsubstituted, mono or poly-substituted by -OH, -OR₂₀, halogen or cyano group, wherein one or more -CH₂- groups may independently be replaced by -O-, -CO-, -CO-O-, -O-CO-, -NR₂₁-, -NR₂₁-CO-, -CO-NR₂₁-, -CH=CH-, -C \equiv C- -and wherein R₂₀ and R₂₁ represents a hydrogen atom or lower alkyl;

Y represents optionally substituted anyl or heteroaryl,

with the proviso, that if P = -N <, n=1, X = -CO- and Sp_2 represents a covalent bond, R_6 may not represent carbohydrate structures A or D for $Sp_3 = -O-$ and R_6 may not represent carbohydrate B for $Sp_3 = -OCH_2-$.

A compound according to claim 1,

with the proviso, that if P = -N <, n=1, X = -CO- and Sp_2 represents a covalent bond, R_b may not represent H or OH and Sp_3 may not represent a covalent bond, -O- or $-OCH_2-$.

- 3. A compound according to claims 1 or 2 wherein P = -N <, n = 1 and X = -CO -, -CS -, $-CH_2 -$ or -NH -.
- 4. A compound according to claims 1 or 2 wherein P = -N <, n = 1 and X = -CS -, $-CH_2 -$ or -NH -.
- 5. A compound according to claims 1 or 2 wherein P = -N < and $-(X)_n = -OOC-, -COO-, -CONH-, -CH=N-.$
- 6. A compound according to claims 1 or 2 wherein P = -C =and $-(X)_n = -NH-N =$ or -O-N =.
- 7. A compound according to claims 1 or 2 having the formula IVa

84

$$P_{1,...}$$
 P_{2} P_{2} P_{2} P_{2} P_{2} P_{2} P_{2} P_{3} P_{4} P_{4} P_{5} P_{5}

ΙVa

wherein R_a , R_b , Sp_1 , Sp_2 , P, X, Y, Z and n are as defined in claims 1 or 2.

A compound according to claims 1 or 2 having the formula
 IVb,

$$R_{22}$$
 R_{21}
 R_{21}

IVb

wherein R_a , R_b , Sp_1 , P, X and n are as defined hereinabove and wherein R_{21} and R_{22} represent H, lower alkyl, lower alkoxy or halogen.

- 9. A compound according to claims 7 or 8 wherein P = -N <, n = 1 and X = -CO -, -CS -, $-CH_2 -$ or -NH -.
- 10. A compound according to claims 7 or 8 wherein P = -N <, n = 1 and X = -CS -, $-CH_2 -$ or -NH -.
- 11. A compound according to claims 7 or 8 wherein P = -N < and $-(X)_n = -OOC-, -COO-, -CONH-, -CH=N-.$
- 12. A compound according to claims 7 or 8 wherein P = -C =and $-(X)_n = -NH-N =$ or -O-N =.
- 13. A pharmaceutical composition comprising a therapeutically

WO 2005/033100

effective amount of a compound of any preceding claim with a pharmaceutically acceptable carrier.

PCT/CH2004/000584

14. A pharmaceutical composition according to claim 13 for the treatment or prevention of artheriosclerosis or for the reduction of cholesterol levels.

85

- 15. A kit comprising a pharmaceutical composition according to claim 13 for use in the treatment or prevention of artheriosclerosis or for the reduction of cholesterol levels.
- 16. A method for the treatment or prevention of artheriosclerosis or for the reduction of cholesterol levels comprising administering to a subject in need of such treatment an effective amount of a compound according to claims 1 to 12.
- 17. Use of a compound according to claims 1 to 12 for the manufacture of a medicament for the treatment or prevention of artheriosclerosis or for the reduction of cholesterol levels.

International Application No PCT/CH2004/000584

A. CLASSI	FICATION OF SUBJECT MATTER			
IPC 7	FICATION OF SUBJECT MATTER C07D405/04 C07H15/00 C07D205/	′08		
According to	International Patent Classification (IPC) or to both national classification	ation and IPC		
B. FIELDS	SEARCHED		,	
	ocumentation searched (classification system followed by classification	on symbols)		
IPC 7	C07D C07H		:	
Degramentel	ion searched other than minimum documentation to the extent that s	ush decuments are included in the fields of	a ush ad	
Documentai	ion searched other than minimum documentation to the extent that s	uch documents are included in the lields so	earcned	
Electronic d	ata base consulted during the international search (name of data bas	se and where practical search terms used	0	
	· · · · · · · · · · · · · · · · · · ·	oo ana, imolo prastical, scalor termo asse	"	
EPO-In	ternal, CHEM ABS Data			
C. DOCUMI	ENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the rele	evant passages	Relevant to claim No.	
Х	MUKERJEE A K ET AL: "RAPID SYNTH		1-3,7-9	
	DEHYDROPEPTIDES CARRYING A BETA-L	_ACTAM		
	MOIETY"			
	JOURNAL OF CHEMICAL RESEARCH. SYN	IOPSES,		
	LONDON, GB, no. 7, 1993, pages 28	30-281,		
	XP009027094			
	ISSN: 0308-2342			
	the whole document			
	_	-/		
			4.4	
			:	
			*	
Y Furth	ner documents are listed in the continuation of box C.	γ Patent family members are listed i	n annex.	
		<u></u>		
° Special ca	tegories of cited documents:	"T" later document published after the inte	ernational filing date	
*A" docume	ent defining the general state of the art which is not	or priority date and not in conflict with	the application but	
consid	ered to be of particular relevance	cited to understand the principle or the invention	eory underlying the	
"E" earlier o	document but published on or after the international	"X" document of particular relevance; the o		
	ate ont which may throw doubts on priority claim(s) or	cannot be considered novel or cannot involve an inventive step when the do		
which is cited to establish the publication date of another "Y" document of particular relevance; the claimed invention				
	ent referring to an oral disclosure, use, exhibition or	cannot be considered to involve an in document is combined with one or mo		
other r	means	ments, such combination being obvior		
"P" document published prior to the international filing date but later than the priority date claimed in the art. *** document member of the same patent family				
Date of the	actual completion of the international search	Date of mailing of the international sea	ren report	
	0.004.00.0004	00/11/000#		
2	8 October 2004	08/11/2004		
Name and n	nailing address of the ISA	Authorized officer		
	European Patent Office, P.B. 5818 Patentlaan 2	The state of the s		
	NL 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,			
	Fax: (+31-70) 340-2040, 1X: 31 651 epo fil, Fax: (+31-70) 340-3016 Klein, D			

International Application No PCT/CH2004/000584

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Х	VAN HEEK, MARGARET ET AL: "In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (1997), 283(1), 157-163, 1997, XP002275919 figure 1	1-3,7-9, 13-17
X	WU, GEORGE GUANGZHONG: "A Concise Asymmetric Synthesis of A.betaLactam-Based Cholesterol Absorption Inhibitor" ORGANIC PROCESS RESEARCH & DEVELOPMENT (2000), 4(4), 298-300, 2000, XP002275920 the whole document	1-3,7-9, 13-17
X	UDUPI, R.H. ET AL: "Synthesis of 1-(2-carboxy-5-nitrophenyl)-3,4-substitute d azetidin-2-ones as antiinflammatory and antimicrobial agents" INDIAN JOURNAL OF HETEROCYCLIC CHEMISTRY (1996), 6(2), 99-102, 1996, XP009027043 the whole document	1-3
X	CLADER, JOHN W. ET AL: "2-Azetidinone Cholesterol Absorption Inhibitors: Structure-Activity Relationships on the Heterocyclic Nucleus" JOURNAL OF MEDICINAL CHEMISTRY (1996), 39(19), 3684-3693, 1996, XP002275922 the whole document	1-3,7-9, 13-17
X	OTTO H-H ET AL: "STEREOCHEMIE DER DEHYDRATISIERUNG UND HALOGENIERUNG DER ALPHAR- UND ALPHAS-ISOMERE VON 3-(ALPHA-HYDROXYBENZYL)-1,4-DIPHENYL-2-AZE TIDINONEN STEREOCHEMISTRY OF DEHYDRATION AND HALOGENATION OF ALPHAR AND ALPHAS ISOMERIC 3-(ALPHA-HYDROXYBENZYL)-1,4-DIPHENYL" LIEBIGS ANNALEN DER CHEMIE, VERLAG CHEMIE GMBH. WEINHEIM, DE, no. 7, 1983, pages 1162-1168, XP001179959 ISSN: 0170-2041 the whole document	1-3,7-9
	-/	

Intermional Application No PCT/CH2004/000584

	FC17CH2004/000584
	Delayant As elein No.
Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
BROWNE, MARGARET ET AL: "Trans diastereoselective synthesis of 3-alkyl substituted.betalactams via the acid chloride-imine reaction of nonactivated acid chlorides" TETRAHEDRON LETTERS (1995), 36(15), 2555-8, 1995, XP004028248 the whole document	1-3,7-9, 13-17
BOSE, AJAY K. ET AL: "Studies on lactams. 101. Microwave-assisted rapid synthesis of.alphaaminobetalactams" TETRAHEDRON LETTERS (1996), 37(39), 6989-6992, 1996, XP004030806 the whole document	1-3,7-9
VAN LEUSEN, ALBERT M. ET AL: "Chemistry of sulfonylmethyl isocyanides. 12. Base-induced cycloaddition of sulfonylmethyl isocyanides to carbon, nitrogen double bonds. Synthesis of 1,5-disubstituted and 1,4,5-trisubstituted imidazoles from aldimines and imidoyl chlorides" JOURNAL OF ORGANIC CHEMISTRY (1977), 42(7), 1153-9, 1977, XP002275923 the whole document	1-3,7,9
BURNETT, DUANE A. ET AL: "Synthesis of 3-(1-hydroxyethyl)-2-azetidinones via ester-imine condensations" JOURNAL OF ORGANIC CHEMISTRY (1985), 50(25), 5120-3, 1985, XP002275924 the whole document	1-3,7-9
BURNETT, DUANE A. ET AL: "2-Azetidinones as Inhibitors of Cholesterol Absorption" JOURNAL OF MEDICINAL CHEMISTRY (1994), 37(12), 1733-6, 1994, XP002275925 the whole document	1,2,5-10
ROSENBLUM, STUART B. ET AL: "Synthesis of 3-arylpropenyl, 3-arylpropynyl and 3-arylpropyl 2-azetidinones as cholesterol absorption inhibitors: application of the palladium-catalyzed arylation of alkenes and alkynes" TETRAHEDRON (2000), 56(31), 5735-5742, 2000, XP004213804 the whole document	1-3,7-9, 13-17
	diastereoselective synthesis of 3-alkyl substituted.betalactams via the acid chloride-imine reaction of nonactivated acid chlorides" TETRAHEDRON LETTERS (1995), 36(15), 2555-8, 1995, XP004028248 the whole document BOSE, AJAY K. ET AL: "Studies on lactams. 101. Microwave-assisted rapid synthesis of alphaaminobetalactams" TETRAHEDRON LETTERS (1996), 37(39), 6989-6992, 1996, XP004030806 the whole document VAN LEUSEN, ALBERT M. ET AL: "Chemistry of sulfonylmethyl isocyanides. 12. Base-induced cycloaddition of sulfonylmethyl isocyanides to carbon,nitrogen double bonds. Synthesis of 1,5-disubstituted and 1,4,5-trisubstituted imidazoles from aldimines and imidoyl chlorides" JOURNAL OF ORGANIC CHEMISTRY (1977), 42(7), 1153-9, 1977, XP002275923 the whole document BURNETT, DUANE A. ET AL: "Synthesis of 3-(1-hydroxyethyl)-2-azetidinones via ester-imine condensations" JOURNAL OF ORGANIC CHEMISTRY (1985), 50(25), 5120-3, 1985, XP002275924 the whole document BURNETT, DUANE A. ET AL: "2-Azetidinones as Inhibitors of Cholesterol Absorption" JOURNAL OF MEDICINAL CHEMISTRY (1994), 37(12), 1733-6, 1994, XP002275925 the whole document BURNETT, DUANE B. ET AL: "Synthesis of 3-arylpropenyl, 3-arylpropynyl and 3-arylpropenyl, 3-arylpropynyl and 3-arylpropenyl, 3-arylpropynyl and 3-arylpropynyl 2-azetidinones as cholesterol absorption inhibitors: application of the palladium-catalyzed arylation of alkenes and alkynes" TETRAHEDRON (2000), 56(31), 5735-5742, 2000, XP004213804

Intermional Application No PCT/CH2004/000584

C (Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	7 C17 CH20047 000564
Category °		Relevant to claim No.
X	KIRKUP M P ET AL: "(-)-SCH 57939: synthesis and pharmacological properties of a potent, metabolically stable cholesterol absorption inhibitor" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 6, no. 17, 3 September 1996 (1996-09-03), pages 2069-2072, XP004135657 ISSN: 0960-894X the whole document	1-3,7-9, 13-17
X	OTTO H-H ET AL: "DARSTELLUNG UND STEREOCHEMIE VON 3-(ALPHA-HYDROXYBENZYL)-1,4-DIPHENYL-2-AZETIDINONEN SYNTHESIS AND STEREOCHEMISTRY OF 3-(ALPHA-HYDROXYBENZYL)-1,4-DIPHENYL-2-AZETIDINONES" LIEBIGS ANNALEN DER CHEMIE, VERLAG CHEMIE GMBH. WEINHEIM, DE, 1983, pages 1152-1161, XP001012817 ISSN: 0170-2041 the whole document	1-3,7-9
X	ROSENBLUM, STUART B. ET AL: "Discovery of 1-(4-Fluorophenyl)-(3R)-'3-(4-fluorophenyl)-(3S)- hydroxypropyl!-(4S)-(4-hydroxyphenyl)-2-az etidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption" JOURNAL OF MEDICINAL CHEMISTRY (1998), 41(6), 973-980, 1998, XP002275926 the whole document	1-3,7-9, 13-17
X	BURNETT, DUANE A. ET AL: "Synthesis of fluorescent biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2002), 12(3), 315-318, 2002, XP002275927 the whole document	1-3,7-9, 13-17
X	BURNETT, DUANE A. ET AL: "Synthesis of iodinated biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2002), 12(3), 311-314, 2002, XP002275928 the whole document	1-3,7-9, 13-17
X	US 5 631 365 A (ROSENBLUM STUART B) 20 May 1997 (1997–05–20) the whole document	1-3,7-9, 13-17

Intermional Application No
PCT/CH2004/000584

		PCT/CH2004/000584				
C.(Continu	C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Cotogory * Citation of document, with indication, where appropriate of the relevant passages. Polyvant to claim No.					
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.				
Х	EP 0 524 595 A (SCHERING CORP) 27 January 1993 (1993-01-27) the whole document	1-3,7-9, 13-17				
Χ	WO 00/63703 A (SCHERING CORP) 26 October 2000 (2000-10-26) the whole document	1-3,7-9, 13-17				
X	US 5 633 246 A (DUGAR SUNDEEP ET AL) 27 May 1997 (1997-05-27) the whole document	1-3,7-9, 13-17				
Х	WO 02/50090 A (SCHERING CORP) 27 June 2002 (2002-06-27) the whole document	1-3,7-9, 13-17				
X	DE 36 20 467 A (CIBA GEIGY AG) 2 January 1987 (1987-01-02) the whole document	1-3,7-9, 13-17				
X	WO 03/026643 A (SCHERING CORP) 3 April 2003 (2003-04-03) * the whole document, in particular page 42 formula X, XI *	1-3,7-9, 13-17				
X	US 5 756 470 A (VAN HEEK MARGARET ET AL) 26 May 1998 (1998-05-26) the whole document	1–17				
X	WO 97/16455 A (SCHERING CORP) 9 May 1997 (1997-05-09) the whole document	1–17				
Χ	US 2003/119428 A1 (DAVIS HARRY R ET AL) 26 June 2003 (2003-06-26) the whole document	1-17				

■national application No. PCT/CH2004/000584

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. X Claims Nos.: 1-7, 9-17 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.2

Claims Nos.: 1-7, 9-17

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty or inventive step. So many documents were retrieved that it is impossible to determine which parts of the claims may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT).

Furthermore, present claims 1-7, 9-17 relate to an extremely large number of possible compounds. In fact, the claims contain so many options, variables or possible permutations that a lack of clarity (and conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear (and concise), namely claim 8.

Nevertheless, most of the references cited are also relevant to the subject-matter of claims 1-7, 9-17.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

Information on patent family members

Interaction No
PCT/CH2004/000584

				1 CT/ CHZ	004/000584
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 5631365	A	20-05-1997	ATU AUA CON CONTRACT DE LA CONTRACT DEL CONTRACT DE LA CONTRACT DE LA CONTRACT DEL CONTRACT DE LA CONTRACT DEL CONTRACT DE LA CONTRACT DE LA CONTRACT DE LA CONTRACT DE LA CONTRACT DEL CONTRACT DE LA CONTRACT.	180249 T 681445 B2 7795294 A 2172149 C 1131416 A ,B 9600839 A3 288891 B6 10399001 I1 69418613 D1 69418613 T2 720599 T3 0720599 A1 2132432 T3 961300 A 3030312 T3 73852 A2 110956 A 2803908 B2 8509989 T 186853 B1 23332 A1 300132 I1 961133 A 274041 A 313589 A1 2138480 C1 46208 A1 35596 A3 427974 B 9508532 A1 RE37721 E1 5767115 A 5846966 A 9407086 A	15-06-1999 28-08-1997 10-04-1995 28-11-2000 18-09-1996 14-08-1996 12-09-2001 12-06-2003 24-06-1999 30-09-1999 10-07-1996 16-08-1999 21-03-1996 30-09-1999 30-09-1999 30-09-1998 22-10-1996 01-05-1999 01-04-1995 01-10-2003 20-03-1996 19-12-1997 08-07-1996 27-09-1999 20-02-1998 05-02-1997 01-04-2001 30-03-1995 28-05-2002 16-06-1998 08-12-1998 14-03-1995
EP 0524595	A	27-01-1993	AT AU BG CN CZE DE EP EP EP FIU IP NO NZ OK	158789 T 658441 B2 2398092 A 61118 B2 2114007 A1 1069024 A 9400142 A3 69222532 D1 69222532 T2 9400342 A 0524595 A1 0596015 A1 2107548 T3 940296 A 67341 A2 922374 A1 2525125 B2 6508637 T 9204327 A1 940221 A 243669 A 9878 A 7994 A3	15-10-1997 13-04-1995 23-02-1993 29-11-1996 04-02-1993 17-02-1993 13-07-1994 06-11-1997 26-02-1998 15-04-1996 27-01-1993 11-05-1994 01-12-1997 21-01-1994 28-03-1995 27-01-1993 14-08-1996 29-09-1994 29-07-1994 21-01-1994 21-01-1994 21-01-1994 21-01-1994 21-01-1994

Information on patent family members

Intermational Application No
PCT/CH2004/000584

	tent document in search report		Publication date		Patent family member(s)	Publication date
					- (-)	date
ΕP	0524595	Α		WO	9302048 A1	04-02-1993
				US	6093812 A	25-07-2000
				ÜS	5561227 A	01-10-1996
				ÜS	5688785 A	18-11-1997
				ÜS	5688787 A	18-11-1997
				ÜS	5306817 A	26-04-1994
				ZA	9205487 A	31-03-1993
WO	0063703	Α	26-10-2000	AU WO	4343500 A 0063703 A1	02-11-2000
				US	2003215869 A1	26-10-2000
				US	6593078 B1	20-11-2003
				US	2002009714 A1	15-07-2003 24-01-2002
						24-01-2002
US	5633246	Α	27-05-1997	US	5624920 A	29-04-1997
				ΑT	213726 T	15-03-2002
				AU	698750 B2	05-11-1998
				AU	4140196 A	17-06-1996
				BR	9509669 A	28-10-1997
				CA	2205202 A1	30-05-1996
				CN	1174548 A ,	
				CZ	9701486 A3	12-11-1997
				DE	69525643 D1	04-04-2002
				DE	69525643 T2	26-09-2002
				DK	792264 T3	22-04-2002
				ΕP	0792264 A1	03-09-1997
				ES	2169162 T3	01-07-2002
				FI	972099 A	16-05-1997
				HK	1002558 A1	14-06-2002
				HU	77088 A2	02-03-1998
				JP	2908031 B2	21-06-1999
				JP	9512833 T	22-12-1997
				KR	235806 B1	01-02-2000
				NO	972272 A	16-05-1997
				NZ	296720 A	29-03-1999
				PL	320092 A1	15-09-1997
				PT	792264 T	31-07-2002
				RU	2159243 C2	20-11-2000
				SK	61697 A3	10-12-1997
				WO	9616037 A1	30-05-1996
				US 	5744467 A	28-04-1998
WO	0250090	Α	27-06-2002	AT	279425 T	15-10-2004
				AU	3104902 A	01-07-2002
				BR	0116212 A	30-12-2003
				CA	2432798 A1	27-06-2002
				CN	1483039 T	17-03-2004
				CZ	20031674 A3	15-10-2003
				EP	1347987 A1	01-10-2003
				HU	0302269 A2	28-10-2003
				JP	2004516299 T	03-06-2004
				NO	20032806 A	19-08-2003
				SK	7702003 A3	07-10-2003
				WO	0250090 A1	27-06-2002
				US	2002137690 A1	26-09-2002
				US	2003105028 A1	05-06-2003

Information on patent family members

Intermenal Application No
PCT/CH2004/000584

Patent document cited in search report	Publication date	Patent family Publication member(s) date
WO 03026643 A	03-04-2003	CA 2460340 A1 03-04-2003 EP 1429756 A2 23-06-2004 W0 03026643 A2 03-04-2003 US 2003119809 A1 26-06-2003
US 5756470 A	26-05-1998	NONE
WO 9716455 A	09-05-1997	AT 219495 T 15-07-2002 AU 712158 B2 28-10-1999 AU 7517996 A 22-05-1997 BR 9611401 A 05-01-1999 CA 2235943 A1 09-05-1997 CN 1205707 A ,B 20-01-1999 CZ 9801294 A3 14-10-1998 DE 69621952 D1 25-07-2002 DE 69621952 T2 16-01-2003 DK 877750 T3 15-07-2002 EP 0877750 A1 18-11-1998 ES 2175141 T3 16-11-2002 HK 1012507 A1 18-10-2002 HU 9802539 A2 30-11-1998 ID 16177 A 11-09-1997 JP 10512592 T 02-12-1998 JP 3385031 B2 10-03-2003 JP 2001048895 A 20-02-2001 NO 981950 A 26-06-1998 NZ 321766 A 29-07-1999 PL 327987 A1 04-01-1999 PT 877750 T 30-09-2002 SK 48398 A3 04-11-1998 TW 448181 B 01-08-2001 WO 9716455 A1 09-05-1997 ZA 9609089 A 29-04-1997
US 2003119428 A	26-06-2003	US 2003105028 A1 05-06-2003 US 2003119757 A1 26-06-2003 US 2003119796 A1 26-06-2003